LabId	PatientId	consensus_sex	inferred_sex	inferred_ethnicity	centerID	CEBPA_Biallelic	ageAtDiagnosis	isRelapse	isDenovo	isTransformed	finalFusion	specificDxAtAcquisition_MDSMPN	nonAML_MDSMPN_specificDxAtAcquisition	priorMalignancyNonMyeloid	priorMalignancyType	cumulativeChemo	priorMalignancyRadiationTx	priorMDS	priorMDSMoreThanTwoMths	priorMDSMPN	priorMDSMPNMoreThanTwoMths	priorMPN	priorMPNMoreThanTwoMths	dxAtInclusion	specificDxAtInclusion	ELN2017	ELN2008	dxAtSpecimenAcquisition	specificDxAtAcquisition	ageAtSpecimenAcquisition	timeOfSampleCollectionRelativeToInclusion	specimenGroups	specimenType	rnaSeq	exomeSeq	totalDrug	rnaSeqAnalysis	analysisExomeSeq	analysisDrug	cumulativeTreatmentTypeCount	cumulativeTreatmentTypes	cumulativeTreatmentRegimenCount	cumulativeTreatmentRegimens	cumulativeTreatmentStageCount	cumulativeTreatmentStages	responseToInductionTx	typeInductionTx	responseDurationToInductionTx	mostRecentTreatmentType	currentRegimen	currentStage	mostRecentTreatmentDuration	vitalStatus	overallSurvival	causeOfDeath	any_different_labs	any_different_labs_also_beataml	different_lab_ids	different_id_karyotype_interval	X..Basophils.in.PB	X..Blasts.in.BM	X..Blasts.in.PB	X..Eosinophils.in.PB	X..Immature.Granulocytes.in.PB	X..Lymphocytes.in.PB	X..Monocytes.in.PB	X..Neutrophils.in.PB	X..Nucleated.RBCs.in.PB	ALT	AST	Albumin	Creatinine	FAB.Blast.Morphology	Hematocrit	Hemoglobin	Karyotype	LDH	MCV	Other.Cytogenetics	Platelet.Count	Surface.Antigens..Immunohistochemical.Stains.	Total.Protein	WBC.Count	any_different_cgs	any_different_cgs_also_beataml	different_cgs_lab_ids	FLT3.ITD	NPM1	ABL1	ASXL1	ASXL2	ATM	BCOR	BCORL1	BRAF	BRCA2	CALR	CBL	CCND2	CCND3	CD36	CEBPA	CHEK2	CIITA	CREBBP	CSF3R	CTCF	CUX1	DNMT3A	EP300	ETV6	EZH2	FBXW7	FLT3	GATA1	GATA2	IDH1	IDH2	IKZF1	JAK1	JAK2	JAK3	KDM6A	KIT	KMT2A	KMT2D	KRAS	MEN1	MPL	MUTYH	MYD88	NF1	NOTCH1	NRAS	PAX5	PDGFRB	PHF6	POT1	PRDM1	PTPN11	RAD21	ROS1	RUNX1	SETBP1	SF3B1	SMC1A	SOCS1	SRSF2	STAG2	STAT3	SUZ12	TCL1A	TET2	TP53	TYK2	U2AF1	WT1	ZRSR2
09-00705	163	Male	Male	White	1	n	73	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	5	Targeted Therapy - Kinase Inhibitor(s)	AC220 (Ambit)	Experimental	30	Dead	425	Dead-Disease	FALSE	FALSE		0	0	94	97	0	NA	2	1	0	NA	19	28	4.1	0.79	M1	19.3	6.8	46,XY[20]	441	100.5	normal	89	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative	7.6	94	TRUE	TRUE	10-00222;10-00792	positive	positive																										negative							negative			negative																																		
10-00136	174	Male	Male	White	1	n	69	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	69	0	Initial Acute Leukemia Diagnosis	Leukapheresis	n	y	y	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Hydroxyurea	Re-induction	3	Dead	419	Dead-Disease	FALSE	FALSE		0	0	80	19	0	NA	5	3	11	NA	56	56	3.2	1.68	M4	NA	7.7	47,XY,+8[cp9]/46,XY[11]	4559	NA	Signal copy for CEP 8 and ETO	66	dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive	5.4	282.1	FALSE	FALSE		positive	negative														negative																																																								
10-00172	175	Female	Male	White	1	n	59	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	IntermediateOrAdverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	59	0	Initial Acute Leukemia Diagnosis	Leukapheresis	n	y	y	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Quizartinib|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	Dead	541	Dead-Disease	FALSE	FALSE		0	0	91	99	0	NA	31	16	5	NA	84	90	1.9	0.86	M4	22.9	7.9	47,XX,+13[18]/46,XX[2]	3587	90.5	trisomy 13	48	Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positive	4.6	29.7	FALSE	FALSE		positive	negative														negative												negative							negative			negative																																		
10-00507	45	Female	Female	White	1	n	70	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Leukapheresis	n	y	n	n	y	n	2	Standard Chemotherapy|Intrathecal	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Cytarabine, Methotrexate	2	Consolidation|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	5	Dead	511	Dead-Other	FALSE	FALSE		0	0	97	97	0	NA	10	0	3	NA	30	38	2.8	0.92	M1	NA	10.9	46,XX[20]	592	NA	normal	8	CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive	5.8	112.3	FALSE	FALSE		positive	positive																																																																						
10-00542	174	Male	Male	White	1	n	69	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	69	163	Relapse|Post-Chemotherapy	Peripheral Blood	n	y	y	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Hydroxyurea	Re-induction	3	Dead	419	Dead-Disease	FALSE	FALSE		0	0	87	80	0	NA	11	0	9	NA	14	20	3.9	0.67	M4	36	12.6	47,XY,+8[cp20]	NA	91	trisomy 8	134	CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive	6.3	35.9	FALSE	FALSE		positive	negative																																																																						
10-00669	17	Female	Female	White	1	n	27	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Juvenile pilocytic astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	Dead	1463	Dead-Disease	FALSE	FALSE		3	0			0	NA	7	2	2	NA	8	15	2.3	0.69		17.7	6.3	46,XX[20]	426	101.6	Normal	13		5.4	58.8	FALSE	FALSE		positive	positive														No Mutation info: RAF: 10-20%																																																								
10-00692	201	Male	Male	White	1	n	60	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|Hydroxyurea|Quizartinib|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Experimental	Refractory	Standard Chemotherapy	5	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	380	Alive	FALSE	FALSE		0	0	40	51	0	NA	5	11	23	NA	23	31	3.1	1.8	NOS	30.8	10.6	46,XY[20]	NA	103.1	normal	136	partial CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR, and partial TdT/positive	6.3	65.2	FALSE	FALSE		positive	positive																																																																						
10-00715	203	Male	Male	White	1	n	70	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	70	0	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Quizartinib	Experimental	155	Dead	400	Dead-Disease	FALSE	FALSE		0	1	75	30	0	NA	64	0	4	NA	16	22	3.7	0.9	M0	25.8	9.1	46,XY[18]	137	89.5	normal	43	partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive	6.3	2.5	FALSE	FALSE		negative	negative														negative												negative							negative			negative																																		
10-00791	191	Female	Female	White	1	n	60	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Relapse	Bone Marrow Aspirate	n	y	y	n	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	Dead	394	Dead-Disease	FALSE	FALSE		0	0	83	41	0	NA	3	1	28	NA	42	45	3.7	1.06	NOS	30.9	10.4	46,XX[20]	451	100.4	normal	57	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	6.3	48.2	FALSE	FALSE		positive	positive																																																																						
10-00792	163	Male	Male	White	1	n	73	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	378	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	5	Targeted Therapy - Kinase Inhibitor(s)	AC220 (Ambit)	Experimental	30	Dead	425	Dead-Disease	TRUE	FALSE	10-00793	0	0	95	84	0	NA	3	3	3	NA	21	26	3.8	1.04	M1	27.8	9.9	46,XY[20]	195	101.8	normal	20	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive; Negative for expression of CD34 and HLA-DR	5.8	53.5	FALSE	FALSE		positive	positive																																																																						
10-00819	127	Male	Male	White	1	n	74	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	77	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	y	n	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	Refractory	Standard Chemotherapy	1025	Supportive/Palliative Care	Mitoxantrone	Supportive/Palliative Care	18	Dead	1264	Dead-Unknown	FALSE	FALSE		0	0	85	77	0	NA	10	2	9	NA	14	23	4	1.63	M4	31.3	10.7	46,XY[17]	419	103.3	normal	69	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	6.4	16.1	FALSE	FALSE		positive	negative																																																																						
11-00049	174	Male	Male	White	1	n	69	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	IntermediateOrAdverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	70	333	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Hydroxyurea	Re-induction	3	Dead	419	Dead-Disease	TRUE	FALSE	11-00046	0	0	90	97	0	NA	5	0	1	NA	29	36	2.9	0.82	M4	26.3	9.2	47,XY,+8[cp20]	575	88.3	trisomy 8	68	CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive	4.7	62.9	FALSE	FALSE		positive	negative																																																																						
11-00090	211	Female	Female	White	1	n	65	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	n	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	387	Dead-Unknown	FALSE	FALSE		0	0	70	75	0	NA	6	3	8	NA		NA	NA	NA	NOS	25.9	9.1	46,XX[20]	NA	94.3	normal	123	CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive	NA	51.8	FALSE	FALSE		positive	positive														negative												negative							negative			negative																																		
11-00162	176	Male	Male	White	1	n	66	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	MYELOPROLIFERATIVE NEOPLASMS	Mastocytosis	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	386	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Quizartinib	Experimental	57	Dead	365	Dead-Disease	FALSE	FALSE		0	0	75	63	0	NA	8	0	23	NA	107	47	3.7	0.83	NOS	35	12	46,XY[20]	226	95.2	normal	74	CD13, CD33, partial CD34, CD38, CD117 and CD123	5.6	11.9	FALSE	FALSE		negative	positive																																																																						
11-00170	203	Male	Male	White	1	n	70	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	71	185	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	y	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Quizartinib	Experimental	155	Dead	400	Dead-Disease	FALSE	FALSE		0	0	80	80	0	NA	3	2	1	NA	36	29	2.2	1.04		22	7.4	46,XY[20]	NA	89.7	normal	10	CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT	4.6	23.1	FALSE	FALSE		positive	positive																																																																						
11-00178	191	Female	Female	White	1	n	60	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	138	Residual Disease|Post-Chemotherapy	Peripheral Blood	n	y	n	n	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	Dead	394	Dead-Disease	FALSE	FALSE		0	1	95	60	0	NA	17	14	6	NA	34	28	3.4	1.06	NOS	25.7	9.1	46,XX[20]	268	86.8	normal	18	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	6.1	21.5	FALSE	FALSE		positive	positive																																																																						
11-00254	191	Female	Female	White	1	n	60	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	181	Residual Disease|Post-Chemotherapy	Peripheral Blood	n	y	n	n	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	Dead	394	Dead-Disease	FALSE	FALSE		0	0			0	NA	2	1	0	NA	67	67	2.6	1.6		27	9.3	46,XX[20]	NA	81.8	normal	21		5.9	79.7	FALSE	FALSE		positive	positive																																																																						
11-00261	127	Male	Male	White	1	n	74	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	77	166	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	y	n	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	Refractory	Standard Chemotherapy	1025	Supportive/Palliative Care	Mitoxantrone	Supportive/Palliative Care	18	Dead	1264	Dead-Unknown	TRUE	FALSE	11-00235	-20	0		96	0	NA	2	1	0	NA	13	24	3	1.48	M4	NA	8.7	46,XY[20]	696	NA	normal	15	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	5.4	459.6	TRUE	TRUE	10-00819;11-00235	positive	negative																										D835																																												
11-00295	45	Female	Female	White	1	n	70	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	337	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Intrathecal	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Cytarabine, Methotrexate	2	Consolidation|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	5	Dead	511	Dead-Other	FALSE	FALSE		0	2	92	66	0	NA	11	0	18	NA	26	41	4.1	0.85	M1	32.5	11.2	46,XX[20]	386	98.3	normal	25	CD13, CD33, CD38, CD56, CD117, and MPO positive	6.7	31.1	FALSE	FALSE		positive	positive																																																																						
11-00319	211	Female	Female	White	1	n	65	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	151	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	y	n	y	n	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	387	Dead-Unknown	TRUE	TRUE	11-00090	0	0	72	45	0	NA	19	5	30	NA	61	44	4.1	0.74	NOS	33.1	11.7	46,XX,t(1;15)(p32;q15)[19]/46,XX[1]	443	95	normal	93	CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive	6.6	18.4	FALSE	FALSE		positive	positive																										negative																																												
12-00023	550	Female	Female	White	1	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Dead	397	Dead-Disease	FALSE	FALSE		0	0	68		1	NA	30	49	3	NA	14	18	3	0.85	M5	21.9	7.6	46,XX[20]	313	102.9	Normal	125	Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR	5.5	14.9	FALSE	FALSE		negative	negative							G596R							negative												negative			negative	negative			negative			negative			negative							negative																							2400/10000 copies	
12-00051	635	Female	Female	White	1	n	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	707	Dead-Disease	FALSE	FALSE		0	0	88	93	0	NA	6	0	1	NA	19	26	3.4	0.88		28.2	9.6	46,XX[20]	678	99.9	Normal	19	partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive	6.8	17.9	FALSE	FALSE		positive	positive														negative												negative			negative	negative			negative			negative			negative							negative																							8000/10000 copies (High)	
12-00066	559	Male	Male	White	1	n	70	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	70	34	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	153	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	Dead	311	Dead-Disease	TRUE	FALSE	12-00032	0	5	36	9	5	NA	21	38	22	NA	19	22	3.6	1.18	M4	28.7	9.7	46,XY[20]	231	99.6	Normal	47	CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive	7.1	21	TRUE	FALSE	12-00262	positive	negative																										negative			negative	negative			negative			negative			negative		negative					negative																								
12-00069	652	Male	Male	HispNative	1	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	Dead	309	Dead-Disease	FALSE	FALSE		1	0	81	60	0	NA	5	24	4	NA	42	45	3.3	0.93	NOS	NA	8.7	46,XY[20]	673	NA	Normal	83	CD13, CD34, CD38, CD117, CD123, HLA-DR	6.9	179.1	TRUE	TRUE	12-00362	positive	negative														negative												negative			negative	negative			negative			negative			negative		negative					negative																								
12-00127	707	Male	Male	White	1	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Leukapheresis	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	23	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	740	Dead-Disease	FALSE	FALSE		0	0	93	99	0	NA	1	3	1	NA	15	19	1.7	1.03	M1	24	8.2	46,XY[20]	NA	92.7	Normal	62	partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive	4.4	64.3	TRUE	FALSE	12-00128	negative	positive														negative												FLT3 I836 deletion;MAF not available			negative	negative			negative			negative			negative							negative																								
12-00150	722	Male	Male	AdmixedBlack	7	n	NA	FALSE	FALSE	FALSE	Unknown	FALSE	TRUE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	18	0	Unknown	Peripheral Blood	y	n	y	y	n	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
12-00211	764	Female	Female	White	1	n	50	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	50	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	27	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Alive	1396	Alive	FALSE	FALSE		0	0	90	82	0	NA	1	0	2	NA	19	30	2.8	0.86		26.4	9.1	46,XX,t(11;17)(q13;q21)[20]	1165	97.7	While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene	8	dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO	5.3	84.1	FALSE	FALSE		negative	positive														negative												A680V;negative			negative	negative			negative			negative			negative							negative																							5000/10,000 copies	
12-00258	799	Female	Female	White	1	n	81	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Anal carcinoma|Breast Cancer|Breast Cancer	y	y	n	n	y	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	81	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	n	y	y	n	y	1	Supportive/Palliative Care	1	Azacitidine	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Azacitidine	Supportive/Palliative Care	42	Dead	147	Dead-Disease	FALSE	FALSE		-112	0			0	NA	12	33	7	NA	60	64	3.2	1.08	M5	26.6	8.8	46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]	2700	92.4		46		6.3	37.1	FALSE	FALSE		negative	negative																																																																						
12-00294	825	Male	Male	White	1	n	72	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Leukapheresis	y	n	y	y	n	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	3	Dead-Other	FALSE	FALSE		0	0	95	96	0	NA	3	0	1	NA	47	58	2.7	0.96	M4	16.5	5.6	46,XY[20]	697	114	Normal	51	Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive	4.9	97	FALSE	FALSE		positive	negative														negative												negative			negative				negative			negative										negative																								
12-00301	829	Male	Male	White	1	n	65	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	65	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	n	n	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MiDAC	Consolidation	108	Dead	1287	Dead-Other	FALSE	FALSE		-4	0		15	0	NA	11	71	2	NA	71	48	2.7	1.54	M4	25.9	8.8	46,XY,inv(16)(p13q22)[20]	454	95.9	CBFB rearrangement	14		6.1	20.7	FALSE	FALSE		negative	negative														negative												negative			negative				negative			negative			negative							negative																								
12-00362	652	Male	Male	HispNative	1	n	71	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	262	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	y	n	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	Dead	309	Dead-Disease	TRUE	FALSE	12-00330	-36	3	34	33	1	NA	28	5	23	NA	90	37	3.7	0.63	NOS	21.8	7.3	46,XY[20]	477	94.3	Normal	322	dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive	6.5	7.6	FALSE	FALSE		positive	negative																																																																						
12-00371	555	Male	Male	Asian	1	n	56	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	309	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	n	y	y	n	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	64	Dead	1735	Dead-Disease	TRUE	FALSE	12-00224	-121	0	77.5	75	1	NA	16	1	4	NA		NA	NA	NA	NOS	26.3	9.3	46,XY[4]	NA	87.8	Normal	9	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	NA	7.9	FALSE	FALSE		positive	positive																																																																						
12-00372	555	Male	Male	Asian	1	n	56	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	309	Relapse|Post-Chemotherapy	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	64	Dead	1735	Dead-Disease	TRUE	TRUE	12-00371;12-00224	-121	0	77.5	75	1	NA	16	1	4	NA		NA	NA	NA	NOS	26.3	9.3	46,XY[4]	NA	87.8	Normal	9	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	NA	7.9	FALSE	FALSE		positive	positive																																																																						
12-00423	923	Male	Male	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	Unknown	NA		FALSE	FALSE		0	0	46	66	1	NA	24	5	4	NA	18	34	3.2	1.05	M2	26.4	8.8	46,XY[20]	551	89.1	Normal	72	CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)	7	16.5	FALSE	FALSE		negative	negative																										D835																																												
12-00426	50	Male	Male	White	1	n	11	TRUE	FALSE	FALSE	DEK-NUP214	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	14	950	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	y	n	y	y	n	y	5	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)|Intrathecal	13	Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|Methotrexate|Etoposide, Cytarabine	8	Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	9	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	187	Dead	1655	Dead-Disease	TRUE	FALSE	12-00403	0	0	80	0	3	NA	78	3	16	NA	42	38	4.3	0.66	M2	41.6	14.3	48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]	NA	102.9	DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.	50	CD13, CD33, CD34, CD38, CD117,  CD123, dim HLA-DR, partial MPO	7.6	2.2	FALSE	FALSE		positive																																																																							
13-00004	652	Male	Male	HispNative	1	n	71	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	72	297	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	y	n	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	Dead	309	Dead-Disease	TRUE	TRUE	12-00330;12-00362	-71	11	65	13	11	NA	52	3	10	NA	47	54	2.3	0.91	NOS	23.3	7.7	46,XY[20]	888	91	Normal	49	dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive	5.8	6.8	FALSE	FALSE		positive	negative																																																																						
13-00007	29	Male	Male	White	1	n	34	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	36	574	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	43	Dead	595	Dead-Unknown	TRUE	FALSE	12-00161	0	1	90	30	0	NA	46	30	8	NA	43	11	2.8	0.92		25.5	9.1	46,XY,add(17)(p13)[19]/46,XY[1]	123	85	Normal	14	partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR	5.8	0.6	FALSE	FALSE		positive	positive																																																																						
13-00028	953	Male	Male	White	1	n	24	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	24	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide	5	Consolidation|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	DLI	Donor Lymphocyte Infusion	Unknown	0	Alive	1207	Alive	FALSE	FALSE		0	0	88	94	0	NA	3	40	3	NA	13	14	2.8	0.62	M4	31.7	10.9	47,XY,+10[18]/46,XY[2]	419	86.3	Normal	89	CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO	5.8	21.7	FALSE	FALSE		negative	negative														negative							negative					negative							negative			negative			negative						p.V1578delV; MAF 50%	negative																								
13-00034	958	Female	Female	White	2	n	61	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	y	Follicular lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	61	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	16	Dead-Disease	FALSE	FALSE		0	1	50	89	1	NA	0	0	0	NA	61	NA	2.5	0.84		25.3	8.4		NA	102.8		24	CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-DR(partial dim +), MPO(+), TdT(-).	4.5	53	FALSE	FALSE		negative	negative																										negative																																												
13-00098	1011	Female	Female	Black	2	n	64	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Induction	5	Unknown	NA		FALSE	FALSE		0	1.4	76	0	0.1	NA	94.3	1.5	2.7	NA	22	20	3.6	0.48		32.6	10.9	46,XX[14]	184	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],	32	CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)	7.5	1.5	FALSE	FALSE		negative	positive																																																																						
13-00106	231	Female	Male	HispNative	1	n	31	FALSE	FALSE	FALSE	DEK-NUP214	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	33	687	Residual Disease|Post-Transplant|Post-DLI	Bone Marrow Aspirate	n	y	y	n	y	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	9	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	7	Consolidation|Salvage|Unknown|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	DLI	Donor Lymphocyte Infusion	Unknown	-1	Dead	838	Dead-Disease	FALSE	FALSE		0	1	83		0	NA	60	3	36	NA	81	48	3	0.5	NOS	30.5	11.3	46,XX,t(1;19)(p32;q13.3),t(6;9)(p22;q34),t(12;16)(p12;q21)[cp20]	NA	82.6	t(6;9)(p22;q34)	13	CD13, CD33, CD34, CD38, CD58, dim CD64, dim CD117, TdT and partial MPO	6.6	0.9	FALSE	FALSE		negative	negative																																																																						
13-00118	685	Male	Male	White	1	n	54	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	349	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	7	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Consolidation|Salvage|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Re-induction	160	Dead	1378	Dead-Disease	TRUE	FALSE	12-00109	-349	3	71	83	2	NA	5	10	4	NA	35	31	3.9	0.81	M4	33.7	11.7	47,XY,+21[15]/46,XY[5]	438	100.6	Trisomy 21	119	CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123	7.1	33.8	FALSE	FALSE		negative	positive																																																																						
13-00123	1027	Male	Male	White	1	n	83	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Colon Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	83	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	9	Dead-Disease	FALSE	FALSE		-1	0		>90	0	NA	9	7	4	NA	242	341	1.9	2.48	M5	17.6	6.2	47,XY,+8[6]/46,XY[13]	2037	94.5	trisomy 8	14	Immunophenotype:  CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive	3.6	85.9	FALSE	FALSE		negative	positive																										D835																																												
13-00145	1045	Male	Male	White	2	n	70	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	194	Dead-Disease	FALSE	FALSE		-22	NA		78	NA	NA	12	5	3	NA		NA	NA	1.12		24.7	8.2	46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]	NA	89.2	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	18		NA	24.4	FALSE	FALSE		positive	negative																																																																						
13-00146	1046	Female	Female	White	1	n	7	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	7	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	9	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	Dead	158	Dead-Other	FALSE	FALSE		0	0	85	30	0	NA	42	0	27	NA	18	19	3.9	0.41		27.7	9.4	46,XX,t(8;21)(q22;q22)[19]/46,XX[1]	747	90.5	AML/ETO fusion, t(8;21)	71	CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive	7.3	4.8	FALSE	FALSE		negative	negative														negative							negative					negative			negative				negative			D816V; MAF 50%			negative							negative																				negative				
13-00147	819	Female	Female	AdmixedAsian	3	n	57	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	58	215	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Dead	257	Dead-Disease	TRUE	FALSE	12-00288	-14	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		positive	positive																										negative																																												
13-00149	1049	Male	Female	White	1	n	78	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Bladder Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	79	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Dead	267	Dead-Disease	FALSE	FALSE		0	0	87	72	1	NA	17	4	1	NA	19	41	3.4	0.75		32.3	10.6	45,X,-Y[19]/46,XY[1]	460	103.6	Normal	15	CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +	6.2	8.5	FALSE	FALSE		negative	negative														1031?1032 ins AAC; MAF 50%							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			p.R369R; MAF 50%	
13-00150	1051	Male	Male	White	1	n	52	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Adverse	Adverse	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	53	234	Post-Transplant|Post-Chemotherapy|Residual Disease	Peripheral Blood	y	n	y	y	n	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	5	Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	80	Dead	404	Dead-Disease	FALSE	FALSE		-2	0		59	0	NA	9	2	29	NA	32	34	3.7	0.68		34	11.1	45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]	167	102.8	Deleted 5q	152		6.7	14	FALSE	FALSE		negative	negative																																																																						
13-00157	1054	Female	Female	White	1	n	60	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	104	Alive	1379	Alive	FALSE	FALSE		0	0	80	32	0	NA	11	13	23	NA	32	50	2.9	0.64		41.1	13.4	46,XX[20]	660	86.1	normal	228	partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive	7.4	53.9	FALSE	FALSE		negative	positive														negative							p.Q696fs*9; MAF 40% 					negative			p.R132H; MAF 40%				negative			negative			negative		negative					negative						p.G503A; MAF 40%			negative											negative			negative	
13-00160	967	Male	Male	White	1	n	70	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	93	Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Maintenance	-1	Dead	1165	Dead-Unknown	TRUE	FALSE	13-00049	-93	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[19]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
13-00163	1058	Male	Male	HispNative	1	n	24	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	24	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Unknown|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	400	Alive	FALSE	FALSE		0	0	50	6	0	NA	19	52	16	NA		NA	NA	NA	M4	26.3	9.2	47,XY,inv(16)(p13q22),+22[20]	NA	91.5	inv(16)	53	- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO	NA	13.8	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			p.D816H; MAF ~50%			negative		negative					negative									negative											negative			rs16754; MAF ~50%	
13-00165	1060	Female	Female	White	3	n	33	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	33	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Dead	439	Dead-Treatment	FALSE	FALSE		-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[7]	NA	NA		NA		NA	NA	FALSE	FALSE		positive	positive																																																																						
13-00166	1061	Male	Male	White	1	n	65	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	67	0	Post-Chemotherapy|Residual Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	8	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine	6	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Cladribine	Unknown	5	Dead	1020	Dead-Unknown	FALSE	FALSE		0	0		77	0	NA	15	1	3	NA	18	10	3.6	1.01	M2	28.1	9.3		132	93.5		22		6.3	19.5	FALSE	FALSE		negative	negative																																																																						
13-00186	1072	Male	Male	White	1	n	74	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	126	Dead-Unknown	FALSE	FALSE		0	0	60	29	1	NA	26	18	24	NA	250	160	3.2	0.59		22	7.1	46,XY[20]	399	87.4		107	partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive	7	11.8	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									p.A142Gfs*4; MAF 30% 					p.P95L; MAF 48%						negative			negative	
13-00195	1078	Male	Male	White	1	n	66	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	74	Alive	972	Alive	FALSE	FALSE		0	0	90	24	0	NA	14	61	1	NA	19	14	2.4	1.13	M5	23.9	7.9	46,XY[20]	387	103.6	normal	122	CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive	6.3	28	FALSE	FALSE		negative	positive														negative			p.Q2208H; MAF 50%				p.R882H; MAF 50%					negative			negative	negative			negative			negative			negative							negative									negative											negative			rs16754; MAF 50%	
13-00201	1082	Male	Male	White	1	n	56	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Dead	247	Dead-Treatment	FALSE	FALSE		0	0	90	64	2	NA	12	17	2	NA	70	53	4.2	0.97	NOS	32.2	10.7	46,XY[20]	683	87	normal	38	CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+	7.9	61.2	FALSE	FALSE		positive	positive														negative							p.N879D; MAF 50%					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
13-00202	1086	Male	Male	White	3	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	752	Dead-Other	FALSE	FALSE		-1	NA	73	32	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	NA	atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes,	NA	22.79	FALSE	FALSE		negative	positive														negative																																																								
13-00204	1088	Female	Female	White	1	n	65	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)	1	Induction	Unknown	Standard Chemotherapy	5	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	3	Dead	7	Dead-Other	FALSE	FALSE		0	0	72	57	0	NA	36	1	8	NA	24	33	2.9	0.6	M3	20.7	6.8	46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3]	398	90.2	Unusual t(15;17), with the fusion signal on the derivative chromosome 15	10	partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive	5.6	9.8	FALSE	FALSE		positive	negative														negative							negative					negative			negative	negative			negative			negative			negative							negative									negative		p.K66N; MAF 40%									negative			rs16754; MAF 50%	
13-00218	1094	Female	Female	White	1	n	41	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	41	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	1397	Alive	FALSE	FALSE		0	0	80	52	0	NA	44	3	1	NA	48	30	2.6	0.35	NOS	23.6	8.2	46,XX,t(8;21)(q22;q22)[12]/45,idem,-X[6]/46,XX[2]	389	94.4	RUNX1T1 / RUNX1 t(8;21): 87% of cells had a dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	9	CD13, dim CD33, CD34, CD38,     CD58, dim/partial CD64, CD117, dim CD123, HLA-DR, and MPO	6.8	5.8	FALSE	FALSE		negative	negative														negative							negative					negative			negative				negative			negative			negative		negative					negative																			p.N752fs*60; MAF 40% 	negative			negative	
13-00226	928	Female	Female	White	1	n	83	FALSE	FALSE	TRUE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	83	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	ATRA, Arsenic Trioxide|Idarubicin	2	Induction|Symptom Control	Complete Response	Standard Chemotherapy	253	Standard Chemotherapy	Idarubicin	Symptom Control	0	Alive	1429	Alive	FALSE	FALSE		0	0	75	2.1	0	NA	17	2	23	NA	14	9	3.7	0.7	M3	23.4	8.1	46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]	367	86.2	16q deletion	NA	CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive	6.8	6	FALSE	FALSE		negative	negative														negative							negative					D835H; MAF Unlisted			negative				p.V617F; MAF 90%			negative			negative		negative					negative									negative											negative				
13-00232	1101	Female	Female	White	1	n	22	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	22	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	1001	Alive	FALSE	FALSE		0	0	55	29	2	NA	7	33	24	NA	67	16	2.2	0.64	M4	24	8	46,XX[24]	373	95.2	normal	34	CD7, CD13, CD33, CD34, CD38, CD56, partial CD64,     CD117,        dim CD123, HLA-DR and MPO+	6.5	29.4	FALSE	FALSE		negative	negative														p.D107fs*; MAF ~50%							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			rs16754; MAF ~50%	
13-00236	1103	Female	Female	White	1	n	2	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	5	0	Residual Disease|Post-Transplant|Post-Chemotherapy	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1 (Bortezomib, Cytarabine, Etoposide, Idarubicin)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	153	Bone Marrow Transplant	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	Alive	1993	Alive	FALSE	FALSE		-10	0			2	NA	67	6	25	NA	20	34	3.3	0.49	M5	27.8	9.4	46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8]	NA	96.9		106		6.9	1.5	FALSE	FALSE		negative	negative																																																																						
13-00237	1104	Male	Male	White	1	n	72	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	Dead	176	Dead-Unknown	TRUE	TRUE	13-00255	0	0		<5	2	NA	8	70	20	NA	66	26	3.6	0.69	M4	25.9	8.7	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	219	92.2	12p deletion	23	CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive	7.2	22.8	TRUE	TRUE	13-00255	negative	negative		p.A619fs*14; MAF 50%												negative							negative			p.R583*; MAF 95%		D835			negative	negative			negative			negative			negative		negative					negative						p.D61H; MAF 15%			p.P345?S356del; MAF 25%										p.Y867H; MAF 50%	negative			negative	
13-00242	1093	Male	Male	Black	2	n	62	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	15	Post-Chemotherapy	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction|Re-induction	Complete Response i	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	5	Dead	254	Dead-Disease	TRUE	FALSE	13-00217	0	0	0.5	0	0	NA	100	0	0	NA	8	16	3	0.69	NOS	25	9	46,XY,add(2)(p23),t(3;22)(p21;q13),add(3)(q26),del(6)(q13q27),add(9)(q22),add(9)(q13),add(10)(p11.2),del(14)	224	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[198],(5'MLL,3'MLL)x2(5'MLLcon3'MLLx2)[199]	22	CD2(-), CD7(partial and variably +), CD13(+), CD14(-), CD15(-), CD33(bright +), CD34(+), CD36(variably +), CD38(bright +), CD45(+), CD64(-), CD117(variably +), HLA-DR(partial +).	6	0.6	TRUE	FALSE	13-00217	negative	negative																																																																		positive				
13-00245	1108	Male	Male	Asian	1	n	8	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	8	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Intensification	Complete Response	Standard Chemotherapy	11	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	62	Alive	857	Alive	FALSE	FALSE		0	0	30	17	0	NA	33	17	20	NA		NA	NA	0.53	M2	29.3	10.3	46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]	NA	93.5	t(8;21)	109	dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO	NA	19.5	FALSE	FALSE		negative	negative																										negative																																												
13-00247	1105	Female	Female	White	1	n	53	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	53	4	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	109	Alive	199	Alive	TRUE	FALSE	13-00239	-4	NA		22	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,t(8;21)(q21.3;q22)[18]/46,XX[2]	588	NA	RUNX1T1/RUNX1 fusion	NA		NA	5.1	TRUE	FALSE	13-00239	negative	negative														negative							negative					negative			negative						p.V1113fs*; MAF 30%	p.D820G; MAF 4%			negative							negative																				negative				
13-00250	1111	Male	Male	White	1	n	78	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	356	Dead-Disease	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
13-00253	1113	Female	Female	White	1	n	42	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	42	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	273	Dead-Disease	FALSE	FALSE		0	0	70	9	0	NA	43	6	38	NA	36	28	3.5	0.81	M7	34.8	12		762	85.2	Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.	13	CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive	6.8	7.9	FALSE	FALSE		negative	negative														p.V119?M120insV; MAF 30% 							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
13-00255	1104	Male	Male	White	1	n	72	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	8	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	Dead	176	Dead-Unknown	TRUE	TRUE	13-00237	-8	0		5	1	NA	3	77	8	NA	57	27	3.5	0.61	M4	26.3	8.7	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	324	92.8	12p deletion	19		7.2	56.5	FALSE	FALSE		negative	negative		p.A619fs*14; MAF 50%												negative							negative			p.R583*; MAF 95%		D835			negative	negative			negative			negative			negative		negative					negative						p.D61H; MAF 15%			 p.P345?S356del; MAF 25%										p.Y867H; MAF 50%	negative			negative	
13-00260	1117	Male	Male	White	1	n	14	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	1	Induction	Complete Response	Standard Chemotherapy	133	Standard Chemotherapy	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	Induction	133	Alive	1011	Alive	FALSE	FALSE		0	0	62	64	0	NA	28	1	7	NA	15	9	4.1	0.58	M2	18.5	6.3	45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]	486	105.8	RUNX1T1/ RUNX1 fusion and t(8;21),	63	CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive	7.9	13.3	FALSE	FALSE		negative	negative														negative							negative					negative			negative				negative			negative			negative							negative																				p.S366A; MAF 50% 				
13-00262	1118	Female	Female	White	2	n	64	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	21	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	124	Dead	455	Dead-Disease	FALSE	FALSE		-1	NA	81	94	NA	NA	6	NA	NA	NA	87	47	2.8	0.53		27.2	9.7	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	743	NA	nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	11	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +).	5.2	26	FALSE	FALSE		positive	positive																																																																						
13-00266	1119	Male	Male	White	1	n	77	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Dead	129	Dead-Disease	FALSE	FALSE		1	NA		47	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,-7,+13,i(17)(q10)[20]	NA	NA	Monosomy 7	NA	CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive	NA	25.3	FALSE	FALSE		negative	negative		p.W583*; MAF 50%												negative							negative		p.N384*; MAF 40%		p.T196A; MAF 50%	negative			negative				negative			negative			negative							negative														p.P95H; MAF 70%						negative				
13-00268	1121	Male	Male	White	1	n	56	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) 	Salvage	6	Dead	113	Dead-Disease	FALSE	FALSE		0	0		5	0	NA	0	10	84	NA	22	24	3.4	0.94	NOS	27.8	9.1		808	90.4		136		5.8	40.8	FALSE	FALSE		negative	negative																																																																						
13-00270	1123	Female	Female	White	1	n	18	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	18	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	Alive	151	Alive	FALSE	FALSE		0	0	50	22	0	NA	24	49	20	NA	13	15	3.6	0.77	M4	21	7.4	46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]	415	97.8	CBFB rearrangement and inv(16)	23	Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive	7.6	8.8	FALSE	FALSE		negative	negative														negative												Negative FLT3-D835 was observed in GeneTrails;negative			negative				negative			negative			p.G13D; MAF 10%							p.G13D; MAF 30%																				negative				
13-00273	1126	Female	Male	White	1	n	51	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	3	Dead	221	Dead-Disease	FALSE	FALSE		-2	2			0	NA	14	13	68	NA	31	20	3.1	0.95		24.7	8.2	46,XX[20]	NA	86.2	Normal	99		6.8	21.7	FALSE	FALSE		positive	positive														negative							p.R882H; MAF 50%					negative			negative				negative			negative			negative							negative																							rs16754; no MAF available	
13-00281	1131	Female	Female	White	4	n	79	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	1	Salvage			NA	Standard Chemotherapy	Azacitidine, Lenalidomide	Salvage	137	Dead	189	Dead-Disease	FALSE	FALSE		0	NA	73	56	NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46,XX,del(16)(p11.2)[3]/46,XX[2]	NA	NA		NA	CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR	NA	8.7	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	R140Q			negative			negative			negative							negative																				negative				
13-00286	1137	Male	Male	White	4	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	3	HiDAC|7+3 (Cytarabine, Idarubicin)|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	1150	Alive	FALSE	FALSE		2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[7]	NA	NA		NA		NA	NA	FALSE	FALSE		positive	positive							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
13-00294	1098	Female	Female	White	2	n	31	TRUE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	36	1020	Relapse|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	n	y	y	n	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	9	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	24	Dead	2661	Dead-Unknown	FALSE	FALSE		-4	2	18	0	0	NA	14	8	68	NA		NA	NA	NA		29.6	10.2	46,XX	NA	NA	nuc ish(DXZ1x2)[200]	91		NA	1.3	FALSE	FALSE		negative	negative																										negative																																												
13-00331	1153	Female	Female	White	4	n	35	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	37	1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	Dead	761	Dead-Treatment	FALSE	FALSE		0	NA	92	97	NA	NA	NA	NA	NA	NA		NA	NA	NA	M5	NA	NA	46,XX[5]	NA	NA		NA	CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR	NA	140	FALSE	FALSE		negative	positive							negative							negative							negative					D835			positive	negative						negative			negative							negative																				negative				
13-00338	1157	Female	Female	White	4	n	53	TRUE	FALSE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	60	0	Post-Chemotherapy|Relapse	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Gemtuzumab	Re-induction	-1	Alive	2522	Alive	TRUE	FALSE	13-00337	0	NA	82	25	NA	NA	NA	19	NA	NA		NA	NA	NA	M4eo	NA	NA	47,XX,t(16;16)(p13;q22),+22[20]	NA	NA	Positive	NA		NA	4.3	TRUE	FALSE	13-00337	negative	negative							negative							negative							negative					D835			negative	negative						negative			negative							negative																				negative				
13-00342	1159	Male	Male	Asian	4	y	31	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	32	0	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI 	6	Allogeneic - Sibling|Consolidation|Salvage|Unknown|Induction|Re-induction	Complete Response	Standard Chemotherapy	8	Supportive/Palliative Care	Decitabine	Salvage	-1	Alive	902	Alive	FALSE	FALSE		0	NA	28	23	NA	NA	NA	6	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		NA	CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)	NA	4	FALSE	FALSE		negative	negative							negative							Double mutation							negative					negative			negative	negative						negative			negative							negative																				negative				
13-00346	1162	Female	Female	White	2	n	46	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	47	0	Post-Chemotherapy|Post-Transplant|Residual Relapse	Peripheral Blood	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	7	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit)	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response i	Standard Chemotherapy	9	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	-1	Dead	479	Dead-Disease	TRUE	FALSE	13-00347	0	0	41	42	0	NA	40	0	10	NA	33	38	3.6	NA		23	7.9	46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4]	NA	NA	Normal	11	CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +)	6.7	0.8	TRUE	FALSE	13-00347	positive	negative																										D835																																												
13-00353	1161	Female	Female	Asian	1	n	30	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	30	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	31	Dead	270	Dead-Disease	FALSE	FALSE		0	0	64	65	0	NA	28.9	25.4	19.3	1.7	48	33	3.6	0.64		21.8	7.5	46,XX,t(9;11)(p11;q34)[19]/46,XX[1]	NA	111.8	Disruption of MLL signal and t(9;11)	29	CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive	6.1	29.25	FALSE	FALSE		negative	negative														negative			p.T910S; MAF 40%				negative					p.D835; MAF 35%			negative				negative			negative			negative		negative					negative																				negative			negative	
13-00354	1163	Male	Male	Asian	4	n	73	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	73	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Stanford Protocol 9153 (TLI, ATG)	Allogeneic - Mismatched Unrelated Donor	-1	Dead	330	Dead-Other	FALSE	FALSE		0	NA	84	71	NA	NA	NA	6	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		NA	" CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO"	NA	16.2	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
13-00365	1171	Female	Female	White	4	n	72	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine, Lenalidomide|Temozolomide, Vorinostat	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Temozolomide, Vorinostat	Re-induction	-1	Dead	420	Dead-Unknown	TRUE	FALSE	13-00366	-13	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]	NA	NA		NA		NA	NA	TRUE	FALSE	13-00366	positive	positive							negative							negative							negative					negative			negative	negative						negative			negative							negative																				positive				
13-00383	1181	Female	Female	White	4	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor			NA	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	9	Dead	719	Dead-Disease	FALSE	FALSE		0	NA	34	8	NA	NA	NA	15	NA	NA		NA	NA	NA		NA	NA	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	NA	NA		NA	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	NA	4.2	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
13-00384	1181	Female	Female	White	4	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor			NA	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	9	Dead	719	Dead-Disease	TRUE	TRUE	13-00383	0	NA	34	8	NA	NA	NA	15	NA	NA		NA	NA	NA		NA	NA	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	NA	NA		NA	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	NA	4.2	TRUE	TRUE	13-00383	negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
13-00393	1184	Male	Male	HispNative	2	n	52	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	52	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	15	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	Dead	1237	Dead-Disease	FALSE	FALSE		0	NA	21	5	NA	NA	68	4	23	NA	17	23	3.6	0.89		28.3	8.5	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	183	NA	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	22	partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO	7.5	3.42	FALSE	FALSE		negative	negative																																																																						
13-00396	1187	Male	Male	White	1	n	63	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Consolidation	-1	Dead	228	Dead-Treatment	FALSE	FALSE		-2	1.8	51	3.5	0.9	NA	41.2	37.7	11.4	0	20	20	3.2	1.37	M4	33.7	11	42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]	NA	92.6	Extra MLL signal	24	CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.	7.1	5.23	FALSE	FALSE		negative	negative														negative												negative			negative				negative			negative			negative		negative					negative																				p.R273S; MAF 40%			negative	
13-00406	1190	Male	Male	White	1	n	62	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	62	0	Initial Acute Leukemia Diagnosis	Leukapheresis	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	2	Dead-Disease	FALSE	FALSE		0	0	95	66.3	0	NA	9.5	1.9	4.8	0.2	93	104	3.2	1.85	M5	26.2	8.5	46,XY[20]	2941	104.8	Normal	92	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	250.23	TRUE	TRUE	13-00409	positive	negative														negative							p. R882C; MAF 50%					negative			negative				negative			negative			negative							negative									Intron 5, 3' splice site mutation; MAF 50%											negative				
13-00409	1190	Male	Male	White	1	n	62	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	IntermediateOrAdverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	62	1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	2	Dead-Disease	TRUE	TRUE	13-00406	0	0	95	95	0	NA	9.5	1.9	4.8	0.2	93	104	3.2	1.85	M5	26.2	8.5	46,XY[20]	2941	104.8	Normal	92	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	250.23	FALSE	FALSE		positive	negative														negative							p.R882C; MAF 50%					negative			negative				negative			negative			negative							negative									Intron 5, 3' splice site mutation; MAF 50%											negative				
13-00417	1193	Male	Male	White	4	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	Dead	127	Dead-Unknown	FALSE	FALSE		0	NA	84	44	NA	NA	NA	3	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		NA	CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38	NA	2	FALSE	FALSE		positive	positive							negative							negative												negative			negative	negative						negative			negative							negative																				negative				
13-00420	1194	Male	Male	White	2	n	75	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	34	Dead	383	Dead-Disease	FALSE	FALSE		-98	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]	NA	NA	nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
13-00424	1196	Male	Male	White	4	n	77	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Lenalidomide	Induction	-1	Dead	23	Dead-Other	TRUE	FALSE	13-00423	-6	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,del(9)(q13q34)[3]/46,XY[14]	NA	NA		NA		NA	NA	TRUE	FALSE	13-00423	negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				positive				
13-00425	1197	Female	Female	White	2	n	40	FALSE	TRUE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	40	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	5	Alive	486	Alive	FALSE	FALSE		-1	NA	84	29	NA	NA	63	3	5	NA	21	23	3.7	0.65		35	12	46,XX,t(9;11)(p22;q23)[20]	613	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	34	brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR	6.5	9.1	FALSE	FALSE		negative	negative																																																																						
13-00450	1224	Female	Female	White	2	n	79	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	79	0	Post-Chemotherapy|Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	7+3 (Cytarabine, Idarubicin)|Crenolanib	2	Induction|Experimental	Complete Response	Standard Chemotherapy	4	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	14	Dead	124	Dead-Disease	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		positive	positive																																																																						
13-00454	1226	Female	Female	HispNative	2	n	31	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	31	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	95	Unknown	NA		FALSE	FALSE		0	NA		45	3	NA	25	20	7	NA		NA	NA	1.04		22	7.4	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	229	NA	nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[200],(CBFBx2)(5CBFB sep 3CBFBx1)[147/200]	30	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), MPO(+), TdT(partial +)	NA	13.63	FALSE	FALSE		negative	negative														negative												negative																																												
13-00466	1566	Male	Male	White	2	n	71	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine	Salvage	-1	Dead	973	Dead-Disease	FALSE	FALSE		0	0.5		0	2.5	NA	56.8	2.6	37.6	NA	21	27	3.9	0.93		33.4	11.2		195	NA		89		6.9	2	FALSE	FALSE		negative	negative																																																																						
13-00468	1233	Male	Male	White	1	n	61	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	126	Dead	370	Dead-Disease	FALSE	FALSE		0	NA	17	10	NA	NA	27.7	NA	39.2	NA	47	22	3.8	0.5		25.8	8.5	47~49,XY,-21,+1~4mar[cp21]/46,XY[2]	NA	86.6	Monosomy 21	40	CD13, CD33, CD34. CD45, subset CD64, CD79a, CD117,HLA-DR, and subset TdT positive).	7.6	5.5	FALSE	FALSE		negative	negative														negative				p.T618I; MAF 50%			negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			benign SNP rs16754 (R369R: no amino acid change); MAF 50%	
13-00487	1243	Female	Female	White	1	n	35	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	35	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	94	Alive	358	Alive	FALSE	FALSE		0	0	49.4	28.6	1.8	NA	19.6	37.5	7.1	0	20	17	3.1	0.88	M4	14.3	4.8	46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]	505	100.7	Trisomy 22	36	Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive.	7.8	49.4	FALSE	FALSE		negative	negative														negative			P552S; MAF 50%									negative			negative	negative			negative		K395N; MAF 50%	D816V; MAF 1%			negative		negative					G13D; MAF 6%									negative											negative			negative	
13-00493	1246	Male	Male	White	2	n	62	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Post-Chemotherapy|Residual Relapse	Peripheral Blood	y	y	y	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	Dead	568	Dead-Unknown	TRUE	FALSE	13-00494	0	0	81	59	0	NA	0	0	10	NA	34	15	4	NA		30.2	10.7	46,XY	NA	NA		17	CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).	6	1.8	TRUE	FALSE	13-00494	positive	positive												Foundation, P203S; MAF 8%			Foundation; T367fs*15; MAF 9%						Foundation, R882H; MAF 9%					Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%																																												
13-00496	1247	Female	Female	White	2	n	33	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	Alive	1480	Alive	TRUE	TRUE	13-00497	0	0	72	18	0	NA	38	26	3	NA	85	30	3.4	NA		25.9	9	47,XX,inv(16)(p13.1q22),+22	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	18	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	6.1	26.3	TRUE	TRUE	13-00497	negative	negative														negative												negative										negative																																		
13-00497	1247	Female	Female	White	2	n	33	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	Alive	1480	Alive	FALSE	FALSE		0	0	72	18	0	NA	38	26	3	NA	85	30	3.4	NA		25.9	9	47,XX,inv(16)(p13.1q22),+22	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	18	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	6.1	26.3	FALSE	FALSE		negative	negative														negative												negative										negative																																		
13-00500	1248	Male	Male	White	2	n	71	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	55	Dead	156	Dead-Unknown	FALSE	FALSE		0	0	76	58	2	NA	38	6	14	NA	27	25	3.1	NA		25	8.5	46,XY	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	93	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)	5.8	7.5	FALSE	FALSE		negative	negative														negative												negative										negative																																		
13-00513	1255	Male	Male	White	1	n	55	FALSE	TRUE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	Dead	246	Dead-Disease	FALSE	FALSE		-274	1.4	75		8.5	NA	11.4	8.5	34	0.2	62	31	3.8	1.44	M5	38.1	12.2	46,XY,t(9;11)(p22;q23)[20]	497	87.6	MLL rearrangement and t(9;11)	32		7.9	10.21	FALSE	FALSE		positive	positive																																				negative																																		
13-00515	1257	Male	Male	White	2	n	73	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	39	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	33	Dead	658	Dead-Unknown	FALSE	FALSE		0	1	32	67	2	NA	8	3	14	NA	15	30	4.1	NA		32.8	11	46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]	NA	NA	18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	90	CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-)	5.8	24.2	FALSE	FALSE		positive	negative																										negative																																												
13-00522	1261	Female	Female	White	3	n	68	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	y	y	MYELOPROLIFERATIVE NEOPLASMS	Secondary myelofibrosis	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	49	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	3	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	339	Dead-Other	FALSE	FALSE		0	NA	29	40	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]	NA	NA		NA		NA	11.36	FALSE	FALSE		negative	negative																																																																						
13-00532	1281	Male	Male	HispNative	2	n	21	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	22	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	13	HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine	4	Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	15	Dead	537	Dead-Disease	FALSE	FALSE		0	0	88	92	0	NA	8	0	0	NA	22	20	3.3	0.51		25.8	9.1		208	NA		NA		6.4	3.2	FALSE	FALSE		negative	negative																																																																						
13-00535	1355	Female	Female	White	2	n	51	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	2197	Dead	259	Dead-Disease	FALSE	FALSE		0	NA	50	24	1	NA	28	5	42	NA		NA	NA	0.71		26.1	8.7	46,XX[20]	335	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	108	CD2(-), CD4(partial dim +), CD5(-),CD7(-), CD11b(-), CD15(partial +/subset bright +), CD16(-), CD22(partial +), CD33(bright +), CD34(partial +), CD36(partial +), CD38(variably +), CD41(partial +), CD45(moderately +), CD56(-), CD61(partial +), CD64(-), CD71(+), CD117(+), HLA-DR(variably +), Gly-A(-).	NA	4.06	TRUE	FALSE	13-00582	negative	positive																										negative																																												
13-00537	757	Female	Male	White	1	n	32	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	38	488	Residual Disease|Post-Transplant	Bone Marrow Aspirate	y	y	y	n	y	y	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	9	HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	6	Consolidation|Salvage|Induction|Re-induction|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine, Sirolimus	Salvage	127	Dead	2513	Dead-Disease	TRUE	FALSE	13-00507	-18	NA	90	30	NA	NA	56.8	NA	9.9	NA	62	39	3.5	0.6		30.6	10.2	46,XX[19]/46,XY[1]	145	91.3	Normal	17	CD7, CD13, CD33, CD34, dim CD45, CD56, CD117, CD123, and HLA-DR positive.	7.1	2	TRUE	FALSE	13-00507	negative	negative														Q305?Q312del RNVETQ; MAF: 50%							negative					negative			negative	negative	p.G151R; MAF: 40%		negative			negative			negative		negative				p.G2152S; MAF 50%;p.G2152S; MAF: 50%	negative									negative											negative			negative	
13-00540	1283	Male	Male	White	3	n	55	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	55	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	Unknown	NA		FALSE	FALSE		0	NA		54	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	PML-RARA+ 0.70743	NA	Large population of atypical CD117 positive, bright myeloperoxidase positive, CD34 negative, HLA-DR negative immature myeloid cells, representing approximately 90% of the leukocytes.	NA	1.04	FALSE	FALSE		negative	negative																																																																						
13-00544	1285	Male	Male	White	2	n	68	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	68	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	5	Dead	29	Dead-Disease	FALSE	FALSE		0	NA		41	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	9.5	FALSE	FALSE		negative	negative																																																																						
13-00545	1286	Male	Male	White	4	n	71	FALSE	FALSE	FALSE	GATA2-MECOM	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	555	Dead-Disease	TRUE	TRUE	13-00546	2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XY,-7,t(3;3)[20]	NA	NA		NA		NA	NA	TRUE	TRUE	13-00546	positive	negative							negative							negative							negative					D835			negative	negative						negative			negative							negative																				negative				
13-00546	1286	Male	Male	White	4	n	71	FALSE	FALSE	FALSE	GATA2-MECOM	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	555	Dead-Disease	FALSE	FALSE		2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XY,-7,t(3;3)[20]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative							negative							negative							negative					D835			negative	negative						negative			negative							negative																				negative				
13-00551	1314	Male	Male	Black	2	n	51	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	51	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	1487	Alive	FALSE	FALSE		-3	NA		1.0	NA	NA	17	35	23	NA	16	14	3.7	0.8		25	8.7	46,XY[20]	NA	83.8		16		6.8	3.2	FALSE	FALSE		negative	negative														negative												negative																																												
13-00552	1315	Male	Male	White	3	n	74	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	75	0	Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	Dead	415	Dead-Disease	FALSE	FALSE		-7	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]	NA	NA	normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22	NA		NA	NA	FALSE	FALSE		positive	negative																																																																						
13-00554	1339	Male	Male	White	1	n	64	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	584	Dead-Disease	FALSE	FALSE		0	0.8	30		1.5	0	71.5	1.5	24.7	0	21	17	3.6	0.77		28.1	9.1	46,XY[21]	180	117.1	Loss of ERG1 signal	47	CD13, CD33, CD34, dim CD38, CD117, and HLA-DR positive (10/31/13).	7.1	1.3	FALSE	FALSE		negative	negative														negative				p. H599N; MAF 50%			negative					negative			negative				negative			negative			negative		negative					negative									negative											C238R; MAF 5% (not confirmed by Sanger seq)			negative	
13-00557	1233	Male	Male	White	1	n	61	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	43	Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	126	Dead	370	Dead-Disease	FALSE	FALSE		0	NA	17	2	NA	NA	32.2	NA	34.2	NA	34	15	3.7	0.3		32.4	10.4	46~49,XY,-21,+1~4mar[cp20]	NA	87.2	Monosomy 21	21	CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, HLA-DR and partial TdT positive; aberrant monocytic population: CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive.	7	7.2	FALSE	FALSE		negative	negative																																																																						
13-00558	1341	Male	Male	White	1	n	61	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Dead	213	Dead-Treatment	FALSE	FALSE		0	0	25	20	13	NA	6	12	55	0.9	45	34	3.1	0.8		31.1	9.8	42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,	NA	88.9	Monosomy 5	243	CD13, CD33, CD34, CD117, and MPO+.	6.4	96.64	FALSE	FALSE		negative	negative																																																																						
13-00563	1343	Female	Female	White	4	n	64	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	249	Bone Marrow Transplant	Fludarabine, BCNU, Melphalan	Allogeneic - Sibling	-1	Alive	1021	Alive	TRUE	FALSE	13-00562	-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]	NA	NA		NA		NA	NA	TRUE	FALSE	13-00562	positive	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
13-00572	1348	Male	Male	HispNative	3	n	39	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	39	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	7	Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	Dead	169	Dead-Disease	FALSE	FALSE		0	NA	59.3	28	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]	NA	NA	Normal	NA	Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.	NA	1.7	FALSE	FALSE		negative	negative																																																																						
13-00573	1349	Male	Male	White	1	n	85	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	86	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	169	Dead	333	Dead-Disease	FALSE	FALSE		0	0			0	NA	17	44	39	0	15	9	3.5	0.9		25.7	8.2		175	88		18		6.9	13.22	FALSE	FALSE		negative	negative																																																																						
13-00578	1353	Female	Female	White	2	n	30	FALSE	FALSE	FALSE	DEK-NUP214	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	31	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	52	Dead	568	Dead-Disease	TRUE	TRUE	13-00581	3	NA		47	NA	NA	NA	NA	NA	NA	49	31	4.2	0.85		NA	NA	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	329	NA		10		6.3	20.2	TRUE	TRUE	13-00581	positive	negative																										D835																																												
13-00581	1353	Female	Female	White	2	n	30	FALSE	FALSE	FALSE	DEK-NUP214	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	31	3	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	52	Dead	568	Dead-Disease	FALSE	FALSE		0	NA	65	52	0	NA	10	0	28	NA		26	3.9	0.87		22.4	7.9	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	NA	90.9		20	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).	NA	43.3	FALSE	FALSE		positive																											D835																																												
13-00593	1257	Male	Male	White	2	n	73	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	37	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	39	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	33	Dead	658	Dead-Unknown	FALSE	FALSE		0	6	66	40	2	NA	19	20	8	NA	22	36	4.3	NA		34.7	11.6	46,XY	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	67	CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +)	6.2	13.9	FALSE	FALSE		positive	negative																																																																						
13-00600	1368	Male	Male	White	1	n	53	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	y	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	53	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	45	Alive	242	Alive	FALSE	FALSE		0	0	30	35	1.2	NA	16	7.4	30.7	0	45	31	3.2	0.94		25.4	8.6		389	99.6	Monosomy 7	24	CD13, partial CD33, CD34, partial CD56, partial CD64, CD117, partial CD123, HLA-DR and MPO-positive	6.5	3.28	FALSE	FALSE		negative	negative														negative												negative			negative				negative			negative			negative		negative					negative																				negative			negative	
13-00601	1369	Male	Male	White	2	n	NA	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	Intermediate		MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	NA	4	Unknown	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	60	Standard Chemotherapy	Decitabine	Induction	60	Dead	116	Dead-Unknown	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA		NA	NA	FALSE	FALSE		negative	negative																																																							negative															
13-00602	1370	Male	Male	White	2	y	63	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1433	Alive	FALSE	FALSE		-2	NA		85	0	NA	9	3	3	NA	16	27	2.9	0.75		NA	NA	46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].	682	NA	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]	NA		6.6	33	FALSE	FALSE		negative	negative																										negative																																												
13-00614	1374	Male	Male	White	3	n	67	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	67	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	753	Dead-Disease	TRUE	FALSE	13-00613	0	NA	20		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	normal	NA	Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45.	NA	NA	TRUE	FALSE	13-00613	negative	negative														negative																																																								
13-00615	1375	Female	Male	HispNative	4	n	62	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Induction	-1	Alive	239	Alive	FALSE	FALSE		0	NA	52	57	NA	NA	NA	6	NA	NA		NA	NA	NA		NA	NA	46,XY,t(8;21)(q22;q22)[14]	NA	NA		NA	CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO	NA	12.9	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative									negative							positive																				negative				
13-00619	1373	Female	Female	White	2	n	47	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	2	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Experimental			NA	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	Dead	934	Dead-Unknown	TRUE	FALSE	13-00612	0	0		72	0	NA	28	0	0	NA	10	17	2.8	0.56		14.5	5.3		291	NA		10		5.1	1.2	FALSE	FALSE		negative	positive																																																																						
13-00622	1377	Female	Female	White	4	n	48	FALSE	FALSE	FALSE	GATA2-MECOM	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	48	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	5	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Re-induction	-1	Dead	123	Dead-Other	FALSE	FALSE		0	NA	36	0	NA	NA	NA	15	NA	NA		NA	NA	NA	M1	NA	NA	45,XX,?add(2)(q35~37),inv(3)(q21q26),-7[4]/46,XX[1]	NA	NA		NA	CD38, CD7, CD13, partial CD33, partial CD11c, dim CD5, dim CD19, CD4, HLA-DR, partial CD15, and partial CD117	NA	0.3	FALSE	FALSE		negative	negative																																																																						
13-00625	1378	Male	Male	White	4	n	21	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	21	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI 	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	177	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI 	Allogeneic - Sibling	-1	Alive	605	Alive	FALSE	FALSE		0	NA	66	1	NA	NA	NA	17	NA	NA		NA	NA	NA	M1	NA	NA	45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]	NA	NA		NA	CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT	NA	2.1	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							positive																				negative				
13-00650	2737	Male	Male	White	7	n	NA	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	20	2	Unknown	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	positive																																																																						
13-00654	1394	Male	Male	White	3	n	62	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) 	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	-1	Dead	979	Dead-Disease	FALSE	FALSE		-1	NA	93	58	NA	NA	NA	NA	NA	NA		NA	NA	NA	M5a	NA	NA	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	NA	NA	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present	NA	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	NA	14.66	FALSE	FALSE		negative	negative														negative																						negative																																		
13-00655	1394	Male	Male	White	3	n	62	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	62	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) 	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	-1	Dead	979	Dead-Disease	TRUE	TRUE	13-00654	-1	NA	93	58	NA	NA	NA	NA	NA	NA		NA	NA	NA	M5a	NA	NA	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	NA	NA	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present	NA	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	NA	14.66	TRUE	TRUE	13-00654	negative	negative														negative																						negative																																		
13-00658	1396	Male	Male	White	1	n	60	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	114	Alive	201	Alive	FALSE	FALSE		0	0.8	30	42.4	4.5	NA	19.7	8.3	15.9	0.3	49	23	3.5	1.22		30.6	10.6	46,XY[21]	536	95.6	Normal	141	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	7.2	11.93	FALSE	FALSE		negative	positive														p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%							negative					p.I836delI; MAF 25%			negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
13-00659	1397	Male	Male	White	1	n	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	5	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Dead	386	Dead-Unknown	FALSE	FALSE		0	0	54	54	0	NA	14	59.6	5.3	0	463	477	2.7	1.14	M4	19.3	6.6	47,XY,+8[16]/46,XY[4]	NA	93.7	Trisomy 8	47	partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive	5.7	16.66	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					p.G12R, MAF 50%																				negative			negative	
13-00660	1398	Male	Male	Black	1	n	72	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Alive	60	Alive	FALSE	FALSE		0	2.6	41		0	NA	15.3	9.3	28.8	0.6	36	31	3.8	1.66		23.3	7.2	46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]	398	82	Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.	42	CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.	6.6	12.44	FALSE	FALSE		negative	negative										p.L370del; MAF 63%				negative							negative					negative			negative	negative			p.V617F; MAF 43%			negative			negative							negative									p.R166G; MAF 22%											negative		p.Q157R; MAF 40%		
14-00001	1400	Male	Male	HispNative	1	n	56	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	n	y	n	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	111	Alive	217	Alive	FALSE	FALSE		0	0.8	95	95	0	NA	25.6	0	0	0.7	27	16	3.4	0.97		11.1	3.7	46,XY[20]	314	95.7	Normal	20	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	7.1	13.26	TRUE	TRUE	14-00004	positive	positive														negative							negative					negative			negative	p.R140Q; MAF 50%			negative			negative			negative		negative					negative									negative											negative			negative	
14-00004	1400	Male	Male	HispNative	1	n	56	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	111	Alive	217	Alive	TRUE	TRUE	14-00001	0	0.8	95	95	0	NA	25.6	0	0	0.7	27	16	3.4	0.97		11.1	3.7	46,XY[20]	314	95.7	Normal	20	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	7.1	13.26	TRUE	TRUE	14-00001	positive	positive														negative							negative					negative			negative	p.R140Q; MAF: 50%			negative			negative			negative		negative					negative									negative											negative			negative	
14-00012	1406	Male	Male	White	4	n	72	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	33	Dead-Disease	TRUE	FALSE	14-00013	0	NA	94	71	NA	NA	NA	0	NA	NA		NA	NA	NA	M5	NA	NA	48,XYY,+8[21]	NA	NA		NA	CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15	NA	24.2	TRUE	FALSE	14-00013	negative	positive							negative							negative							negative					D835			negative	negative						negative			negative							negative																				negative				
14-00015	1161	Female	Female	Asian	1	n	30	TRUE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	31	147	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	31	Dead	270	Dead-Disease	FALSE	FALSE		0	0	75	35	0	NA	9.9	9.9	37.2	0.8	37	39	3.1	0.56		22.1	7.7	46,XX,t(9;11)(p22;q23)[20]/46,XX[1]	NA	89.8	MLL disruption and t(9;11)	39	dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive	6	43.72	FALSE	FALSE		negative	negative														negative												MAF 70%							negative			negative																																		
14-00021	1408	Male	Male	White	4	n	74	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924	4	Salvage|Induction|Re-induction|Symptom Control	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	-1	Dead	357	Dead-Disease	TRUE	FALSE	14-00022	-49	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00023	1409	Female	Female	White	1	n	74	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	Alive	28	Alive	FALSE	FALSE		0	0.9			0	NA	11.4	44.7	35.1	7.1	17	28	2.6	0.79		28.1	9.4		645	98.3		71		6.2	35.91	FALSE	FALSE		negative	positive																																																				p.E76Q; MAF 40%																		
14-00026	1410	Male	Male	HispNative	2	n	38	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	39	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage|Unknown|Induction|Maintenance	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	6	Unknown	NA		FALSE	FALSE		0	NA		16	NA	NA	20	10	54	NA	152	49	4.3	0.77		30.5	10.6		340	NA		215		7	4.01	FALSE	FALSE		negative	negative																																																																						
14-00034	1431	Male	Male	White	1	y	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	906	Alive	FALSE	FALSE		0	0	50	25	0	NA	45.3	19.6	9.3	6	27	20	3.7	1.01		30.6	10.1	46,XY[20]	NA	98.4	Normal	15	CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO	6.3	3.85	FALSE	FALSE		negative	negative														c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%												negative			negative	negative			negative			negative					negative														negative														negative	
14-00041	1434	Female	Female	White	4	n	71	FALSE	TRUE	FALSE	GATA2-MECOM	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	AG-221	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	AG-221	Hypomethylating/Low Dose Cytarabine	-1	Alive	952	Alive	TRUE	FALSE	14-00042	0	NA	22	8	NA	NA	NA	10	NA	NA		NA	NA	NA	M4	NA	NA	46,XX,inv(3)?(q21q25)[21]	NA	NA		NA	CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR	NA	2.6	TRUE	FALSE	14-00042	negative	negative							negative							negative							negative					negative			negative	positive						negative			negative							negative																				negative				
14-00044	1153	Female	Female	White	4	n	35	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	37	160	Residual Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	Dead	761	Dead-Treatment	TRUE	TRUE	13-00331	-159	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[5]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	positive																																																																						
14-00045	1435	Female	Female	HispNative	2	n	47	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	48	0	Post-Chemotherapy|Post-Transplant|Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	582	Dead-Unknown	FALSE	FALSE		0	0	62	66	0	NA	7	0	13	NA	24	40	3.4	NA		35.5	12.1	46,XX	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	29	CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)	5.8	58.5	FALSE	FALSE		positive	negative														negative												negative			negative	negative																																								
14-00052	1438	Male	Male	White	4	n	71	FALSE	TRUE	FALSE	GATA2-MECOM	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	23	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	262	Dead-Unknown	FALSE	FALSE		-14	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XY,inv(3)(q21q26),-7[20]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00053	1438	Male	Male	White	4	n	71	FALSE	TRUE	FALSE	GATA2-MECOM	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	23	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	262	Dead-Unknown	TRUE	TRUE	14-00052	-14	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XY,inv(3)(q21q26),-7[20]	NA	NA		NA		NA	NA	TRUE	TRUE	14-00052	negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00060	1441	Male	Male	White	1	n	68	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	Adverse		MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	68	0	Unknown	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	299	Dead-Unknown	FALSE	FALSE		-13	0		15	1.7	NA	38.7	3.4	30.3	0	27	23	3	1.18		21	7	45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]	1138	88.6		26	CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive	5.7	2.42	FALSE	FALSE		negative	negative																																																																						
14-00061	202	Male	Male	White	1	n	68	TRUE	FALSE	FALSE	None	FALSE	FALSE	y	Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	72	1207	Relapse	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine	3	Consolidation|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	9	Dead	1238	Dead-Disease	FALSE	FALSE		-2	0			0	NA	14.9	0.8	2.5	0		NA	NA	NA		22.7	7.6	47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]	556	93.8	Missing ABL and ASS signal	32		NA	47.2	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									p.R162S; MAF 50%					p.P95R; MAF 44%						negative			negative	
14-00063	1443	Female	Female	White	3	n	80	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	80	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Unknown	1	Bevacizumab	1	Unknown			NA	Unknown	Bevacizumab	Unknown	-1	Dead	10	Dead-Disease	FALSE	FALSE		-4	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00064	1444	Male	Male	White	2	n	58	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	59	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	8	E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	357	Dead-Disease	FALSE	FALSE		0	1	10	6	0	NA	32.7	12.6	53.7	NA	45	19	3.7	0.69		26.8	9.4	46,XY[20]	88	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	75	CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	5.8	1.6	FALSE	FALSE		negative	negative														negative												negative			negative	negative																																								
14-00066	1446	Male	Male	White	1	n	51	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	51	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|Azacitidine	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	567	Alive	FALSE	FALSE		0	0.9	10		3.5	0.4	54.5	3	37.7	0	83	52	3.8	1.12		32.8	11	46,XY,del(20)(q12)[14]/46,XY[6]	284	100.9	20q deletion	99	The analysis shows CD34+ blasts comprise approximately 4.2% of total CD45+ events and show variable expression of CD13, CD33, CD117, and dim partial CD123.  Please see below for antibodies tested.  B-cells (2% of lymphocyte gate) show polytypic surface light chain expression.	8.2	2.31	FALSE	FALSE		negative	negative					p.V797fs*19;MAF 10									negative												negative			negative				negative			negative			negative							negative																				negative		p.S34F, MAF 34		
14-00067	1448	Female	Female	White	2	n	62	FALSE	FALSE	FALSE	None	TRUE	FALSE	y	Breast Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	Adverse		MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	62	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Allogeneic - Mismatched Unrelated Donor	Refractory	Standard Chemotherapy	61	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	689	Dead-Unknown	FALSE	FALSE		0	NA	12	1	NA	NA	NA	NA	NA	NA	80	54	4.3	NA		24.7	8.3	44~45,XX,add(4)(p16),der(5)t(5;12)(q13;q14),-7,-12,del(17)(p11.2p13),+1~3mar[cp14]/45,idem,dup(11)(q23q14)[1]/44,idem,add (1)(p36.3)[cp3]/46,XX[2]	NA	NA	nuc ish(D5S721x2,D5S23x2,EGR1x1)[149/200],(D7Z1,D7S522)x1[155/200],(D8Z2,D20S108)x2[200], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	91	CD2(-), CD4(variably +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+), TdT(-), MPO(-)	7.9	5.9	FALSE	FALSE		negative	negative														negative												negative																																												
14-00078	1450	Male	Male	White	1	n	17	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	17	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	74	Standard Chemotherapy	Clofarabine, Cyclophosphamide, Etoposide	Re-induction	5	Dead	713	Dead-Disease	FALSE	FALSE		0	0			0	NA	48.5	0.6	1.2	1.6	18	11	3.5	0.7		25.6	9.1		NA	87.4	Normal	25		6.9	4.34	FALSE	FALSE		negative	negative														negative							negative					negative			negative				negative			negative	PTD		negative							negative																				negative			MAF A382fs*6; 40%	
14-00081	1453	Female	Female	White	1	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine, Lenalidomide	Re-induction	28	Unknown	NA		FALSE	FALSE		0	0	46.0	49.1	0	NA	20.5	8	17	0.9	32	39	3.3	0.73	M2	20.7	6.4	42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,	685	79	5q deletion	11	partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.	6.6	12.87	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative								V186D			V173M; MAF 80%			negative	
14-00083	1989	Male	Male	White	4	n	46	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	Unknown	NA		FALSE	FALSE		-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	positive							negative							negative							positive					negative			positive	negative						negative			negative							positive																				negative				
14-00092	1461	Female	Female	White	1	n	63	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	566	Alive	FALSE	FALSE		0	1.7	13	14	0.8	NA	9.4	28.2	49.6	1.6	18	26	2.8	0.74	M4	21.2	7.3	46,XX[20]	514	101.4	Normal	57	CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive	6.1	63.75	FALSE	FALSE		negative	positive														negative			p.V319I; MAF 50%				p.T138I; MAF 50%								negative	negative									negative							p.Q61H; MAF 40%																				negative				
14-00096	1464	Male	Male	White	4	n	56	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Complete Response	Standard Chemotherapy	27	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Dead	198	Dead-Unknown	TRUE	FALSE	14-00098	0	NA	72	88	NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]	NA	NA		NA	CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).	NA	12.9	TRUE	FALSE	14-00098	positive	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00111	584	Male	Male	White	1	n	60	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	62	783	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide, Fludarabine, TBI	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	-1	Dead	1278	Dead-Disease	FALSE	FALSE		0	1.4	20		1.4	0.5	33.8	4.5	58.4	0	114	45	4.3	0.75		31.1	11.2	46,XY,del(20)(q11.2)[2]/46,XY[18]	177	99	20/200 cells (10%) were missing a signal for D20S108 (20q12) 	83	CD13, CD33, CD34, CD38, CD117, and dim HLA-DR positive	7.1	2.22	FALSE	FALSE		negative	negative														negative							negative					negative			negative				V617F; MAF 1.3% (Clinical significance of this very low-level mutation is unknown.) 						negative							negative														p.P95H ; MAF 40%						negative				
14-00113	1466	Male	Male	White	3	n	41	FALSE	FALSE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	44	0	Post-Chemotherapy|Post-Transplant	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	7	Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate	5	Allogeneic - Sibling|Consolidation|Induction|Maintenance|Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Etoposide, TBI	Allogeneic - Sibling	-1	Alive	1968	Alive	TRUE	FALSE	14-00112	-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	48% PML/RARA translocation	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00125	1477	Female	Female	White	1	n	10	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	10	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	3	Induction|Intensification|Re-induction	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	29	Alive	142	Alive	FALSE	FALSE		-2	0.8			0	NA	10.5	21	7.3	0.5		NA	2.1	0.41		24.7	8.3	46,XX,inv(16)(p13q22)[17]/46,XX[3]	702	88.5	CBFB rearrangement and inverted 16	31		NA	55.35	FALSE	FALSE		negative	negative																																																																						
14-00126	1451	Male	Male	White	3	n	46	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Intermediate	Not Enough Information	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	46	14	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	0	Alive	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00127	1481	Male	Male	White	1	n	37	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	38	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Azacitidine	Maintenance	-1	Dead	207	Dead-Disease	FALSE	FALSE		-1	0		95	0	NA	0.9	0	0	0.1	17	56	1.8	0.6		23	7.9	48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl	NA	86.8	Extra chromosome 5	20	CD10, CD13, CD33, CD34, CD56 and HLA-DR positive	5.3	38.47	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					p.G13D, MAF 46%									negative											p.R273H, MAF 96%			negative	
14-00134	1484	Female	Male	White	1	n	63	TRUE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Post-Transplant|Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Allogeneic - Sibling|Salvage|Re-induction|Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	-1	Dead	168	Dead-Disease	FALSE	FALSE		0	0	30	14	0.9	NA	3.6	21.2	69	1	27	21	3.7	0.8		34.4	11.3	49,XX,+X,+8,+10[13]/46,XY[7]	245	95.3	Trisomy 8	299	dim CD13, CD33, CD34, CD117, CD123, and dim HLADR	7.3	6.23	FALSE	FALSE		positive	positive														negative							p.R882H; MAF 30%					negative			negative	negative			negative	p.V722I; MAF 50%		negative			negative							negative																				negative				
14-00135	1485	Male	Male	White	1	n	72	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Decitabine	3	Consolidation|Induction|Maintenance	Unknown	Standard Chemotherapy	38	Standard Chemotherapy	Azacitidine	Maintenance	36	Dead	252	Dead-Disease	FALSE	FALSE		0	0	55	46	0	NA	27.8	27	20.6	0	32	31	2.2	1.37	M4	20.6	6.6	43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]	435	85.8	Previous FISH results were consistent with the deleted 5q and trisomy 9	33	CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+	5.9	20.82	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											p.H193R; MAF 92%			negative	
14-00141	1488	Male	Male	Asian	4	n	85	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	85	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	Dead	357	Dead-Disease	TRUE	FALSE	14-00142	-15	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[14]	NA	NA		NA		NA	NA	TRUE	FALSE	14-00142	negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00150	1494	Male	Male	White	4	n	77	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	78	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Dead	71	Dead-Treatment	TRUE	FALSE	14-00151	0	NA	67	67	NA	NA	NA	0	NA	NA		NA	NA	NA	M4	NA	NA	45,X,-Y,del(7)(p15)[4]/46,XY[16]	NA	NA		NA	CD34, CD117, CD2,PARTIAL CD4, CD13, CD33, CD38, PARTIAL CD64, PARTIAL CD11c, HLA-DR AND DIM MPO	NA	1.6	TRUE	FALSE	14-00151	negative	negative							negative							Double positive							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00152	1495	Male	Male	White	3	n	75	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	Dead	335	Dead-Disease	FALSE	FALSE		-1	NA	64	7	NA	NA	NA	NA	NA	NA		NA	NA	NA	M4	NA	NA	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	NA	NA	Normal	NA	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	NA	4.67	FALSE	FALSE		negative	negative																																																																						
14-00171	1505	Male	Male	White	1	n	62	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Unknown|Bone Marrow Transplant	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Azacitidine|Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Unknown|Induction	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	182	Alive	431	Alive	FALSE	FALSE		0	0	39	5	0.9	NA	84.1	8.8	2.7	0	35	15	3.2	1.13		30.8	10.6	46,XY[20]	168	107.7	Normal	131	partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and TdT-positive	5.8	2.51	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									p.S100F; MAF 17%											negative			negative	
14-00173	1495	Male	Male	White	3	n	75	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	75	5	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	Dead	335	Dead-Disease	TRUE	TRUE	14-00152	-6	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	NA	NA	Normal	NA		NA	NA	TRUE	TRUE	14-00152	negative	negative																																																																						
14-00175	1508	Male	Male	White	3	n	46	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	46	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	8	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin) 	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Post-Transplant Relapse	Complete Response	Standard Chemotherapy	-1	DLI	Donor Lymphocyte Infusion	Post-Transplant Relapse	-1	Dead	1005	Dead-Disease	TRUE	FALSE	14-00176	0	NA	25.9	0.5	NA	NA	NA	NA	NA	NA		NA	NA	NA	M5	NA	NA		NA	NA	Normal	NA	Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes	NA	3.6	TRUE	FALSE	14-00176	negative	negative																																				negative																																		
14-00180	924	Male	Male	White	1	n	72	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	4	3+7 (Cytarabine, Daunorubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Lenalidomide	Salvage	-1	Dead	622	Dead-Unknown	FALSE	FALSE		0	0	45		1	1	48	5.1	44.9	2	28	25	3.9	1		22.7	7.4	46,XY[20]	166	103.7		68		6.6	0.98	FALSE	FALSE		negative	positive							negative														negative					negative			p.R132S; MAF 20%	negative			negative			negative			negative							negative														p.P95L; MAF 35%					p.Q642*, p.C1135Y; MAF 7%,7%  	negative				
14-00184	1513	Male	Male	White	1	n	5	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	5	0	Initial Acute Leukemia Diagnosis|Post-Transplant	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	9	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Alive	690	Alive	FALSE	FALSE		0	0		80	0	NA	33	0	0	0	12	32	3	0.44	M5	17.1	5.7	46,XY[25]	1072	98.8	MLL rearrangement	34	CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive	7.4	95.2	FALSE	FALSE		negative	negative																																																																						
14-00193	1519	Male	Male	White	2	n	56	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	57	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	3	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	3	Dead	421	Dead-Disease	FALSE	FALSE		0	0		54	0	NA	38	8	0	NA	15	23	3	1.3		NA	NA	46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]	409	NA	nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]	NA		6.6	8.2	FALSE	FALSE		negative	negative																																														Q61H; MAF 5%																								
14-00212	1527	Female	Female	HispNative	1	n	47	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		n	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Intermediate		MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	47	0	Residual Disease	Peripheral Blood	n	y	y	n	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	-1	Alive	FALSE	FALSE		0	NA	10	17	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	47,XX,+8,del(11)(q23)[18]	283	NA	Missing MLL signal	NA	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR	NA	31.85	FALSE	FALSE		negative	negative										p.C381Y;MAF: 58%				negative									p.V66I; MAF 50%			negative							negative			negative																													p.Q491fs*8 (4 bp insertion with frame-shift); MAF 40%					
14-00228	1532	Female	Female	White	1	n	46	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Consolidation	339	Alive	788	Alive	FALSE	FALSE		0	0	80	45	1.6	NA	9.9	14.9	10.7	0	52	28	2.5	0.77	M4	25.2	8.4	46,XX[20]	550	88.1	Normal	107	dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+	6.3	57.23	FALSE	FALSE		negative	positive														negative							p.R882C; MAF 46%					negative			negative	negative			negative			negative			negative		negative					negative						p.E76Q; MAF 40%			negative											negative			negative	
14-00231	1533	Female	Female	White	2	n	57	FALSE	FALSE	FALSE	Complex	FALSE	FALSE	y	Ovarian cancer|Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	57	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	Dead	138	Dead-Unknown	FALSE	FALSE		0	0	76	79	0	NA	9	5	4	NA	45	41	3.2	NA		28.6	9.6	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	64	CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)	6.3	19.5	FALSE	FALSE		negative	negative														negative			MYST3-CREBBP fusion; MAF unlisted									negative			negative	negative																									Y414*; MAF 16%															
14-00240	1540	Female	Female	Black	2	n	78	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	n	y	y	1	Other	1	Azacitidine	1	Supportive/Palliative Care			NA	Other	Azacitidine	Supportive/Palliative Care	-1	Dead	37	Dead-Disease	FALSE	FALSE		-17	NA		1	NA	NA	6	49	35	NA	9	15	2.9	1.09		26.1	8.3	45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]	342	NA	nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]	50		6.7	51.64	FALSE	FALSE		negative	negative														negative												negative																																												
14-00242	1536	Male	Male	White	2	n	63	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	Intermediate	Not Enough Information	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	63	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	4	Azacitidine|Decitabine|Rigosertib|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	1000	Dead-Disease	FALSE	FALSE		0	NA	22	1	3	NA	54	3	37	NA	38	29	4.3	0.95		33.3	11.7	46,XY[20]	195	104.3	nuc ish(FGFR3,IGH)x2[200],(D5S721,D5S23,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(IGH,BCL2)x2[198],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	115	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD33(+), CD34(bright +), CD33(-), CD38(dim and variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+)	7	1.9	FALSE	FALSE		negative	negative																																																																			V15A; MAF 49.0%			
14-00244	1410	Male	Male	HispNative	2	n	38	FALSE	FALSE	TRUE	GATA2-MECOM	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	39	89	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	y	n	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage|Unknown|Induction|Maintenance	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	6	Unknown	NA		FALSE	FALSE		0	0	37	26	0	NA	17	12	44	NA		NA	NA	NA		23.9	8.3	46,XY,t(3;3)(q21;q26.2),del(5)(q13q31)[cp12]/43~45,idem,-7[cp3]/46,XY[6]	NA	NA	nuc ishFGFR3,IGH)x2[200],(D5S721x2,D5S23x2,EGR1x1)[130/200],(D7Z1x1,D7S522x1)[50/200],(D8Z2,D20S108)x2[198],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],IGH,BCL2)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[198]	55	CD2(-),CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(slightly bright +),CD34(+), CD36(equivocal), CD38(partial dim +), CD45(+), CD56(variably +), CD64(-), CD117(+), HLA-DR(+/variable).	NA	4.3	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
14-00245	1528	Male	Male	White	1	n	62	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	62	19	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	5+2 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	721	Alive	TRUE	FALSE	14-00215	-19	NA	20		NA	NA	NA	NA	NA	0	27	14	2.6	0.78		30.3	10.7	46,XY,der(7)t(7;11)(q22;q13)[14]/46,XY[6]	136	81.9	Missing D7S486 signal	31	dim/partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR positive	6.6	0.49	TRUE	FALSE	14-00215	negative	negative														negative							p.R309G; MAF 31%					negative			p.R132C; MAF 33%				negative			negative	PTD		negative							negative																								
14-00253	1545	Male	Male	White	4	n	72	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	2	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	5+2 (Cytarabine, Idarubicin)	Re-induction	-1	Dead	283	Dead-Disease	TRUE	FALSE	14-00254	0	NA	78	15	NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	50,XY,+8,+9,+13,+22[17]/46,XY[3]	NA	NA		NA	CD34, CD38, PARTIAL CD56, CD13, PARTIAL CD64, HLA-DR, CD117, PARTIAL MPO, PARTIAL CD79A, AND DIM PARTIAL TDT	NA	1.2	TRUE	FALSE	14-00254	negative	negative							negative							negative							negative					negative			positive	negative						negative			negative							negative																				negative				
14-00259	1546	Female	Female	White	1	n	65	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Fludarabine	Consolidation	4	Dead	439	Dead-Disease	FALSE	FALSE		0	0.1	70		0.1	1.7	8.3	85.2	4.6	0.2	16	13	2.7	0.87	M4	30.4	9.6	46,XX[20]	506	101.7	Normal	112	CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive	7.4	58.86	FALSE	FALSE		positive	positive														negative							p.R882H; MAF 50%					negative;MAF 12%			negative				negative			negative			negative		negative					negative						p.F71L; MAF 14%			negative											negative			negative	
14-00268	1552	Male	Male	White	2	n	74	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Dead	795	Dead-Disease	FALSE	FALSE		0	0	45	25	4	NA	57	4	35	NA	21	33	2.7	0.65		24.5	8.3	46,XY,idic(7)(q11.2)[1]/47,idem,+8[9]46,XY[10]	266	99.9	nuc ish(RUNX1T1x3,RUNX1x2)[133/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	68	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (partial +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO (partial +), TdT(-)	5.6	1.5	FALSE	FALSE		negative	negative					V1445fs*8; MAF 65%									negative									A215fs*2; MAF 35%			negative																													F330fs*154+; MAF 35%													S34F; MAF 34%		
14-00270	1553	Female	Female	HispNative	2	n	40	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	Intermediate	Intermediate-I	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	39	0	Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	Unknown	NA		FALSE	FALSE		0	NA	8	2	NA	NA	27	6	65	NA	73	53	NA	0.65		22.7	7.7	46,XX[20]	249	NA	nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	13		NA	3.42	FALSE	FALSE		positive	negative																																																																						
14-00272	1554	Female	Female	HispNative	4	y	34	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	34	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	24	Standard Chemotherapy	HiDAC	Consolidation	105	Alive	833	Alive	FALSE	FALSE		-1	NA	87	87	NA	NA	NA	0	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	NA	99.3	FALSE	FALSE		negative	negative							negative							Double positive: p.Ser17Profs*99 and p.Lys313dup												negative			negative	negative						negative			positive							negative																				negative				
14-00273	1554	Female	Female	HispNative	4	n	34	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	34	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	24	Standard Chemotherapy	HiDAC	Consolidation	105	Alive	833	Alive	TRUE	TRUE	14-00272	-1	NA	87	87	NA	NA	NA	0	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	NA	99.3	TRUE	TRUE	14-00272	negative	negative							negative							Double positive: p.Ser17Profs*99 and p.Lys313dup												negative			negative	negative						negative			positive							negative																				negative				
14-00279	1558	Female	Female	HispNative	4	n	52	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	52	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	8	Alive	36	Alive	FALSE	FALSE		0	NA	91	79	NA	NA	NA	0	NA	NA		NA	NA	NA		NA	NA	46,XX,inv(16)(p13.1q22)[cp20]	NA	NA		NA	CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO	NA	28.1	FALSE	FALSE		negative	negative							negative							negative												negative			negative	negative						negative			negative							negative																				negative				
14-00289	1561	Male	Male	White	1	n	23	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	mediastinum mass	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	23	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) 	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	Dead	318	Dead-Disease	TRUE	FALSE	14-00288	0	3.2	3	20.4	2.1	NA	25.8	1.1	36.6	43.4	32	131	3	0.91		17.9	5.7	48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]	16499	95.2	Low-level tetraploidy or near-tetraploidy	24		5.6	40.76	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative			negative			negative			negative							p.G12C; MAF 86%																				p.G245S; MAF 87%				
14-00311	1569	Female	Female	White	3	n	73	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	73	1	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	17	Dead-Disease	TRUE	FALSE	14-00306	-1	NA	54.8	25	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	43,XX,-5,add(7)(q22),t(10;13)(p13;q22),-12,-17[12]/46,XX[8]	NA	NA	deletion 5q31 involving the EGR1 locus in 96/200 (48.0  percent) cells scored,  deletion 7q31 involving the D7S486 locus in 85/200 (42.5  percent) cells scored.	NA	Large population of CD34 positive myeloblasts, representing approximately 50% of the leukocytes, consistent with acute myeloid leukemia	NA	0.92	TRUE	FALSE	14-00306	negative	negative														negative																																																								
14-00329	1585	Female	Female	White	3	n	72	FALSE	TRUE	FALSE	GATA2-MECOM	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |7+3 (Cytarabine, Idarubicin) plus Sorafenib|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	4	Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Other	SGN-CD33A	Experimental	-1	Alive	323	Alive	TRUE	FALSE	14-00328	0	NA	59.3	40	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,inv(3)(q21;q26.2)[20]	NA	NA	3q21.3q26.2 (RPN1/MECOM): rearrangement present	NA	Most of the atypical cells (percentages shown) are myeloid blasts that express dim CD7, dim CD13, CD33, CD34, CD117, weak myeloperoxidase, and HLA-DR, but do not express cytoplasmic CD3, TDT,   CD14(MO2), CD42b, CD61, or CD64.	NA	44.76	FALSE	FALSE		negative	negative																																																																						
14-00331	1586	Male	Male	HispNative	2	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	Unknown	NA		TRUE	FALSE	14-00330	0	1	81	68	NA	NA	5	2	2	NA	85	52	3.1	0.85		28.8	10.1	46,XY[20]	1205	NA	nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]	20	CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +), HLA-DR(partial +), MPO(+), TdT(-).	6.2	152.75	TRUE	FALSE	14-00330	negative	positive																																																																						
14-00334	17	Female	Male	White	1	n	27	TRUE	FALSE	FALSE	None	FALSE	FALSE	y	Juvenile pilocytic astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	31	1339	Post-Transplant|Post-Chemotherapy|Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	Dead	1463	Dead-Disease	TRUE	FALSE	14-00333	0	0	93	48	0	NA	59.4	1.9	12.3	3.2	13	20	3.4	0.8		31.6	10.9	46,XX,del(6)(q13q23)[18]/46,XY[2]	527	93.5	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal	33	partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive	6.7	5.3	FALSE	FALSE		positive	positive																																																																						
14-00335	1598	Female	Female	White	4	n	79	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	79	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	2	Hydroxyurea|Azacitidine, MLN4924	2	Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	63	Standard Chemotherapy	Azacitidine, MLN4924	Induction	63	Dead	263	Dead-Unknown	FALSE	FALSE		-33	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,add(5)(q31),del(17)(p11.2)[12]/46,XX[3]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative							negative							negative												negative			negative	negative			positive			negative			negative							negative																				positive				
14-00355	1602	Male	Male	White	4	n	78	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	78	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	Azacitidine|Sorafenib|Decitabine, Midostaurin	3	Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	317	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	8	Dead	705	Dead-Disease	TRUE	FALSE	14-00356	-14	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[25]	NA	NA		NA		NA	NA	TRUE	FALSE	14-00356	positive	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00359	1604	Male	Male	White	3	n	58	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) 	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	210	Alive	761	Alive	TRUE	FALSE	14-00360	-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]	NA	NA	8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present	NA		NA	NA	FALSE	FALSE		negative	negative																																				negative																																		
14-00369	1612	Male	Male	White	4	n	72	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Dead	39	Dead-Disease	FALSE	FALSE		0	NA	78	1	NA	NA	NA	1.8	NA	NA		NA	NA	NA		NA	NA	47,XY,+8[17]/46,XY[3]	NA	NA		NA	CD38, CD13, HLA-DR, CD33 (DIM PARTIAL), CD4 (DIM), MPO (DIM PARTIAL), AND TDT	NA	2.2	FALSE	FALSE		negative	negative							negative							negative												negative			positive	negative						negative			negative							negative																				negative				
14-00376	1614	Male	Male	White	1	n	48	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	Intermediate		MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	48	0	Unknown	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine|Busulfan, Cyclophosphamide	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	116	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	714	Alive	FALSE	FALSE		0	0	17	5.3	0	NA	67.3	22.1	5.3	0	36	20	3.5	0.82		32.5	10.2	47,XY,+8[18]/46,XY[2]	155	83.5	Trisomy 8	105	CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+	7.9	0.94	FALSE	FALSE		negative	negative														negative							p.R882C; MAF 45%					negative			p.R132C; MAF 44%	negative			negative			negative			negative		negative														negative										p.P455R; MAF 45%	negative			negative	
14-00380	1616	Male	Male	White	3	n	67	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	Azacitidine|Decitabine|Clofarabine	2	Hypomethylating/Low Dose Cytarabine|Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	30	Dead-Treatment	FALSE	FALSE		-10	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]	NA	NA	43% del 5q31, 56% del 7q31, 58% del20q	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00395	17	Female	Male	White	1	n	27	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Juvenile pilocytic astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	31	1354	Post-Transplant|Residual Disease	Peripheral Blood	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	Dead	1463	Dead-Disease	TRUE	TRUE	14-00334	-15	0			0.8	0.4	75.6	18.9	4.3	5.1	13	22	3.6	0.66		21.6	7.5	46,XX,del(6)(q13q23)[18]/46,XY[2]	512	91.5	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal	28		6.9	2.54	FALSE	FALSE		positive	positive																																																																						
14-00401	1630	Female	Female	White	2	n	78	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	970	Dead-Unknown	FALSE	FALSE		0	0	10	0	4	NA	50	8	38	NA	17	21	4.3	0.57		27.6	8.9	46,XX[20]	230	97.5	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	221	CD2 (-), CD4(partial dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD33(variable to bright +), CD34(+), CD36(-), CD38(bright +), CD45(moderately +), CD56(-), CD64(-), CD117(bright +), HLA-DR(variable +), MPO(partial+) and TdT(-).	6.9	2.7	FALSE	FALSE		negative	negative		L823fs*1; MAF 47%																			F609fs*3; MAF 42%								negative	R172K; MAF 45%																								R560C; MAF 45%																
14-00404	1631	Male	Male	White	1	n	54	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	2	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Salvage|Induction	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Azacitidine	Salvage	196	Dead	317	Dead-Disease	FALSE	FALSE		0	0	29	0	0.9	NA	75.2	17.9	6	0	16	17	3.4	1.02	M4	22.4	8.3	46,XY,add(5)(q23),der(11)t(11;20)(p11.2;p11.2),der(17)t(5;17)(q31;p12),-20,del(21)(q21)+mar[cp21]	NA	90.3	21q deletion	30	CD13, CD33, CD34, CD117, MPO and HLA-DR	6.7	2.12	FALSE	FALSE		negative	negative														negative												negative			negative	negative			negative			negative					negative														negative											p.T312fs*25 (one nucleotide insertion); MAF 30%			negative	
14-00423	1644	Female	Female	White	4	n	51	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	51	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Stanford Protocol 9022 (BU/CY)	Allogeneic - Matched Unrelated Donor	-1	Alive	795	Alive	TRUE	FALSE	14-00422	0	NA	74	61	NA	NA	NA	1	NA	NA		NA	NA	NA	M4eo	NA	NA	46,XX,inv(16)(p13q22)[20]	NA	NA		NA	CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT	NA	34.4	TRUE	FALSE	14-00422	negative	negative							negative							negative												negative			negative	negative						negative			negative							negative																				negative				
14-00425	1646	Female	Female	White	1	n	47	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	47	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	26	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	31	Alive	461	Alive	FALSE	FALSE		0	0			0	NA	14.8	13.1	13.9	0.9	19	37	3.3	0.6	M3	19.5	6.5	46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]	819	70.8		9		7.1	25.11	FALSE	FALSE		positive	negative							negative							negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
14-00430	1651	Female	Female	White	1	n	75	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	75	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	80	Dead-Disease	FALSE	FALSE		0	0	62	17	0.9	NA	64.3	11.3	5.2	0	11	9	3.2	0.88	M2	33.7	10.5	47,XX,+8[20]	216	93.9	Trisomy 8	38	CD13, partial dim CD33, CD34, CD38, dim CD58, CD117, CD123, dim HLA-DR, and partial MPO.	7	2.37	FALSE	FALSE		negative	negative		p.A636V; MAF 52%												negative							negative					negative			negative	p.R140Q; MAF 27%			negative			negative	PTD		negative		negative					negative									p.T437A; MAF 13%					p.P95R; MAF 28%						negative			negative	
14-00434	1648	Female	Female	White	4	n	69	FALSE	TRUE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	69	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Unknown	Standard Chemotherapy	365	Standard Chemotherapy	Hydroxyurea	Induction	365	Alive	0	Alive	FALSE	FALSE		0	NA	94	83	NA	NA	NA	0	NA	NA		NA	NA	NA	M5a	NA	NA	46,XX[1]	NA	NA		NA	CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117	NA	137.6	FALSE	FALSE		negative	negative							negative							negative												negative			negative	negative						negative			negative							negative																				negative				
14-00447	1655	Female	Female	HispNative	1	n	48	FALSE	TRUE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	48	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|Idarubicin and Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	458	Alive	FALSE	FALSE		0	0			0	NA	9.5	0	6	0	51	152	3.1	0.85	M5	30.4	9.7	47,XX,+8,t(9;11)(p22;q23)[20]	4484	80.4	MLL rearrangement	87		6	49.29	FALSE	FALSE		negative	negative														negative							negative					MAF 10%			negative	negative		p.I878V; MAF 50%	negative			negative			negative		negative					negative									negative											negative			negative	
14-00448	1656	Female	Female	White	4	n	78	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Uterine Sarcoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	78	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Refractory	Standard Chemotherapy	111	Standard Chemotherapy	Azacitidine, MLN4924	Induction	111	Dead	161	Dead-Disease	TRUE	TRUE	14-00449	0	NA	78	77	NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	NA	5.6	TRUE	TRUE	14-00449	negative	negative							negative							negative												negative			positive	negative						negative			negative							negative																				negative				
14-00449	1656	Female	Female	White	4	n	78	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Uterine Sarcoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	78	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Refractory	Standard Chemotherapy	111	Standard Chemotherapy	Azacitidine, MLN4924	Induction	111	Dead	161	Dead-Disease	FALSE	FALSE		0	NA	78	77	NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	NA	5.6	FALSE	FALSE		negative	negative							negative							negative												negative			positive	negative						negative			negative							negative																				negative				
14-00451	1657	Male	Male	White	1	n	69	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	70	0	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	3	3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	4	Dead	182	Dead-Disease	FALSE	FALSE		0	1.7	55		0.6	NA	70	21.1	6.6	NA		NA	NA	NA		26.6	9.1	46,XY,del(5)(q22q33),del(21)(q22q22)[cp20]	NA	85.2	5q deletion	3	CD13, CD15, CD34 (subset), CD38, CD58, CD64, CD117, CD123 and HLA-DR.	NA	1.2	FALSE	FALSE		negative	negative					p.L1483* (premature protein truncation); MAF 90%									negative							negative					negative			negative	negative			negative			negative	PTD		negative		negative					negative									negative											negative		p.S34F; MAF 40%	negative	
14-00454	1665	Male	Male	White	4	n	65	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	66	0	Post-Chemotherapy|Residual Relapse	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	8	HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	395	Dead-Disease	TRUE	FALSE	14-00455	0	NA	96	85	NA	NA	NA	5	NA	NA		NA	NA	NA		NA	NA	46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]	NA	NA		NA	CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117	NA	0.1	TRUE	FALSE	14-00455	negative	negative							negative							negative												negative			negative	positive						negative			negative							negative																				negative				
14-00458	1662	Male	Male	White	1	n	51	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	Intermediate		MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	51	0	Unknown	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|Azacitidine, Lenalidomide	2	Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	117	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	286	Dead-Treatment	FALSE	FALSE		0	0	4	6	0	NA	38.9	1.1	56.7	NA	58	51	3.5	0.87		22.4	7.5	47,XY,+8[2]/46,XY[18]	438	93.7	Trisomy 8	20	CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression	5.9	2.23	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			p.A382fs*4; MAF 44%	
14-00464	1664	Female	Female	White	4	n	22	FALSE	TRUE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	22	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	4	Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	-1	Alive	453	Alive	FALSE	FALSE		0	NA	65	90	NA	NA	NA	0.1	NA	NA		NA	NA	NA	M1	NA	NA	46,XX,t(9;11)(p22;q23)[22]	NA	NA		NA	CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO	NA	40.2	FALSE	FALSE		negative	negative							negative							negative												D835			negative	negative						negative			negative							negative																				negative				
14-00473	1666	Female	Female	White	1	n	62	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HAM (Cytarabine, Mitoxantrone)	Salvage	7	Dead	167	Dead-Other	TRUE	FALSE	14-00468	0	6.1	22	17.4	5.2	16.5	31.3	1.7	21.8	0.2	13	11	3.2	0.78		29.5	9.5	59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]	444	101.4	Trisomy 9	34	CD13, CD34, CD58 and CD117	7	10.75	TRUE	FALSE	14-00468	negative	negative	negative													negative							negative					negative	p.N160S; MAF:40%		negative	negative			negative			negative	negative		negative		negative					p.G12D; MAF:11%									negative											p.R280T;  MAF 36%			negative	
14-00476	1670	Male	Male	HispNative	4	n	47	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	47	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	5	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	Dead	228	Dead-Disease	FALSE	FALSE		0	NA	70	79	NA	NA	NA	2	NA	NA		NA	NA	NA	M5	NA	NA	46,XY,t(11;19)(q23;p13.1)[20]	NA	NA		NA	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	NA	261.2	FALSE	FALSE		positive	negative																																																																						
14-00477	1670	Male	Male	HispNative	4	n	47	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	47	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	5	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	Dead	228	Dead-Disease	TRUE	TRUE	14-00476	0	NA	70	79	NA	NA	NA	2	NA	NA		NA	NA	NA	M5	NA	NA	46,XY,t(11;19)(q23;p13.1)[20]	NA	NA		NA	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	NA	261.2	FALSE	FALSE		positive	negative																																																																						
14-00484	1672	Male	Male	White	1	n	62	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	63	0	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Alive	121	Alive	FALSE	FALSE		0	0			0	0.9	59.3	31.9	3.5	0		NA	NA	NA		24.6	8.5	46,XY[19]	NA	89.5		46	Partial CD7, CD13, CD33, CD34, CD38, partial CD56, CD58, CD117, CD123, HLA-DR, and partial TdT	NA	2.78	FALSE	FALSE		negative	negative					p.N119fs*40; MAF 65%		negative							negative							negative					negative			negative	negative			negative			negative			negative							negative									p.K117R; MAF 36%											negative				
14-00487	1675	Female	Female	White	3	n	44	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	IntermediateOrAdverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	44	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	-1	Dead	342	Dead-Unknown	FALSE	FALSE		-1	NA	86.1	65	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	NA	11.38	FALSE	FALSE		positive	negative														negative																																																								
14-00488	1675	Female	Female	White	3	n	44	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	44	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	-1	Dead	342	Dead-Unknown	TRUE	TRUE	14-00487	-1	NA	86.1	65	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	NA	11.38	TRUE	TRUE	14-00487	positive	negative														negative																																																								
14-00495	1246	Male	Male	White	2	n	62	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	254	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	Dead	568	Dead-Unknown	FALSE	FALSE		-28	NA			NA	NA	NA	NA	NA	NA	23	26	2.9	NA		27.9	9.6	45,XY,der(12;16)(q10;p10)[2]/46,XY[18]	NA	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]	30		5	27.4	FALSE	FALSE		positive	positive												P203S; MAF unlisted			T367fs*15; MAF unlisted						R882H; MAF unlisted																																																	
14-00496	1683	Male	Male	White	3	n	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) 	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	129	Unknown	NA		TRUE	FALSE	14-00497	-1	NA	37	20	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	283	Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm	NA	16.11	TRUE	FALSE	14-00497	negative	positive														negative																						negative																																		
14-00498	1684	Female	Female	White	1	n	62	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	4	Dead	81	Dead-Disease	FALSE	FALSE		0	0	50	57.4	0	0	38.4	1	3.2	0	16	9	2	0.46		22.2	7.4		184	87.4	Tetrasomy 8	6	partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable)	6	0.81	FALSE	FALSE		positive	negative																																																																						
14-00499	1689	Male	Male	White	1	n	68	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Acute undifferentiated leukaemia	Adverse	Intermediate-I	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Acute undifferentiated leukaemia	68	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	HyperCVAD Course B (Cytarabine, Methotrexate)|EWALL Protocol|Bu/Cy/TBI|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	3	Bone Marrow Transplant	Bu/Cy/TBI	Allogeneic - Matched Unrelated Donor	-1	Dead	385	Dead-Other	FALSE	FALSE		0	1	42	43.8	0.9	0	26.7	5.7	20.9	0	23	20	3.5	1.27		32.5	11.2	46,XY[20]	170	100.9	c/w karyotype	57	partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive	6.3	2.22	FALSE	FALSE		negative	negative														negative							negative					negative		p.L359V; MAF: 40%	negative	negative			negative			negative			negative		negative					p.G12S; MAF: 15%									p.R107H; MAF: 19%											negative			negative	
14-00502	1691	Male	Male	White	7	n	NA	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Blastic plasmacytoid dendritic cell neoplasm	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Blastic plasmacytoid dendritic cell neoplasm	NA	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00504	1693	Male	Male	White	2	n	35	FALSE	TRUE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	35	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	-1	Alive	1226	Alive	FALSE	FALSE		-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]	NA	NA	nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	NA		NA	NA	FALSE	FALSE		positive	positive		D943fs*6; MAF 25%												negative												D835			negative	negative							MLL-AF9 fusion																																	
14-00514	1696	Male	Male	White	2	n	71	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	107	Dead	53	Dead-Disease	FALSE	FALSE		0	0		50	1	NA	17	1	13	NA	19	42	3.2	1.83		23.7	7.7		766	92.2		11		7.1	45.6	FALSE	FALSE		negative	negative																													negative	negative																																								
14-00521	1700	Female	Female	White	4	n	60	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	60	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	7	Alive	35	Alive	TRUE	FALSE	14-00520	0	NA	56	1	NA	NA	NA	1.4	NA	NA		NA	NA	NA	M1	NA	NA	46,XX[21]	NA	NA		NA	CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT	NA	1	TRUE	FALSE	14-00520	negative	negative							negative							negative												negative			negative	negative						negative			negative							negative																				negative				
14-00527	1702	Male	Male	Black	2	n	62	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Post-Chemotherapy|Relapse	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Maintenance	5	Alive	534	Alive	FALSE	FALSE		0	0	82	47	2	NA	34	9	9	NA	11	28	3.8	0.95		36.8	12.1	46,XY[20]	932	87.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	127	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +).	7.2	11.7	FALSE	FALSE		negative	negative																										negative				negative																																								
14-00528	1533	Female	Female	White	2	n	57	TRUE	FALSE	FALSE	Complex	FALSE	FALSE	y	Ovarian cancer|Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	58	111	Post-Chemotherapy|Relapse	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	Dead	138	Dead-Unknown	TRUE	TRUE	14-00231	-111	0		58	0	NA	14	3	19	NA	24	116	3.7	NA		21.4	7.7	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	10	CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).	6	11.2	FALSE	FALSE		negative	negative																																																																						
14-00536	1707	Female	Female	White	1	n	69	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	70	0	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Unknown	3	7+3 (Cytarabine, Idarubicin)|Lenalidomide|Azacitidine	2	Unknown|Induction	Unknown	Standard Chemotherapy	75	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	8	Dead	344	Dead-Disease	FALSE	FALSE		0	0	78	15	0	0	75	0.9	10.7	0	9	8	2.5	0.5		24.9	8.5	47,XX,del(5)(q22q35),+8[20]	158	86.5	5q deletion	26	CD13, partial CD33, CD34, CD38, dimCD45, CD58, partial CD64, CD117, HLA-DR, and MPO positive.	5.9	1.75	FALSE	FALSE		negative	negative														negative							p.R882H; MAF 37%			p.K400del; MAF 48%		negative			p.R132C; MAF 37%	negative			negative			negative																														p.I251M; MAF 34%				
14-00537	1708	Male	Male	HispNative	2	n	17	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	17	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	74	Alive	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00542	1710	Female	Female	HispNative	4	n	27	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	137	Alive	250	Alive	TRUE	TRUE	14-00543	0	NA	69	68	NA	NA	NA	1	NA	NA		NA	NA	NA	M2	NA	NA	48,XX,+3,+10[2]/46,XX[18]	NA	NA		NA	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	NA	5.1	TRUE	TRUE	14-00543	negative	positive							negative							negative												negative			negative	negative						negative			negative							negative																				negative				
14-00543	1710	Female	Female	HispNative	4	n	27	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	137	Alive	250	Alive	FALSE	FALSE		0	NA	69	68	NA	NA	NA	1	NA	NA		NA	NA	NA	M2	NA	NA	48,XX,+3,+10[2]/46,XX[18]	NA	NA		NA	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	NA	5.1	FALSE	FALSE		negative	positive							negative							negative												negative			negative	negative						negative			negative							negative																				negative				
14-00546	1711	Female	Female	White	1	n	69	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	69	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	-1	Unknown	NA		FALSE	FALSE		0	0	83	77	0	0	16.1	5.3	4.5	1.2	31	51	3.2	1.05	M3	22.7	8.1	45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1]	1816	92.3	PML/RARA fusion	33	dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative	5.7	16.03	FALSE	FALSE		negative	negative																																																																						
14-00555	1717	Female	Female	Black	2	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	54	0	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	390	Dead-Disease	FALSE	FALSE		0	0	68	54	0	NA	60	2	0	NA	33	27	2.2	0.51		28.4	9.7	46,XX,del(17)(p11.2p13)[19]/46,XX[1]	183	86.1	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[197]	10	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD16(-), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(dim to moderately +), CD56(-), CD64(-), CD117(partial +), HLA-DR(-), TdT(predominantly -), MPO(+).	6.1	NA	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
14-00559	1721	Male	Male	White	2	n	68	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	976	Alive	FALSE	FALSE		0	0	79	54	NA	NA	10	42	30	NA	8	26	4	NA		20.8	6.8	46,XY	NA	NA	IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted	61	CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-)	7.1	41.4	FALSE	FALSE		negative	positive														negative							R882C; MAF 50%					negative			negative	negative																G13D; MAF 44%																								
14-00564	1719	Male	Male	White	1	n	57	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	10	Standard Chemotherapy	Decitabine	Induction	10	Dead	35	Dead-Unknown	FALSE	FALSE		0	0	45		0.9	27.8	18.2	12.2	40.9	0	32	19	2	0.83		26.9	9.1	44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]	NA	97.1	EGR1/5p; 88% of cells were missing a signal for both probes, consistent with monosomy 5 	77	CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+	6.7	5.92	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative							negative			negative	p.R248Q; MAF 80%			negative	
14-00567	1723	Female	Female	White	1	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Mismatched Unrelated Donor	-1	Dead	462	Dead-Treatment	FALSE	FALSE		-3	0			0	0	6.7	5.1	0	0.1	20	20	2.6	0.62	M5	21.4	7	46,XX,idic(7)(q11.2)[20]	373	93.9		19	CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive	5.8	78.71	FALSE	FALSE		negative	negative					p.T870fs*46 (2 bp deletion); MAF 50%									negative							negative					negative			p.R132C; MAF 50%	negative			negative			negative	PTD		negative							negative						p.S502L; MAF 50% 														negative				
14-00573	1727	Male	Male	HispNative	1	n	45	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	45	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) 	Salvage	4	Dead	259	Dead-Disease	FALSE	FALSE		0	0			0	7	14.8	25.2	19.1	0	50	32	3.5	0.78		24.2	8.3	47,XY,der(7)t(1;7)(q10;p10),+8[20]	NA	89		59	CD13, variable CD33, CD34, CD38, CD117, CD123, HLA-DR positive	7.1	22.95	FALSE	FALSE		negative	negative										Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 86%				negative							negative			p.S538L; MAF 85% 		negative		p.K389delinTFFM; MAF 46% 	negative	negative			negative			negative			negative		negative					negative									p.S308fs*174; MAF 46% 											negative			negative	
14-00578	1730	Male	Male	White	1	n	75	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	IntermediateOrAdverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	75	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	-1	Dead	327	Dead-Disease	FALSE	FALSE		0	0	90		0	0	6	2.6	0	0.1	18	49	2.6	0.94	M5	26.8	9.1	46,XY[20]	1173	105.5	Normal	45	dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive	6.8	98.9	FALSE	FALSE		positive	negative														negative							p.P777L; MAF 50%					negative			negative	p.R140Q; MAF 45%			negative			negative	PTD; no MAF available		negative							negative																				negative			Intron 1 splice site (at invariant AG splice donor); MAF 90% 	
14-00581	1731	Female	Female	Black	4	n	68	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	68	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Dead	70	Dead-Disease	TRUE	FALSE	14-00580	-1	NA	33	37	NA	NA	NA	8	NA	NA		NA	NA	NA		NA	NA	42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]	NA	NA		NA	CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO	NA	29.1	TRUE	FALSE	14-00580	negative	negative							negative							Triple positive												negative			negative	positive						negative			negative							negative																				negative				
14-00588	1737	Female	Female	White	2	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	53	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI 	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI 	Allogeneic - Matched Unrelated Donor	-1	Dead	137	Dead-Treatment	FALSE	FALSE		-1	0	9	4	0	NA	61	10	22	NA	14	40	3.3	0.65		22.1	7.4	46,XX,del(9)(q22q34)[20].	NA	93.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	38	CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)	5.8	2.1	FALSE	FALSE		negative	negative																					R882C; MAF 43%								negative	negative																																							splice site 1099-6_1104delCTGCAGGATGTG; MAF 28%	
14-00597	1604	Male	Male	White	3	n	58	FALSE	FALSE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	100	Post-Chemotherapy	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) 	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	210	Alive	761	Alive	TRUE	FALSE	14-00596	0	NA	.4		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	NA		NA	29.18	FALSE	FALSE		negative	negative																																																																						
14-00599	1739	Male	Male	White	1	n	69	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	69	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	63	Dead	470	Dead-Disease	FALSE	FALSE		0	0			0	0	78.5	15.1	6.4	2.9	21	15	3.1	1.01	M0	23.5	7.5	47,XY,+8[2]/46,XY[18]	NA	101.7	Consistent with karyotype	47	dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive	6.7	2.05	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative	PTD		negative		negative					negative									p.H242fs*14; MAF 42% 											negative		p.S34F; MAF 40%	negative	
14-00602	1746	Male	Male	White	4	n	69	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	IntermediateOrAdverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	69	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	79	Standard Chemotherapy	MEC, Lenalidomide	Salvage	5	Dead	304	Dead-Disease	FALSE	FALSE		-8	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[22]	NA	NA		NA		NA	NA	FALSE	FALSE		positive	negative							negative							negative												negative			positive	negative						negative			negative							negative																				negative				
14-00603	1746	Male	Male	White	4	n	69	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	69	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	79	Standard Chemotherapy	MEC, Lenalidomide	Salvage	5	Dead	304	Dead-Disease	TRUE	TRUE	14-00602	-8	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[22]	NA	NA		NA		NA	NA	TRUE	TRUE	14-00602	negative	positive							negative							negative												negative			positive	negative						negative			negative							negative																				negative				
14-00608	1749	Female	Female	White	4	n	75	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	77	716	Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	1131	Dead	1134	Dead-Other	FALSE	FALSE		-710	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[8]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00613	1752	Male	Male	White	2	n	31	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	31	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	Unknown	NA		FALSE	FALSE		-1	NA	80	56	2	NA	17	21	3	NA	63	39	3.9	0.91		28.8	10.2	46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]	434	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5CBFB sep 3CBFBx1)[164/200]	34	CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +).	8.2	41.35	FALSE	FALSE		negative	negative																																																																						
14-00618	1754	Male	Male	White	2	n	77	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Lung Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	78	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Unknown	NA		FALSE	FALSE		0	NA	73	84	NA	NA	10	NA	6	NA	9	13	4.2	0.82		NA	NA	46,XY[20]	165	NA		NA		6.5	13.8	FALSE	FALSE		negative	negative				S1993fs*23; MAF 44%										L81fs*72; MAF 92%															negative	negative												G382D; MAF 49%																			R1205*; MAF 92%				M823fs*1; MAF 47%					
14-00632	1761	Female	Female	White	1	n	64	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	64	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)	Induction	3	Alive	569	Alive	FALSE	FALSE		0	0	90	30	0	0	37.5	27.7	0	2.6	37	31	1.8	0.52	M4	23.5	7.7	46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]	452	94.4		56	dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.	6.2	6.44	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			p.G12V; MAF 30%							p.G12D; MAF 7%									p.R162K; MAF 85% 											negative				
14-00639	17	Female	Female	White	1	n	27	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Juvenile pilocytic astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	31	1465	Residual Disease|Post-Transplant	Peripheral Blood	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	Dead	1463	Dead-Disease	TRUE	TRUE	14-00640;14-00466	-81	0			0	0	21.6	4.5	0	0.6	80	180	1.9	1		22.2	7.7	46,XX,del(6)(q13q23)[15]/46,XY[5]	1065	81	6q deletion	17		5	17.79	FALSE	FALSE		positive	positive																																																																						
14-00640	17	Female			1	n	27	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Juvenile pilocytic astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Unknown	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	31	1465	Post-Transplant|Residual Disease	Peripheral Blood	y	n	y	n	n	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	Dead	1463	Dead-Disease	TRUE	TRUE	14-00639;14-00466	-81	0			0	0	21.6	4.5	0	0.6	80	180	1.9	1		22.2	7.7	46,XX,del(6)(q13q23)[15]/46,XY[5]	1065	81	6q deletion	17		5	17.79	FALSE	FALSE			positive																																																																						
14-00643	1763	Male	Male	Asian	1	n	37	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	37	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	0	Alive	566	Alive	FALSE	FALSE		0	0.8			0	7.5	17.5	0	37.5	0.4	22	13	3	0.89	M2	15.8	5.5	45,X,-Y,t(8;21)(q22;q22)[20]	411	100.6	RUNX1T1/RUNX1:  94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	42	dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive	7	8.15	FALSE	FALSE		negative	negative														negative										p.F445fs*3; MAF 30% 		negative			negative	negative			negative			p.Y418_D419insFL (exon 8); MAF 29%     ;p.N822K (exon 17); MAF 5% 			negative							negative																			p.G1160E; MAF 49% 	negative				
14-00658	1775	Female	Female	White	3	n	59	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Hypomethylating/Low Dose Cytarabine	-1	Dead	254	Dead-Disease	FALSE	FALSE		-1	NA	51.5	72	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA	Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.	NA	89.17	FALSE	FALSE		positive	positive														negative																						negative																																		
14-00664	1782	Male	Male	White	1	n	75	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response i	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	28	Dead-Other	FALSE	FALSE		0	0			0	0.8	75.6	4.6	19	3.8	21	11	3.3	1.1		27.9	9.3	46,XY[20]	241	99.6	Normal	31	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	6.5	1.31	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									p.Y349*; MAF 26% 					p.P95H; MAF 32% 						negative			negative	
14-00667	1783	Male	Male	White	1	n	57	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	371	Bone Marrow Transplant	Fludarabine, Melphalan, TBI	Allogeneic - Sibling	-1	Dead	245	Dead-Treatment	FALSE	FALSE		-1	0.3			0	0.6	32.6	14.7	51.8	0	82	52	3.4	0.78		29.6	10.1	46,XY[20]	160	93.7	Normal	91	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	7.5	3.53	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									p.I114fs*25; MAF ~50% 											negative		p.S34F; MAF 43%	negative	
14-00670	1787	Male	Male	Black	2	n	63	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG	3	Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child			NA	Bone Marrow Transplant	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	Alive	1059	Alive	FALSE	FALSE		0	0	20	0	0	NA	76	0	24	NA	18	16	4.1	1.24		24.9	8.3	46,XY[20]	148	100.4		72		7.4	1.8	FALSE	FALSE		negative	negative		G646fs*12; MAF 30%											Y325*; MAF 46%			Q320fs*41; MAF 51%				P442fs*16; MAF 38%									negative	R140Q; MAF 46%																														P95H; MAF 40%	R614*; MAF 90%									
14-00672	1786	Male	Male	White	7	n	64	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	n	n	n	n	y	n	MYELOPROLIFERATIVE NEOPLASMS	Essential thrombocythaemia	Intermediate		MYELOPROLIFERATIVE NEOPLASMS	Essential thrombocythaemia	77	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	Ruxolitinib|Imatinib|Hydroxyurea	2	Induction|Re-induction	Refractory	Standard Chemotherapy	4626	Standard Chemotherapy	Ruxolitinib	Re-induction	-1	Alive	5305	Alive	FALSE	FALSE		0	NA	15		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]	NA	NA	Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome. 	NA	dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive	NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00676	1561	Male	Male	White	1	n	23	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	mediastinum mass	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	24	163	Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) 	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	Dead	318	Dead-Disease	TRUE	TRUE	14-00289	0	0	5	10	0	2.9	36.2	1.5	47.8	NA	30	146	3.4	0.82		25.5	7.9	48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]	NA	98.5	Low-level tetraploidy or near-tetraploidy	48	A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells.	6.1	11.28	FALSE	FALSE		negative	negative																																														p.G12C; MAF 97%																				p.G245S; MAF 96%				
14-00681	1797	Male	Male	White	1	n	65	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Cytarabine	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	133	Alive	323	Alive	FALSE	FALSE		0	0			0	0	31.2	0.9	0	0	19	25	3.3	0.78	M1	21.4	7.4	46,XY,del(13)(q12q2?1)[14]	509	103.4	all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype	17	CD13, partial/dim CD33, CD38, CD58, CD117 and MPO	6.6	5.39	FALSE	FALSE		negative	negative														negative							p.R882H; MAF 44% 					negative			negative	p.R172K; MAF 43%			negative			negative			negative							negative																				negative				
14-00690	1800	Female	Female	White	3	n	49	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	49	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	462	Alive	FALSE	FALSE		-1	NA	54	3	NA	NA	NA	NA	NA	NA		NA	NA	NA	M5	NA	NA	46,XX,del(17)(p11.2)[15]/46,XX[5]	NA	NA	consistent with karyotype (68% del 17p13)	NA	Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64.	NA	NA	FALSE	FALSE		negative	positive																																																																						
14-00712	1810	Male	Male	White	1	n	65	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Pancreatic adenocarcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	65	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Other	3	3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	9	Dead	158	Dead-Disease	FALSE	FALSE		0	0	18	12	0.9	32	7.4	35.2	18.5	4.8	44	165	2.9	1.65		20.1	6.7	46,XY,i(17)(q10)[20]	3923	81	TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.	40	CD13, CD33, CD34, CD117, and HLA-DR positive	5.7	161.89	FALSE	FALSE		negative	negative		p.R693fs*10; MAF 49% 												negative			p.S893L; MAF 52% 				negative					negative			negative	negative			negative			negative			negative							p.G12D; MAF 46% 																				negative				
14-00714	1811	Female	Female	White	4	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	n	n	y	n	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	1938	Dead-Disease	TRUE	TRUE	14-00715	0	NA	72	81	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	NA	NA		NA	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	NA	3.8	TRUE	TRUE	14-00715	negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00715	1811	Female	Female	White	4	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	1938	Dead-Disease	FALSE	FALSE		0	NA	72	81	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	NA	NA		NA	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	NA	3.8	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00720	1813	Male	Male	White	2	n	74	FALSE	FALSE	FALSE	DEK-NUP214	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	2	Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	Crenolanib	Maintenance	433	Dead	1003	Dead-Disease	FALSE	FALSE		0	NA	17	0	NA	NA	40	NA	60	NA	19	18	4.2	0.64		25.4	8.8	46,XY,t(6;9)(p23;q34)[18]/46,XY[2].	162	119.8	DEK-NUP214 fusion; MAF unavailable	60	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-).	6.5	2	FALSE	FALSE		positive	negative																					F827fs*4; MAF 35%					S585_D586ins28; MAF 14% 			negative	negative																																								D242fs*13; MAF 25%
14-00725	1814	Female	Female	White	2	n	32	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	32	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	833	Alive	FALSE	FALSE		0	0	24	2	2	NA	54	0	44	NA	10	22	4.4	0.49		25.9	9	47,XX,+8[13]/46,XX[7].	125	97.1	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	67	CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and variable), TdT(-), MPO(+).	7.1	1.4	FALSE	FALSE		negative	negative																													negative	negative																						G60A; MAF 18%																		
14-00730	1817	Female	Female	HispNative	1	n	40	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	40	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	33	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	193	Alive	587	Alive	FALSE	FALSE		0	0	90	20	0	0.8	75.9	0	2.6	2.6	24	15	3.2	0.68	M3	20.3	7.1	46,XX,t(15;17)(q22;q21)[17]/46,XX[3]	259	85.3	58% PML-RARA  (c/w karyotype)	53	CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive	7.3	1.9	FALSE	FALSE		negative	negative		negative					negative							negative							negative					negative			negative	negative	p.E80X; MAF 37%		negative			negative			negative		negative					negative									negative											negative			p.E340X; MAF 32%	
14-00735	1818	Male	Male	Asian	4	n	83	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	83	1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine, Midostaurin	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	Dead	47	Dead-Disease	FALSE	FALSE		-6	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[13]	NA	NA		NA		NA	NA	FALSE	FALSE		positive	positive							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00738	1819	Male	Male	White	1	n	65	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Decitabine	1	Induction	Refractory	Standard Chemotherapy	9	Standard Chemotherapy	Decitabine	Induction	9	Dead	67	Dead-Disease	FALSE	FALSE		0	8	30	7	7.1	2.7	17	12.5	47.3	1.4	33	50	2.3	0.77		20.1	6.2	45,XY,del(5)(q13q33),del(7)(q11.2),dic(8;9)(q24.3;p22),-18,+r[cp8]/45,XY,del(5)(q13q33),-7,der(18)t(7;18)(p11.2;p11.1)[cp6]/45,sdl1,del(4)(q21q31.1),del(12)(p11.2p13)[cp5]/46,XY[1]	NA	77		9	dim CD7, CD13, dim CD33, CD34, CD38, CD58, partial      CD56, CD117, CD123 and HLA-DR positive	6.4	19.99	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			p.V617F; MAF 53% 			negative			negative							negative																				p.V272M; MAF 88% 				
14-00739	1820	Male	Male	White	1	n	39	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	39	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate	3	Induction|CNS|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	216	Dead-Disease	FALSE	FALSE		0	0			0	0	28.3	17.7	3.5	0	19	14	3	0.97		31.1	10.7	46,XY,t(6;11)(q27;q23)[20]	NA	98.4	MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).	31		6.2	21.12	FALSE	FALSE		negative	negative		negative												negative												negative			negative	negative			negative			negative	PTD		negative							negative																				negative				
14-00742	1821	Female	Female	White	2	n	51	FALSE	FALSE	FALSE	Complex	TRUE	FALSE	y	Breast Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	Adverse	Adverse	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	51	0	Unknown	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	4	Unknown	NA		FALSE	FALSE		0	0	9	11	0.8	NA	28.2	13.7	43.6	NA	19	28	2.6	0.7		27.2	9.1	44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+mar[cp3].ishder(15)(PML+,RARA+)[1].	517	92.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]	74	CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)	6.2	NA	FALSE	FALSE		negative	negative														negative												negative			negative	negative																																								
14-00756	1827	Female	Female	White	1	n	40	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	40	0	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	509	Alive	FALSE	FALSE		0	0	3		0	0	57.7	2.7	39.6	5.5	81	45	3	0.71		27.2	9.4	47,XX,+8[11]/46,XX[10]	NA	84.2	RUNX1T1 (8q21.3): 55% of cells had three signals for RUNX1T1 (8q21.3) consistent with trisomy 8, as seen on metaphase analysis	58	population of CD117+ progenitors (~3.5% of total      CD45+ events) that expresses CD13, dim CD33, CD38, CD58, CD117, dim CD123 and HLA-DR, without the expression of CD64.	7	1.09	FALSE	FALSE		negative	negative		p.E1416G; MAF 52% 												negative							negative					negative			negative	negative			negative			negative			negative							negative																				negative				
14-00757	1495	Male	Male	White	3	n	75	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	75	265	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	Dead	335	Dead-Disease	TRUE	TRUE	14-00622;14-00152	-77	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	NA		NA	9.7	FALSE	FALSE		negative	negative																																																																						
14-00761	1833	Female	Female	White	4	n	72	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Residual Disease	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	186	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Re-induction	62	Alive	417	Alive	TRUE	FALSE	14-00760	-22	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00774	1843	Male	Male	White	4	n	84	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	84	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	Dead	67	Dead-Disease	FALSE	FALSE		0	NA	85	88	NA	NA	NA	NA	NA	NA		NA	NA	NA	M0	NA	NA	46,XY[20]	NA	NA		NA	CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT	NA	30	FALSE	FALSE		positive	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
14-00777	1845	Male	Male	Asian	1	y	69	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	69	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	MiDAC	Consolidation	5	Alive	90	Alive	FALSE	FALSE		0	0	60		2.6	2.6	33.6	14.7	18.1	0.7	19	22	2.3	0.87	M4	30.5	9.9	46,XY[20]	NA	99	FISH normal	118	CD7, CD13, CD33, CD34, CD38,  CD64, CD117, HLA-DR and MPO positive	7.3	7.62	FALSE	FALSE		negative	negative														p.P23fs*81; MAF 41%							negative					negative			negative	negative			negative			negative			negative							negative																			p.G1160E; MAF 51%	negative			p.R380fs*5; MAF 31%	
14-00780	1098	Female	Female	White	2	n	31	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	38	1496	Post-Chemotherapy|Post-Transplant|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	9	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	24	Dead	2661	Dead-Unknown	TRUE	TRUE	13-00294	-480	NA	7	1	NA	NA	NA	NA	NA	NA	15	21	4.2	NA		31.9	11	46,XX	NA	NA	nuc ish(DXZ1x2)[200]	45		6.2	2.2	FALSE	FALSE		negative	negative					S259fs*10; MAF 15%						P281R; MAF 19%															D835E; MAF 13%		N297S; MAF 18%			Q44*; MAF 14%							Y2907*; MAF 7%														E76V; MAF 17%				H1100R; MAF 51%	K700E; MAF 18%													
14-00781	1847	Male	Male	White	1	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	MiDAC	Consolidation	5	Dead	162	Dead-Disease	FALSE	FALSE		0	0	95	80	0	2	21	4	1	0.8	29	282	3.2	1.61	M5	31.8	10	47,XY,t(1;11)(p32;q23),+8[cp20]	7759	102.3	c/w karyotype	59	CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive	6.1	71.19	FALSE	FALSE		negative	negative														negative			p.Q1765*; MAF 4% 				negative					negative										negative	negative		p.G13D; MAF 27%		negative					negative																				negative				
14-00787	1848	Male	Male	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	442	Alive	FALSE	FALSE		0	0	90	90.5	0	0	8.2	2.2	0.9	0.8	22	43	3.1	1.21	M1	17.3	5.2	46,XY[20]	1873	96.1	Normal	34	CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)	6.9	427.46	FALSE	FALSE		negative	negative														p.N307_V308ins; MAF 50%							negative								negative	negative						negative	negative		negative		negative					negative									negative											negative			negative	
14-00793	1863	Male	Male	HispNative	1	n	NA	FALSE	FALSE	FALSE	Unknown	FALSE	TRUE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	NA	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
14-00798	1852	Female	Female	White	1	n	36	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	36	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	15	Dead-Other	FALSE	FALSE		0	0	74	82	1.7	1.7	6.7	82.3	3.4	0	45	36	2.7	0.68	M4	20.4	7.1	46,XX,inv(16)(p13.1q22)[20]	NA	87.6	CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. 	12		5.8	117.53	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			p.G12D; MAF 9% 		negative					p.G12D; MAF 10%									negative											negative			negative	
14-00800	1854	Male	Male	White	1	n	68	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	69	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	n	y	y	1	Standard Chemotherapy	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	Dead	114	Dead-Disease	FALSE	FALSE		-30	NA			NA	NA	NA	NA	NA	3.6	26	65	3.1	1.07		20.9	7.2	46,XY[20]	1004	90.1		17		5.4	53.76	FALSE	FALSE		negative	negative										p.C404Y; MAF 28%				negative							negative					negative			negative	negative						negative			negative		negative					negative									negative		p.K666N; MAF 36% 								p.L1047fs*11; MAF 34% 	negative			negative	
14-00801	1855	Male	Male	White	1	n	61	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	61	0	Post-Chemotherapy|Residual Disease|Post-Transplant	Bone Marrow Aspirate	y	y	y	n	y	y	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	5	Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	269	Alive	596	Alive	FALSE	FALSE		1	0.6	3	0	7.2	0.4	31.8	13	47	0	51	76	3.3	0.94		42.5	14	46,XY[23]	753	87.6	Normal	188	maturing myeloid population. Myeloid blasts are about 2%. Monocytes are 6/7% and without antigen aberrancy.Lymphocytes are 10-11%. Mostly T cells and these have a 1:1 CD4:CD8 ratio.There are approximately 20% of lymphocytes as B cells and these are polyclonal. NK cells not increased	6.9	5.16	FALSE	FALSE		negative	negative														negative							negative					negative										negative			negative							negative																				negative				p.R452C; MAF 4%
14-00803	1727	Male	Male	HispNative	1	n	45	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	46	112	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) 	Salvage	4	Dead	259	Dead-Disease	FALSE	FALSE		-2	0			0	0	7.9	76.3	11.4	0	25	12	3.4	0.57		25.1	8.5	47,XY,der(7)t(1;7)(q10;p10)+8[20]	295	93		27		6.5	12.25	FALSE	FALSE		negative	negative										Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 94%				negative							negative			p.S538L; MAF 89%				p.K389delins; MAF 47%	negative	negative			negative			negative			negative							negative									p.S308fs*174; MAF 46%											negative				
14-00815	1814	Female	Female	White	2	n	32	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	32	46	Post-Chemotherapy	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	833	Alive	FALSE	FALSE		-7	0	2	0	0	NA	NA	44	56	NA		NA	NA	NA		23.2	7.7	47,XX,+8[3]/46,XX[17].	130	89.9	nuc ish(D8Z2x3,D20S108x2)[27/200]	113		NA	0.9	TRUE	TRUE	14-00725	negative	negative																																																				positive																		
14-00817	1865	Male	Male	White	3	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	53	0	Initial Acute Leukemia Diagnosis	Leukapheresis	y	n	y	y	n	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Unknown	NA		TRUE	FALSE	14-00818	-1	NA	66	56	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	123	large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes	NA	180	TRUE	FALSE	14-00818	positive	negative														negative																						negative																																		
14-00831	1866	Male	Male	HispNative	2	n	26	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	26	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	5	Unknown	NA		FALSE	FALSE		0	NA	81	37	3	NA	33	1	15	NA	47	44	4.4	0.8		18.6	6.3	46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]	484	NA	nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]	105	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appears partial +), TdT(few +).	6.7	4.95	FALSE	FALSE		negative	negative																																																																						
14-00832	1868	Female	Female	White	1	n	65	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	IntermediateOrAdverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	0	Alive	450	Alive	FALSE	FALSE		0	0.8		30	0	12.5	24.2	28.3	18.4	0	23	29	3	0.78		22.4	7.4		561	107.2		60	CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive	6.6	31.66	FALSE	FALSE		positive	negative	negative													negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative														negative	
14-00901	1870	Male	Male	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	44	Dead	104	Dead-Unknown	FALSE	FALSE		-2	0			0	0	45.5	0.8	0	0.3	14	18	2.4	0.73		21.3	6.9	46,XY,t(1;4)(q21;p14)[20]	178	103.4	Normal	57		7	13.68	FALSE	FALSE		negative	negative					p.S571*; MAF 90% 									negative												negative			negative	negative			negative			negative	PTD		negative		negative					negative																								p.C181F; MAF 88%
15-00009	1876	Male	Male	White	5	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Cyclophosphamide, Fludarabine, TBI|Azacitidine|Venetoclax (ABT-199)	3	Hypomethylating/Low Dose Cytarabine|Experimental|Double Umbilical Cord Blood Transplant (DUCBT)			NA	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	479	Alive	TRUE	FALSE	15-00008	1	NA	40	"rare"	NA	NA	NA	NA	NA	NA	6	9	NA	NA	M0	NA	NA	46,XY[12]	NA	NA	Normal	31	CD34, dim CD45, CD117	NA	0.9	TRUE	FALSE	15-00008	negative	negative														negative												negative			negative	negative			negative																																					
15-00014	1877	Female	Female	White	1	n	77	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	77	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	Dead	16	Dead-Unknown	FALSE	FALSE		1	0	95	9	0	0.9	53	0	28.7	0.8	10	16	4	1.02	M5	25.8	8.6	47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]	601	97	1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (ie. the clone with the i(1)(q10)).	8	CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive	8.2	3.65	FALSE	FALSE		negative	positive		negative												negative							negative					negative;p.V491L; MAF 9%			negative	negative			negative			negative			negative							negative						p.S502L; MAF 44%														negative				
15-00018	1889	Male	Male	White	4	n	57	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	58	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)	3	Consolidation|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	Binimetinib (MEK162)	Experimental	-1	Dead	111	Dead-Disease	TRUE	FALSE	15-00017	0	NA	70	8	NA	NA	NA	10	NA	NA		NA	NA	NA		NA	NA	46,XY[14]	NA	NA		NA		NA	7.1	TRUE	FALSE	15-00017	negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
15-00024	1916	Female	Female	White	4	n	75	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	206	Standard Chemotherapy	Decitabine, Midostaurin	Induction	206	Dead	320	Dead-Unknown	TRUE	FALSE	15-00027	-6	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,t(5;16)(q31;p13)[3]/46,XX[14]	NA	NA		NA		NA	NA	TRUE	FALSE	15-00027	negative	negative							negative							negative							negative					negative			negative	negative						negative			negative							negative																				negative				
15-00029	1919	Male	Male	White	2	n	80	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	80	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Decitabine, ABT-199|Hydroxyurea	2	Unknown|Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine, ABT-199	Unknown	-1	Dead	364	Dead-Disease	FALSE	FALSE		0	0	21	47	0	NA	5	10	41	NA	25	52	4.1	1.26		35	11.1	46,XY[20]	639	90.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	110	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim +).	7.5	64.6	FALSE	FALSE		negative	negative																													negative	negative																																								
15-00043	1924	Female	Female	White	5	n	43	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	44	0	Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	12	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	420	Alive	FALSE	FALSE		-46	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]	NA	NA	Positive for an EVI1 rearrangement	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
15-00045	1925	Female	Female	White	2	n	30	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	30	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	40	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	Alive	854	Alive	FALSE	FALSE		0	0	36	22	0	NA	12	44	5	NA	61	44	4.2	0.59		31.8	11	46,XX,inv(16)(p13q22)[20]	441	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]	33	CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO	7	55	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
15-00051	1929	Female	Female	White	1	n	66	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	66	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	2	Alive	534	Alive	FALSE	FALSE		0	0	95	90.2	0	2.5	4.9	0.8	1.6	0.6	19	23	3	0.5		18.9	6.1		501	100.5	Normal	10	CD13, CD33, dim CD71, CD117, CD123, and MPO	6.4	66.67	FALSE	FALSE		negative	positive	negative													negative							negative					negative			negative	p.R140Q; MAF 46%			negative			negative			negative		negative					negative									negative											negative			negative	
15-00053	1184	Male	Male	HispNative	2	n	52	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	54	506	Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	15	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	Dead	1237	Dead-Disease	TRUE	TRUE	13-00393	-506	NA	6	2	NA	NA	54	23	19	NA	18	25	NA	1.03		37.2	12.1	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	166	NA	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	77		8.2	5.94	FALSE	FALSE		positive	negative																																																																						
15-00056	1933	Male	Male	White	5	n	76	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	0	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	680	Dead-Disease	FALSE	FALSE		0	NA	70	55	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	46	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	NA	4.5	FALSE	FALSE		negative	negative														negative												negative			negative	C.G419A (p.R140Q)			negative																																					
15-00057	1933	Male	Male	White	5	n	76	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	0	Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	680	Dead-Disease	TRUE	TRUE	15-00056	0	NA	70	55	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	46	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	NA	4.5	TRUE	TRUE	15-00056	negative	negative														negative												negative			negative	C.G419A (p.R140Q)			negative																																					
15-00071	1962	Male	Female	White	2	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	0	Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	y	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	918	Dead-Disease	FALSE	FALSE		0	0.9	1	0	3.5	NA	7.8	5.2	82.6	NA	9	16	2.7	1.14		31.3	10.2	45~49,X,-Y,add(5)(q11.2),+der(9;8)(q10;q10),+10,der(11)t(11;17)(p15;q11.2)del(11)(q21q22),add(12)(q12),del(13)(q12q22),-17,add(18)(p11.2),add(19)(q13.3),-20,+1~4mar[cp4]/46,XX[16]	NA	97.2	nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	365	CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-).	4.9	7.5	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
15-00073	1963	Male	Male	White	2	n	81	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	81	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Supportive/Palliative Care|Targeted Therapy - Other	2	AG-221|Hydroxyurea	2	Experimental|Supportive/Palliative Care			NA	Targeted Therapy - Other	AG-221	Experimental	14	Dead	72	Dead-Disease	FALSE	FALSE		-8	0		12.0	0	NA	69	5	12	NA	30	41	3.3	0.76		30.3	10.5	46,XY[20]	227	85.6	nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]	117		8.8	33.1	FALSE	FALSE		negative	negative		Foundation, G646fs*12; MAF 33%																								Foundation, E596_Y597INSYEYDLPYDPRS; MAF 27%				Foundation, R140Q; MAF 45%																									Foundation, Q213fs24; MAF 82%					FOUNDATION, P95R; MAF 48%										
15-00075	1964	Male	Male	White	5	n	80	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	80	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Other	1	AG-221	1	Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	34	Dead-Disease	FALSE	FALSE		1	NA	90	48	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]	NA	NA	Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7	65	positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT	NA	6.6	FALSE	FALSE		negative	negative																													C.G395A; p.R132H; MAF unknown																																									
15-00081	1757	Male	Male	White	3	n	48	FALSE	FALSE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	49	152	Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	6	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Mismatched Unrelated Donor	-1	Dead	443	Dead-Disease	FALSE	FALSE		-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
15-00084	1953	Female	Female	White	1	n	82	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	82	0	Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	122	Dead	35	Dead-Disease	FALSE	FALSE		-21	7.6			4.2	8.5	28	6.8	12.7	0.1	24	22	3.1	0.96		31.5	11	43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]	1304	86.8		21		7.3	17.63	FALSE	FALSE		negative	negative																										negative																																												
15-00123	1969	Male	Male	White	2	n	42	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	832	Alive	FALSE	FALSE		0	NA	81	85	NA	NA	4	7	4	NA	89	50	3	0.94		27.8	9.5		945	95.5		39	partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT	5.7	48.03	FALSE	FALSE		positive	positive														negative												negative																																												
15-00129	1972	Male	Male	White	5	n	68	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	n	n	y	n	1	Unknown	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Unknown	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Unknown	NA		FALSE	FALSE		0	NA	15	rare	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[19]	NA	NA	Normal	51	positive for CD34, CD117,  CD13, CD33 and HLA-DR	NA	2.9	FALSE	FALSE		negative	negative														negative												negative			negative	negative			negative																																					
15-00140	1721	Male	Male	White	2	n	68	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	184	Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	976	Alive	FALSE	FALSE		0	NA	1	0	NA	NA	NA	NA	NA	NA	23	24	4.6	NA		35.4	12	46,XY	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	61	CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)	7.5	2.6	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
15-00143	1876	Male	Male	White	5	n	71	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	71	30	Post-Chemotherapy	Peripheral Blood	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Cyclophosphamide, Fludarabine, TBI|Azacitidine|Venetoclax (ABT-199)	3	Hypomethylating/Low Dose Cytarabine|Experimental|Double Umbilical Cord Blood Transplant (DUCBT)			NA	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	479	Alive	TRUE	FALSE	15-00142;15-00008	-29	NA	4		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[12]	NA	NA	Normal	NA		NA	0.8	TRUE	FALSE	15-00008	negative	negative														negative												negative			negative	negative			negative																																					
15-00147	1981	Female	Female	HispNative	1	n	28	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	30	2	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) 	Salvage	5	Dead	843	Dead-Disease	TRUE	FALSE	15-00137	-27	0			0	0	4.1	0	2.1	32.3	54	37	3.7	0.3	NOS	27.3	9.2	46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]	NA	91.3		8		6.3	20.18	FALSE	FALSE		negative	negative																																																																						
15-00148	1988	Male	Male	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	113	Alive	200	Alive	FALSE	FALSE		0	0	25	39	0	2	58.4	2	12.9	24.7	16	42	2.9	0.92		19.4	6.7	46,XY[20]	1146	97.5	Normal	21	CD13, CD33, CD38, CD58, CD117, CD123, MPO      positive	5.6	3.28	FALSE	FALSE		negative	positive														negative							negative					negative			negative	negative			negative			negative			negative		negative					p.G13D; MAF 17%						p.T73I; MAF4% 														negative				
15-00150	1989	Male	Male	White	4	n	46	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	375	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	5	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	Unknown	NA		FALSE	FALSE		0	0			0	0	7.2	0	8.9	1.5	38	22	2.9	0.82		24.5	8.2	46,XY[20]	NA	87.5	Normal	18		5.4	5.98	FALSE	FALSE		positive	positive														negative							p.R882C; MAF 47%					negative			p.R132C; MAF 47%	negative			negative			negative			negative		negative					p.G13D; MAF 17%																				negative				
15-00159	1993	Male	Male	White	2	n	75	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Prostate Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	0	58	31.0	0	NA	24	9	31	NA	11	23	3.9	1.72		37.6	12.1	46,XY[20]	379	94	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	36	CD4(partial +), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD33(partial +), CD34(+), CD36(subset +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(variably +), MPO(partial +), TdT(small subset +)	6.7	12.8	FALSE	FALSE		negative	negative																													negative	negative																																								
15-00167	1998	Male	Male	White	1	n	42	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	3	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	3	Dead	35	Dead-Other	FALSE	FALSE		0	1.7	>50	55	0.9	4.4	13.2	23.7	14	0	22	30	2.1	0.91		23.2	7.3	46,XY[20]	NA	90.6	Normal	176	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, dim HLA-DR and partial MPO+	6.3	93.94	FALSE	FALSE		negative	positive														negative							negative					negative			negative	p.R140Q; MAF 46% 			negative			negative			negative		negative				p.H2488R; MAF 47%	negative						p.D61A; MAF 44%														negative			negative	
15-00169	2001	Female	Female	Black	2	n	67	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	67	0	Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage|Experimental|Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	449	Dead-Disease	FALSE	FALSE		0	0	24	6	0	NA	77	10	7	NA	29	37	4.1	0.89		30.1	9.9	46,XX[20]	511	NA	nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]	288	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)	8	3.3	FALSE	FALSE		negative	negative																														negative																																								
15-00171	2002	Male	Male	White	5	n	80	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	80	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC	3	Consolidation|Salvage|Experimental			NA	Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Salvage	-1	Dead	309	Dead-Disease	FALSE	FALSE		1	NA	80	86	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]	NA	NA	Positive for deletion of 20q12 in 11.5% of 200 cells	4	positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5	NA	NA	FALSE	FALSE		negative	negative		p.718_724del; MAF 50.3%												negative							negative					negative			negative	negative			negative			negative																			p.S114X; MAF 44.8%					p.P95H; MAF 45.1%						negative				
15-00175	1999	Male	Male	HispNative	1	n	50	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	50	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	Dead	99	Dead-Disease	FALSE	FALSE		0	0	76	93	0	0	6.1	1.7	1.8	0	7	10	2.2	0.44		18.8	6.3	43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]	NA	85.8	deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement	14		5.9	50.74	FALSE	FALSE		negative	negative														negative							negative								negative	negative			negative						negative		negative					 p.Q61K; MAF 37%																				p.R273H; MAF 44%			negative	
15-00180	2005	Male	Male	White	5	n	73	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Unknown	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	FLX925|Azacitidine, Lenalidomide|Venetoclax (ABT-199)	2	Salvage|Experimental			NA	Standard Chemotherapy	Azacitidine, Lenalidomide	Salvage	76	Dead	440	Dead-Unknown	FALSE	FALSE		0	NA	55	39	NA	NA	NA	NA	NA	NA		NA	NA	NA	M5	NA	NA	46,XY[20]	NA	NA	Normal	25	positive for CD34, CD117, CD13, CD33, and HLA-DR	NA	46.8	FALSE	FALSE		negative	negative		p.G643fs; MAF 32.9%												negative												negative		p.A318T; MAF 48.8%	p.G105G; MAF 50%	negative			negative			negative																								p.P95H; MAF 46.9%					p.Q414X; MAF 49.6%					
15-00194	1973	Male	Male	White	1	n	70	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	70	15	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Alive	523	Alive	TRUE	FALSE	15-00131	1	0			0	0	78.1	0.9	1.7	0	46	27	2	0.74		24.4	8.1	47,XY,+4[9]/46,XY[11]	NA	103.8		23		4.7	4.85	TRUE	FALSE	15-00131	negative	negative		p.Q588*; MAF 43% 												negative							negative					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
15-00196	2013	Female	Female	White	5	n	83	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	83	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Targeted Therapy - Other	1	AG-221	1	Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	24	Dead-Disease	FALSE	FALSE		1	NA	85	92	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XX,-7[20]	NA	NA	Monosomy 7	77	positive for CD13, HLA-DR, CD34, and CD117, with aberrant loss of CD33, and with aberrant expression of CD7	NA	20.1	FALSE	FALSE		negative	negative														negative												negative			negative	p.R140Q; MAF 46.4%			negative			p.M541L; MAF 48.7%					negative																													
15-00200	2016	Female	Female	White	5	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	2	Azacitidine|Venetoclax (ABT-199), Azacitidine	2	Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	Venetoclax (ABT-199), Azacitidine	Experimental	115	Alive	868	Alive	FALSE	FALSE		0	NA	65		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		96	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	NA	1.6	FALSE	FALSE		negative	positive		p.A1312V; MAF 33.6%												negative												negative			p.A1312V; MAF 32.1%	negative			negative			negative					negative																													
15-00201	2016	Female	Female	White	5	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	n	y	n	n	2	Standard Chemotherapy|Targeted Therapy - Other	2	Azacitidine|Venetoclax (ABT-199), Azacitidine	2	Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	Venetoclax (ABT-199), Azacitidine	Experimental	115	Alive	868	Alive	TRUE	TRUE	15-00200	0	NA	65		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		96	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	NA	1.6	TRUE	TRUE	15-00200	negative	positive		p.A1312V; MAF 33.6%												negative												negative			p.A1312V; MAF 32.1%	negative			negative			negative					negative																													
15-00208	2018	Female	Female	White	5	n	65	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Clofarabine, Cytarabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Clofarabine, Cytarabine	Re-induction	-1	Dead	238	Dead-Disease	FALSE	FALSE		0	NA	35	44	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,add(2)(q13),-3,-5,add(6)(q21),del(7)(q22),+11,dic(11;17)(p11.2;p11.2),inv(11)(q13q23),add(12)(p12),add(14)(q22),-17,add(19)(p12),-22,+3mar[1]/45-48,sl,+add(1)(q12),del(7)(q22),+3-5mar[cp8]/47-48,sdl1,+8[cp4]/46,XX[3]	NA	NA	FISH assays were positive for loss of 5q31 sequences in 91.5% of cells, and positive for trisomy for 7 centromere with disomy for 7q31 in 54.2% of cells.	51	The myeloblasts were positive for CD34, CD117, CD13, CD33, and HLA-DR. A subset of the myeloblasts showed aberrant expression of CD56.	NA	4.7	FALSE	FALSE		negative	negative														negative									IL34-ETV6 rearrangement			negative			p.G105G; MAF 52.8%	negative			negative			negative				rearrangement intron 3	negative			(From Foundation Medicine) R192*, R1968* - subclonal, R765fs*26 - subclonal, FCHSD2-NF1 fusion																						loss exons 10-11				
15-00229	2024	Male	Male	White	1	n	25	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	25	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	n	y	n	n	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	28	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	28	Alive	28	Alive	FALSE	FALSE		0	0			0	0	22.3	0	0.9	0.7	25	50	3.2	0.9	M3	21.3	7.7	46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1]	921	92.2	FISH c/w PML/RARA fusion	16		6.8	18.25	FALSE	FALSE		positive	negative														negative							negative					negative			negative	negative			negative			negative			negative							negative																				negative				
15-00231	1727	Male	Male	HispNative	1	n	45	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	46	196	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) 	Salvage	4	Dead	259	Dead-Disease	TRUE	TRUE	14-00803	-86	0			0	1.7	7.8	51.3	18.3	0	29	19	3	0.52		20.6	7	47,XY,der(7)t(1;7)(q10;p10)+8[20]	NA	87.3		5		5.8	11.13	FALSE	FALSE		negative	negative																																																																						
15-00237	2028	Female	Female	White	1	n	29	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	IntermediateOrAdverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	29	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide|Transplant	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Bone Marrow Transplant	Transplant	Allogeneic - Matched Unrelated Donor	-1	Alive	476	Alive	FALSE	FALSE		0	0	95	78	0.9	0	11.7	0	13.5	1.8	20	25	3	0.54		23	7.9	46,XX[20]	1119	95.8	Normal	12	dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.	6.1	68.79	FALSE	FALSE		positive	negative																																					PTD																																	
15-00246	2032	Male	Male	White	2	n	65	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	214	Dead	269	Dead-Unknown	FALSE	FALSE		0	NA	10	1.0	0	NA	80	2	17	NA	24	27	4.3	1.48		20.4	7.2	46,XY[20]	275	93.3	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	23	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).	6.9	1.6	FALSE	FALSE		negative	positive																					W297*; MAF 44%					D835Y; MAF 6%		P161A; MAF 51%	negative	negative																																								
15-00248	2033	Male	Male	HispNative	2	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Unknown	NA		FALSE	FALSE		0	0	64	47.4	1.7	NA	23.3	27.6	0	NA	29	26	3.7	1.01		32.9	10.3	46,XY[20]	578	99.7	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	20	CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-).	7.2	20.8	FALSE	FALSE		negative	negative		G967DEL; MAF 45%												A111FS*56; MAF 48%														A318V; MAf 37%	negative	negative																G13V; MAF 37%																								
15-00261	2052	Female	Female	White	1	n	43	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	43	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Cytarabine	Supportive/Palliative Care	125	Dead	245	Dead-Disease	FALSE	FALSE		0	0			0	0	31.9	12.4	2.6	0.1	26	16	3	0.77	M4	22.1	7.5	46,XY[20]	297	95.7	Normal	59		6.5	22.95	FALSE	FALSE		positive	negative														negative							negative					negative													negative							negative									p.K110Q; MAF 38%								p.E261fs*2; MAF 52%			negative				
15-00269	2053	Male	Male	White	2	n	59	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	107	Dead	430	Dead-Unknown	FALSE	FALSE		-1	0	35	27.4	0	NA	36.8	6.6	29.2	NA	13	25	2.9	1.4		23.6	7.6	46,XY[20]	383	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	35		6	3.6	FALSE	FALSE		negative	positive														Y181*; MAF 15%																R140Q; MAF 35%																				splice site 1164-1G>A; MAF 48%										P95R; MAF 37%										
15-00275	1992	Female	Female	White	5	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	53	33	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	29	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	17	Dead	72	Dead-Disease	TRUE	FALSE	15-00157	-33	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]	NA	NA	Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells)	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
15-00276	2059	Male	Male	White	1	n	60	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	Complete Response	Other	167	Standard Chemotherapy	Azacitidine	Salvage	6	Dead	870	Dead-Unknown	FALSE	FALSE		0	0	90	39.6	1	4	47	10	1	0.1	30	26	2.4	1.17	M4	14	4.6	46,XY[20]	612	104.5	Normal	80	dim CD4, dim CD7, dim CD11b,      CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT	5.8	70.84	FALSE	FALSE		negative	positive																										p.V491L; MAF 51%																															p.K666Q; MAF 47%												p.Y395fs*51; MAF 49%	
15-00279	2087	Female	Female	White	3	n	48	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16	4	Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	TBI, VP-16	Allogeneic - Matched Unrelated Donor	-1	Alive	435	Alive	TRUE	FALSE	15-00278;15-00322	0	NA	86	77	NA	NA	NA	NA	NA	NA		NA	NA	NA	M5b	NA	NA	46,XX	NA	NA		NA	Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia.	NA	81	TRUE	FALSE	15-00278;15-00322	positive	positive														negative							p.Arg882Cys; MAF 47.1%					negative			negative	negative			negative			negative			negative							negative																				negative				
15-00281	2061	Male	Male	White	1	n	60	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	60	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	Decitabine	Induction	8	Dead	62	Dead-Unknown	FALSE	FALSE		0	0	15	3.5	3.5	0	92.2	0	0.8	0	46	35	1.8	0.56		22.6	7.1	46,XY[20]	293	89.3	Normal	417	partial dim CD7, CD13, dim CD33, CD34, CD38, CD58, CD117,  HLA-Dr and variable MPO	6.5	0.94	FALSE	FALSE		negative	negative		p.S747fs*25; MAF 38%												negative												negative			p.R132C; MAF 34%				negative						negative							negative									negative					p.P95R; MAF 35%										
15-00287	2073	Male	Male	White	1	n	85	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	85	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	105	Dead	167	Dead-Disease	FALSE	FALSE		2	0			2.5	0	14.6	2.4	0	0.5	14	15	3.5	0.98		33.2	10.7	46,XY[20]	289	89.5	Normal	8		7.4	25.63	FALSE	FALSE		negative	negative														p.K313_V314insK; MAF 50%							negative					negative										negative			negative							negative																			p.I1025L; MAF 50%	negative				
15-00294	2010	Male	Male	White	5	n	68	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	68	34	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Clofarabine	3	Hypomethylating/Low Dose Cytarabine|Unknown|Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	335	Dead-Disease	TRUE	FALSE	15-00187	-34	NA	60		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,r(7)(p1?3q2?2)[12]/46,XY[5]	NA	NA	loss of 7q31 sequences in 85% of assayed cells	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
15-00296	2079	Female	Female	White	1	n	16	FALSE	TRUE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	16	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Induction	10	Alive	318	Alive	FALSE	FALSE		0	0	93	0	0	0	33	67	0	0		NA	NA	0.72	M5	18.2	6.1	46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]	934	100	MLL:  14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis. An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9).	39	CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive	NA	24.72	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative			negative			negative			p.G13D; MAF 6%    		negative					p.Q61H; MAF 19%									negative											negative			negative	
15-00300	2067	Male	Male	White	5	n	76	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	NA	20		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]	NA	NA	Loss of chromosome 5q31 sequences (73.5%)                Loss of chromosome 7 sequences (monosomy 7) (61.5%)                Gain of 21q22 (AML1) sequences (11.5%)                Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences	91		NA	5.6	FALSE	FALSE		negative	negative		p.E1102D; MAF 31.1%												negative							p.F543C; MAF 35.7%					negative			negative	negative			negative			negative																														negative				
15-00302	2068	Female	Female	White	3	n	65	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	21	Dead-Other	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA	Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia	NA	NA	FALSE	FALSE		negative	positive														negative							negative					negative			negative	negative			negative			negative	p.Ile3572Ser (NM_001197104.1); MAF 44.1%		negative							negative																			p.His724fs; MAF 43.5%	negative				
15-00303	2069	Male	Male	White	1	n	64	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	64	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	5	Alive	68	Alive	FALSE	FALSE		-8	0			0	0.9	48.7	30.1	5.3	0	10	7	2.6	1.33		23.2	7.7	46,XY,inv(16)(p13q22)[17]/46,XY[3]	NA	87.2	c/w karyotype	53		5.9	8.69	FALSE	FALSE		negative	negative							negative							negative							negative					negative			negative	negative			negative			negative			p.G12D; MAF 27%		negative				p.G2299S; MAF 47%	negative									negative											negative			negative	
15-00309	2075	Female	Male	White	3	n	63	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	y	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	5	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	395	Dead-Disease	FALSE	FALSE		-11	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[6]	NA	NA		NA		NA	25.7	FALSE	FALSE		positive	positive																																																																						
15-00312	1967	Male	Male	White	5	n	69	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Squamous cell carcinoma	y	y	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	70	55	Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab	2	Induction|Experimental	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Other	Rituximab	Experimental	-1	Unknown	NA		TRUE	FALSE	15-00082	-54	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[18]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		positive	negative																																																																						
15-00320	2084	Female	Female	White	2	n	57	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Crenolanib	1	Induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin) plus Crenolanib	Induction	-1	Dead	81	Dead-Treatment	FALSE	FALSE		0	NA	55	47	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA	It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +).	NA	26.5	FALSE	FALSE		positive	positive		E981G; MAF 49%																			F290fs*24; MAF 40%												N322I; MAF 51%																																					
15-00331	2091	Male	Male	White	5	n	60	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	60	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	581	Dead-Disease	FALSE	FALSE		0	NA	33	23	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]	NA	NA	FISH positive for CBFB rearrangement in 49% of cells	42	Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with decreased expression of CD14 and/or CD64.	NA	29	FALSE	FALSE		negative	negative														negative												negative			negative	negative			negative			negative										p.Q61K; MAF 24.1%																								
15-00338	2094	Female	Female	White	2	n	42	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	42	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Intrathecal	3	ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate	3	Induction|Experimental|Maintenance	Unknown	Intrathecal	22	Standard Chemotherapy	ATRA, 6-MP, Methotrexate	Maintenance	-1	Alive	155	Alive	FALSE	FALSE		0	0	92	83.0	0	NA	11	4	0	NA	35	35	3.9	0.66		22.2	7.6	46,XX,t(15;17)(q24;q21.1)[1]	475	88.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	35	CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).	5.8	NA	FALSE	FALSE		negative	negative																													negative	negative																																								
15-00351	2102	Female	Female	White	1	n	48	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	56	0	Residual Relapse|Post-Chemotherapy|Post-DLI|Post-Transplant	Bone Marrow Aspirate	y	y	n	y	y	n	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	5	Dead	3069	Dead-Disease	FALSE	FALSE		0	0	62	5	0	0	83.2	1.8	0	0	28	21	2.5	0.8		24.1	8.3	46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]	290	94.5	All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).	53	dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive	6.5	1.46	FALSE	FALSE		negative	negative					p.A1262S; MAF 45% 																p.R882H; MAF 15% 						c.-12C>T; MAF 35%																																											
15-00353	2104	Male	Male	White	5	n	60	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	60	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	204	Dead-Disease	FALSE	FALSE		-6	NA	13	rare	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,del(13)(q12q14)[3]/46,XY[17]	NA	NA	Normal	136	CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature cells	NA	3.1	FALSE	FALSE		negative	negative														negative												negative			negative	negative			p.V617F; MAF 3.8%			negative					negative																								p.R1261L; MAF 27.7%					
15-00357	2106	Male	Male	White	5	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	53	0	Post-Transplant|Post-Chemotherapy|Residual Relapse	Peripheral Blood	n	y	n	n	y	n	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	6	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Unknown	NA		TRUE	TRUE	15-00358	1	NA	30	0	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		NA	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	NA	0.7	TRUE	TRUE	15-00358	negative	negative														negative												negative			negative	p.R172K; MAF 30.2%			negative			negative																													p.G335D; MAF 20.7%					
15-00358	2106	Male	Male	White	5	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	53	0	Residual Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	6	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Unknown	NA		FALSE	FALSE		1	NA	30	0	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		NA	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	NA	0.7	FALSE	FALSE		negative	negative														negative												negative			negative	p.R172K; MAF 30.2%			negative			negative																													p.G335D; MAF 20.7%					
15-00361	2108	Female	Female	White	2	n	77	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Supportive/Palliative Care	1	Vincristine, Dexamethasone	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Vincristine, Dexamethasone	Supportive/Palliative Care	13	Dead	29	Dead-Disease	FALSE	FALSE		0	0	86	12.9	0.9	NA	71.6	1.7	8.6	NA	10	24	2.9	0.62		17.9	6.1	45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2]	599	93.7	(D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	5	CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +), CD79a(partial +),	4.8	2.1	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
15-00371	2113	Male	Male	White	2	n	74	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	75	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	48	Dead	324	Dead-Unknown	FALSE	FALSE		0	0	32.0	5.0	0	NA	69	8	18	NA	23	22	4.3	1.21		32.9	11.1	46,XY[18]	199	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	178	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +)	7.1	2.3	FALSE	FALSE		negative	negative																													negative	negative																																								
15-00377	2116	Female	Female	White	1	n	10	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	10	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	33	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	-1	Alive	569	Alive	FALSE	FALSE		0	0	80	75	1.7	6.1	17.4	7.8	11.3	0.7	24	22	3.7	0.51		30.3	9.1	46,XX[20]	688	83.7	Normal	74	variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive	7.3	39.69	FALSE	FALSE		negative	negative														p.G96fs*12; MAF ~50%							negative					negative			negative	negative			negative			negative	PTD (low level mutation)		negative							p.G12D; MAF 5%																				negative				
15-00383	2127	Male	Male	Black	2	n	63	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Ruxolitinib|Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	103	Dead	8	Dead-Disease	FALSE	FALSE		0	1	9	15.4	2.9	NA	20.2	16.3	42.3	NA		NA	NA	0.6		22.7	7	46,XY[20]	1086	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	126	CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).	NA	73.4	FALSE	FALSE		positive	positive		Foundation; W898*; MAF 47%																								negative			negative	negative									Foundation; A59T mutation; MAF 47%																								Foundation; W617*; MAF 49%							
15-00392	2129	Male	Male	HispNative	5	n	56	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	58	0	Post-Chemotherapy|Post-Transplant|Residual Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|Azacitidine	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	1358	Dead-Disease	FALSE	FALSE		1	NA	10	9.5	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	48,XY,+8,+8[14]/46,XY[6]	NA	NA	Gain of chromosome 8 centromere, trisomy 3.5%, and terasomy 19.0%	NA	positive for CD13, HLA-DR, CD34, and CD117, with aberrant expression of CD7 and aberrant loss of CD33, and with a subset of these blasts showing aberrant co-expression of CD34 and myeloperoxidase.	NA	1.6	FALSE	FALSE		negative	negative		p.G642fs; MAF 26.4%												negative							negative					negative			negative	p.R140Q; MAF 36.4%			negative			negative													p.G306E; MAF 65%																	negative		p.Q157R; MAF 43.1%		
15-00395	2119	Male	Male	White	1	n	76	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	Dead	520	Dead-Unknown	FALSE	FALSE		0	0	50	<5	2	0.2	52.2	37.1	8.5	0	18	16	3.7	1.45	M0	22.3	7.6	47,XY,+8[3]/46,XY[17]	NA	118.6	5% trisomy 8 (c/w karyotype)	104	#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive	7.7	4.48	FALSE	FALSE		negative	negative										p.Y371H; MAF 43%				negative							negative			p.K30fs*8; MAF 48%		negative			negative	negative			negative			negative			negative		negative					negative									p.A338fs*; MAF 41%		p.H662Q; MAF 28%									negative			negative	
15-00396	2120	Female	Male	HispNative	1	n	1	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	3	0	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide, Thymoglobulin|Etoposide|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Doxorubicin	4	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Etoposide	Maintenance	-1	Dead	781	Dead-Disease	FALSE	FALSE		0	0	35	7	0	0	16.1	9.8	68.7	0		NA	NA	0.21		29.6	9.3	48,XX,+14,der(14)t(14;17)(q32;q21),+21[10]/46,XY[10]	NA	86.5	37% trisomy 21, 38.5% XX, 61.5% XY (donor)	247	partial CD7, dim/partial CD33, CD34, CD38, CD56, CD58,  and CD117 positive	NA	3.87	FALSE	FALSE		negative	negative																																																																						
15-00406	2130	Female			5	n	59	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		n	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	Adverse		MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	59	0	Post-Chemotherapy	Peripheral Blood	y	n	n	n	n	n	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown			NA	Unknown	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	-1	Unknown	NA		TRUE	TRUE	15-00407	0	NA	2		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	NA	NA	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	NA		NA	2.8	TRUE	TRUE	15-00407	negative	negative		p.686_687del; MAF 40.4%												p.E10K; MAF 26.7%												negative			negative	negative			negative			negative																			p.R142fs; MAF 30%															
15-00407	2130	Female	Female	White	5	n	59	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		n	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	Adverse		MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	59	0	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown			NA	Unknown	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	-1	Unknown	NA		FALSE	FALSE		0	NA	2		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	NA	NA	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	NA		NA	2.8	FALSE	FALSE		negative	negative		p.686_687del; MAF 40.4%												p.E10K; MAF 26.7%												negative			negative	negative			negative			negative																			p.R142fs; MAF 30%															
15-00416	2133	Female	Female	White	5	n	33	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	33	2	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Clofarabine, Cytarabine	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Clofarabine, Cytarabine	Re-induction	-1	Unknown	NA		FALSE	FALSE		1	NA	80		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XX,-17[15]/46,XX[2]	NA	NA	90.5% monosomy 17, 6% trisomy 11q23	21	positive for CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR and MPO	NA	0.1	FALSE	FALSE		negative	negative														negative							p.V468M; MAF 51.2%					negative			negative	p.R172K; MAF 46.1%			negative			negative					negative														p.R174X; MAF 48.2%										p.G355D; MAF 50.5%	p.R43H; MAF 76.7%				
15-00417	2135	Male	Male	White	2	n	44	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	44	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	0	62	19	1	NA	18	35	25	NA	24	90	1.8	0.73		22.4	7.2	47,XY,+21[19]/46,XY[1]	NA	NA	nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	18	CD2(-), CD7(dim + to -), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(variably +)	7.1	8	FALSE	FALSE		positive	negative																																																																						
15-00464	2147	Male	Male	White	2	n	71	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	288	Dead-Unknown	FALSE	FALSE		-3	0.9			2.8	NA	NA	NA	NA	NA	28	27	4.2	1.18		29.3	9.8	46,XY,inv(4)(p14p16.1)[3]/46,XY[16]	194	NA	nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]	73		7.1	NA	FALSE	FALSE		negative	negative					Foundation; Q1337*; MAF 56%														Foundation; R49H; MAF 19%							negative			negative	negative																									Foundation; loss, splice site 477_508+22>GGG; MAF 50%					Foundation; R94_S101del;MAF 39%					Foundation; splice site 3409+2T>G; MAF 51%					
15-00470	2144	Male	Male	HispNative	1	n	32	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	32	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	1	ATRA, Arsenic Trioxide	2	Consolidation|Experimental			NA	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	232	Alive	292	Alive	FALSE	FALSE		-2	0			0	19.6	56.3	0.9	3.6	0.1	31	20	3	0.84		19.1	6.3	46,XY,t(15;17)(q22;q21)[20]	NA	96.5	70% PML/RARA	49		6.9	7.19	FALSE	FALSE		positive	negative														negative							negative					negative			negative	negative			negative			negative			negative		p.E484G, MAF 3%					negative																				negative			p.F451C; MAF 51% 	
15-00471	2142	Male	Male	White	3	y	69	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	69	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	250	Dead-Disease	FALSE	FALSE		0	NA	60		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA	weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.	NA	33	FALSE	FALSE		negative	negative														c.117delC; MAF 27.2%																																																			c.3454G>T; MAF 40.9%				c.1137_1138insA; MAF 43.7%	
15-00479	2167	Male	Male	White	5	n	65	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|Fludarabine, Cyclophosphamide, TBI |Venetoclax (ABT-199)	4	Hypomethylating/Low Dose Cytarabine|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)			NA	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI 	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	210	Dead-Disease	TRUE	FALSE	15-00478	-1	NA	95	62	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]	NA	NA	Gain of 8q22 and 21q22 (88%)	33	positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR	NA	19.8	TRUE	FALSE	15-00478	negative	negative		p.W960X; MAF 29.4%												negative												negative			negative	negative			negative			negative					negative											p.E76V; MAF 29.5%																		
15-00482	1532	Female	Female	White	1	n	46	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	424	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Consolidation	339	Alive	788	Alive	FALSE	FALSE		0	0	70	64.6	3.5	0.9	17.7	0	13.3	0	184	77	2.8	0.72		37	12.6	46,XX[20]	NA	94.4	Normal	138	CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive	5.7	16.95	FALSE	FALSE		negative	positive														negative							p.R882C; MAF 39%								negative	negative			negative			negative			negative		negative					negative						p.E76Q; MAF 41%			negative											negative			negative	
15-00491	2172	Male	Male	White	1	n	83	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	83	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	50	Dead-Unknown	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
15-00492	2140	Male	Male	White	1	n	29	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	29	15	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Mismatched Unrelated Donor	30	Alive	347	Alive	TRUE	FALSE	15-00428	-15	0		27.8	0	0	72.2	0	0	0	42	17	2.7	0.59		22.4	7.6	46,XY,t(6;11)(q27;q23),del(12)(p11.2p13)[13]/46,XY[7]	NA	88.5	MLL Rearrangement (53%), 6;11 translocations, ETV6 (44%), deleted chomosome 12 short arm	193		6	1.23	TRUE	FALSE	15-00428	negative	negative														negative							negative					negative			negative	negative			negative		p.R1363*; MAF 32%	negative	negative				negative					p.G12D; MAF 15%									negative											negative			negative	
15-00514	2188	Female	Female	White	5	n	81	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Bladder Cancer|Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	81	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	2	Azacitidine|Venetoclax (ABT-199)	2	Hypomethylating/Low Dose Cytarabine|Experimental			NA	Targeted Therapy - Other	Venetoclax (ABT-199)	Experimental	-1	Alive	651	Alive	FALSE	FALSE		1	NA	50	11	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,-7,+8[7]/47,sl,+8[6]/46,XX[6]	NA	NA	44% loss chromosome 7, 28% trisomy 8, 28% tetrasomy 8,	104	positive for CD34, CD38, dim CD45, CD117, HLA-DR and MPO	NA	1	FALSE	FALSE		negative	negative														negative												negative			p.R132C; MAF 16.3%	negative			negative			negative					negative																													
15-00525	2192	Female	Female	Black	1	n	36	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	36	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction|Experimental	Complete Response	Standard Chemotherapy	27	Targeted Therapy - Other	ATRA, Arsenic Trioxide	Experimental	-1	Alive	283	Alive	FALSE	FALSE		2	0	90	69.14	0	28.8	1.8	1.8	0.9	0.4	37	27	3.9	0.76	M3	26.3	8.2	46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]	605	89.2	95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17)	25	Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive	7.5	103.66	FALSE	FALSE		positive	negative														negative							negative								negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
15-00534	2195	Male	Male	White	5	n	87	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	87	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-120|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental			NA	Targeted Therapy - Other	AG-120	Experimental	-1	Dead	249	Dead-Disease	FALSE	FALSE		1	NA	60	39	NA	NA	NA	2	NA	NA		NA	NA	NA		NA	NA	47,XY,+21[3]/46,XY[9]	NA	NA	9.5% gain 21q22	43	A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR	NA	139.9	FALSE	FALSE		negative	negative		p.G642fs; MAF 31.6%												p.A66fs; MAF 37.3%															p.R132C; MAF 48.7%																																					p.N107D; MAF 97.6%				
15-00539	2196	Female	Female	White	2	n	72	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	4	Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine	2	Hypomethylating/Low Dose Cytarabine|Maintenance			NA	Other	Clofarabine, Cytarabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	465	Dead-Disease	FALSE	FALSE		-79	0		25	0	NA	2	54	18	NA	41	34	3.6	0.58		27.5	8.8	46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]	NA	NA	nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]	NA		6.2	58.2	FALSE	FALSE		negative	negative																																																							PB		PB													
15-00556	2202	Male	Male	White	1	n	10	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	IntermediateOrAdverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	10	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Intrathecal|Other	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|MiDAC	2	Induction|Re-induction	Refractory	Intrathecal	10	Standard Chemotherapy	MiDAC	Re-induction	31	Alive	75	Alive	FALSE	FALSE		1	0	75	86	0	0	7.5	1.8	4.7	0.1	13	23	3.6	0.47		21.6	6.9	46,XY[20]	970	96		42	variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive	7.8	133.63	FALSE	FALSE		positive	negative														p.R142fs*19; MAF 52%							negative					negative			negative	negative			negative			negative			negative							negative																				negative				
15-00559	2205	Female	Female	HispNative	5	n	42	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	42	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	448	Dead-Unknown	TRUE	FALSE	15-00560	0	NA	50	51	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	256	positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO	NA	10.7	TRUE	FALSE	15-00560	negative	negative		p.G652S; MAF 41.3%												negative							p.S307fs; MAF 45.6%					negative			c.C315T; p.G105G; MAF 46.6%	p.R140Q; MAF 43.8%			negative			negative					negative																			p.P95H; MAF 42.2%										
15-00563	2204	Female	Female	White	1	n	2	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	2	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	136	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	428	Alive	FALSE	FALSE		0	0	80	52.2	0	1.8	46	0	0	0.2	22	53	NA	0.24	M1	22	6.9	46,XX,t(6;11)(q27;q23)[19]/46,XX[1]	NA	92.8		40	CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive	NA	57.08	FALSE	FALSE		negative	negative																																																																						
15-00571	2213	Male	Male	White	3	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Alive	36	Alive	TRUE	TRUE	15-00572	0	NA	84	91	NA	NA	NA	NA	NA	NA		NA	NA	NA	M2	NA	NA	46,XY[20]	NA	NA	Normal	NA	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	NA	25	TRUE	TRUE	15-00572	positive	negative		p.Glu635Argfs*15; MAF 9%																p.Tyr779*; MAF 5.4%												p.Arg140Gln; 37.7%																			p.Arg319*; MAF 88.6%						p.Arg166Gln; MAF 35.3%			p.Arg790Gln; 9.2%										p.Gln157Pro; MAF 51.3%		
15-00572	2213	Male	Male	White	3	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Alive	36	Alive	TRUE	TRUE	15-00571	0	NA	84	91	NA	NA	NA	NA	NA	NA		NA	NA	NA	M2	NA	NA	46,XY[20]	NA	NA	Normal	NA	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	NA	25	FALSE	FALSE		negative	negative		p.Glu635Argfs*15; MAF 9%																p.Tyr779*; MAF 5.4%												p.Arg140Gln; 37.7%																			p.Arg319*; MAF 88.6%						p.Arg166Gln; MAF 35.3%			p.Arg790Gln; 9.2%										p.Gln157Pro; MAF 51.3%		
15-00578	2214	Female	Female	White	1	n	62	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	4	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	Alive	27	Alive	FALSE	FALSE		0	0	95	67.25	0	0	9.5	23.3	0	0.1	54	57	3.3	0.78	M5	27.4	9.1	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	861	93.2	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	26	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	6.8	87.72	FALSE	FALSE		negative	negative		p.R693*; MAF 19%			p.S209L (possibly a benign germline polymorphism); MAF 48%									negative							negative					p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%;negative			negative	negative			negative			negative	negative		negative							p.G12S; MAF 19%																				negative				
15-00581	2222	Female	Female	White	2	n	74	FALSE	FALSE	FALSE	None	TRUE	FALSE	y	Uterine Sarcoma|Breast Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome associated with isolated del(5q)	Adverse		MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome associated with isolated del(5q)	74	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	2	Lenalidomide|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Maintenance			NA	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	Dead	187	Dead-Unknown	FALSE	FALSE		0	NA	4	2	1	NA	37	7	50	NA	42	42	3.6	0.68		22.4	7.4	42~44,XX,-3,del(4)(q25q33),der(5)t(3;5)(q21;q22),del(7)(p15p22),-9,-9,-13,-16,add(17)(p11.2),add(19)(p13.3), +mar1,+mar2[cp4]/41~43,idem,-del(7),+der(7)t(7;15)(p12;q15)add(7)(q11.2),+der(7;9)(q11.2;q13)del(7)(q11.2q22), -15,-21,+mar3[cp5]/42~44,idem,-del(7),+der(7),+der(7;9),-15,-add(19)	NA	NA	nuc ish(D5S2064x2,D5S630x2,EGR1x1) [91/200],(D7Z1x3,D7S522x2)[11/200],(D8Z2,D20S108)x2[196],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[196],(PMLx3,RARAx2)[28/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[101/200]	18	CD2(-), CD7(partial dim +), 11b(-), CD13(+), CD14 (-), CD15(-), CD33(variably +), CD34(bright +), CD36(+), CD38(slightly variably +), CD45(+), CD117(variably +), HLA-DR(-).	6.6	2.5	FALSE	FALSE		negative	negative																										negative			negative	negative																																				Foundation; R337L				
15-00593	2225	Female	Female	White	3	n	71	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Follicular lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	280	Dead-Disease	FALSE	FALSE		-1	NA	82	66	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,del(7)(q22q36)[20]	NA	NA	ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present	NA	CD7, CD13, weak CD33, CD34, CD117, and HLA-DR	NA	133.7	FALSE	FALSE		negative	negative																																																																					c.1138delinsAA; MAF 31.2%	
15-00595	2226	Male	Male	White	2	n	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	8	Unknown	NA		FALSE	FALSE		0	0	91	61	0	NA	46.1	1.7	9.4	NA	391	343	2.8	0.74	M1	22.8	7.1	92<4n>,XXYY[13]/46,XY[7]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x3~4[193/200],(D7Z1,D7S522)x3~4[194/200],(D8Z2, D20S108)x3~4[195/200],(RUNX1T1,RUNX1)x3~4[191/200],(ABL1,BCR)x3~4[191/200],(5'MLL,3'MLL)x3~4(5'MLL con 3'MLLx3~4)[193/200],(PML,RARA)x3~4[191/200],(5'CBFB,3'CBFB)x3~4(5CBFB con 3CBFBx3~4)[192/200]	34	CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably +), CD56(-), CD61 (-), CD64(-), (cont.above)	5.8	9.4	FALSE	FALSE		positive	negative														negative															p.R132C; MAF unlisted	negative																																								
15-00608	2232	Female	Female	White	5	n	61	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	464	Alive	TRUE	FALSE	15-00606	1	NA	40	28	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]	NA	NA	65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)	26	positive CD13, CD34, dim CD45, CD117 and HLA-DR	NA	4.8	TRUE	FALSE	15-00606	negative	negative					p.1189_1192del; MAF 33.1%									negative												negative			negative	negative			negative			negative					negative					p.G12D; MAF 10%														p.P95H; MAF 34.4%										
15-00610	2233	Female	Female	White	5	n	42	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	42	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI 	3	Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI 	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	505	Alive	FALSE	FALSE		0	NA	35	2	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	35	The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an	NA	49.7	FALSE	FALSE		positive	negative														negative												negative			negative	negative			negative			negative					negative														p.L29S; MAF 52.7%															
15-00614	2234	Male	Male	White	1	n	51	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	51	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/TBI	Allogeneic - Mismatched Unrelated Donor	-1	Alive	296	Alive	FALSE	FALSE		0	0			0	0	85.8	1.9	8.5	0	25	25	3	0.93	M0	25.1	8.2	60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]	634	81.8	EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.	77		6.5	0.5	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative							p.G13D; MAF ~40%																				Splice site (5' splice site mutation in intron 4); MAF 44%				
15-00615	2235	Female	Female	Asian	3	n	24	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	24	0	Initial Acute Leukemia Diagnosis	Leukapheresis	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	6	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Dead	633	Dead-Disease	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		positive	negative														p.Gln41fs; MAF 4%																				p.Gln865Glu; MAF 48.9%																																				
15-00616	2236	Female	Female	White	1	n	68	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	314	Dead-Disease	FALSE	FALSE		-14	2.6		49	5.1	6.8	36.8	0.9	14.5	0.2	18	16	2.8	0.67		21.9	7.5	43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]	821	88.7		8	CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive	7.2	11.01	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative																														p.I254N; MAF 40%				
15-00626	2239	Male	Male	White	5	n	77	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	77	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Experimental	Refractory	Standard Chemotherapy	212	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	38	Dead-Disease	FALSE	FALSE		0	NA	70	72	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	47,XY,+11[8]/46,XY[12]	NA	NA	35% gain of 11q23	174	CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.	NA	33.1	FALSE	FALSE		negative	negative		p.G642fs; MAF 32.1%												p.K90fs; MAF 39.1%										p.F246fx; MAF 91.4%		negative			negative	p.R140Q; MAF 49.2%			negative			negative					negative														p.L29S; MAF 52.9%						p.D884fs; MAF 89.8%				p.P1723S; MAF 48.4%					
15-00633	2241	Female	Female	White	3	n	52	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	52	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	-1	Alive	544	Alive	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,t(9;11)(p22;q23)[5]	NA	NA	11q23 (MLL): rearrangement present	NA		NA	NA	FALSE	FALSE		negative	negative																																							p.Gly13Asp; MAF 38.9%																															
15-00650	2251	Male	Male	White	1	n	85	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	85	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Refractory	Standard Chemotherapy	232	Standard Chemotherapy	Azacitidine	Induction	232	Dead	80	Dead-Unknown	FALSE	FALSE		0	0	36	23.7	0	8.7	20.2	27.2	20.2	1.6	24	23	3.4	0.88	M4	31.5	9.6	46,XY,del(12)(p11.2p13)[20]	200	95.7	ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. 	46	CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58.	7	40.53	FALSE	FALSE		negative	negative																																														p.Q61R; MAF 30%																						p.S34F ; MAF 50%		
15-00653	2254	Female	Female	White	2	n	52	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	52	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	633	Dead-Disease	FALSE	FALSE		-1	0	83	48.6	0	NA	9.4	0.9	40.2	NA	21	47	3.3	0.55	M1	25.3	8.3	46,XX[20]	NA	NA	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	48	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).	6.6	22.1	FALSE	FALSE		negative	positive														negative												Foundation; A680V; MAF 6%			negative	negative					Foundation; P738fs*2;MAF 31%																														Foundation; Q742*; MAF 45%					
15-00655	2260	Female	Female	White	3	n	70	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	70	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	Alive	543	Alive	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,del(7)(q22q36)[11]/46,XX[2]	NA	NA		NA		NA	NA	FALSE	FALSE		positive	negative																					c.2645G>A; MAF 41.8%								c.394C>T; MAF 46.7%																										c.486G>C; MAF 89.5%															
15-00670	2265	Male	Male	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	IntermediateOrAdverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea	4	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	276	Alive	FALSE	FALSE		-1	0	92	98	0	0.8	2.6	0	0	0.1	35	23	3.2	0.86		19.9	6.8	46,XY[7]	330	106.4	Normal	49	dim CD33, CD34, CD38, dim CD45, CD117, and MPO	8	84.96	FALSE	FALSE		positive	negative														negative							p.R882H; MAF ~50%					negative			p.R132S; MAF ~50%	negative			negative			negative			negative							negative														p.P95L; MAF ~40% 						negative				
15-00674	2269	Female	Female	White	5	n	54	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Sorafenib	1	Induction	Complete Response	Standard Chemotherapy	19	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin) plus Sorafenib	Induction	19	Dead	36	Dead-Other	FALSE	FALSE		0	NA	75		NA	NA	NA	39	NA	NA		NA	NA	NA		NA	NA	50,XX,+8,+10,+12,+21[20]	NA	NA	- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells	9	CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO	NA	37.2	FALSE	FALSE		negative	negative														negative										p.D146H; MAF 51.6%		negative			negative	negative			negative			negative					negative														p.D171N; MAF 19.8%															
15-00680	2272	Male	Male	White	1	n	68	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	23	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	Alive	447	Alive	FALSE	FALSE		0	0.9	86	74.8	0	0	2.6	20.8	0.9	0.2	20	28	2.9	1.49	M5	33	10.8	46,XY[20]	1211	95.9	Normal	83	Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive	7.2	134.36	FALSE	FALSE		positive	positive																															p.Q156H; MAF 45%																										p.K666Q; MAF 50%													
15-00682	2273	Female	Female	White	5	n	83	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Squamous cell carcinoma|Lung Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Targeted Therapy - Other	1	AG-221	1	Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Unknown	NA		TRUE	TRUE	15-00683	0	NA	45		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	NA	NA	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	133	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	NA	2.2	TRUE	TRUE	15-00683	negative	negative														negative												negative			p.G105G; MAF 50%	p.R140Q; MAF 37.8%			negative								negative																													
15-00683	2273	Female	Female	White	5	n	83	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Squamous cell carcinoma|Lung Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	n	y	n	n	1	Targeted Therapy - Other	1	AG-221	1	Experimental			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Unknown	NA		FALSE	FALSE		0	NA	45		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	NA	NA	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	133	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	NA	2.2	FALSE	FALSE		negative	negative														negative												negative			p.G105G; MAF 50%	p.R140Q; MAF 37.8%			negative								negative																													
15-00688	2276	Female	Female	White	1	n	63	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	9	Standard Chemotherapy	Decitabine	Induction	9	Dead	25	Dead-Other	FALSE	FALSE		0	1.8	41	2.6	0.9	0	79.6	0.9	14.2	0	21	19	2.7	0.98		27.7	9.4	45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]	404	88.5	EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo	6	CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.	7.6	1.61	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative							negative																				p.R248Q; MAF 56%		p.Q157P; MAF 41%		
15-00692	2277	Female	Female	White	2	n	72	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	73	0	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	112	Dead	565	Dead-Disease	TRUE	FALSE	15-00690	0	0	81	43	0	NA	51	3	2	NA	11	16	4.5	0.99	M0	28.2	9.6	46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	10	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +)	6.9	35	FALSE	FALSE		negative	negative														Foundation; M1fs*60; MAF 34%												negative			negative	negative																																				Foundation; splice site 560-2insA; MAF 44%				
15-00693	2279	Female	Female	White	1	n	66	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	66	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	Bortezomib|3+7 (Cytarabine, Daunorubicin)|MiDAC|Fludarabine, Cytarabine	4	Allogeneic - Sibling|Consolidation|Induction|Experimental	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Cytarabine	Allogeneic - Sibling	-1	Alive	838	Alive	FALSE	FALSE		0	0	60		0	0.9	29.8	54.4	1.8	0.5	23	19	2.5	0.84		24.2	7.7	47,XX,+6[6]/46,XX[19]	453	104.8	IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above	92	dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.	7.4	14.94	FALSE	FALSE		positive	negative					p.G1659E MAF ~10%,																																									p.Q61R MAF ~5%									p.P240fs*22; MAF 37%, RUNX1: splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% 															
15-00701	2280	Female	Female	White	1	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	50	0	Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Other	Hydroxyurea	Hypomethylating/Low Dose Cytarabine	365	Dead	302	Dead-Unknown	FALSE	FALSE		-111	0			0	2.6	8.8	17.6	2.6	0		NA	NA	NA	M0	19.8	6.4	48,XX,+11,+13[19]	NA	93.4		31		NA	206.64	FALSE	FALSE		negative	negative																																																																						
15-00702	2281	Female	Female	White	1	n	35	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	35	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	HiDAC	Consolidation	112	Alive	188	Alive	FALSE	FALSE		0	1.7	42	29.6	0.9	0	40	18.3	7.8	0.2	54	23	3.5	0.6		20.3	6.8	46,XX,inv(16)(p13.3q22)[21]	319	102.5	CBFB: 83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.	63	Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.	6.7	12.78	FALSE	FALSE		negative	negative														negative							negative					negative							negative			negative			negative							p.Q61P; MAF 15% 																				negative				
15-00704	2282	Female	Male	White	1	n	40	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	47	0	Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	8	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	6	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	10	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Dead	3241	Dead-Disease	FALSE	FALSE		0	0.4			0	1.6	46.5	15.6	35.9	0	51	35	3.6	1		35.2	11.7	46,XY[20]	NA	107.3	Normal	125		6.9	2.56	FALSE	FALSE		negative	negative																																																																						
15-00717	2295	Male	Male	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Alive	123	Alive	FALSE	FALSE		0	0.4	68	0	0.1	3	17	62.6	16.9	0.1	29	17	3.7	1.51	M5	27.7	8.9	46,XY[20]	296	104.9	Normal	74	dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	8	16.84	FALSE	FALSE		negative	positive		negative																			p.S714C; MAF 35%					negative			negative	negative			negative						negative		negative					p.G13V; MAF 6%						p.A72V; MAF 10%													p.Q876*; MAF 6%	negative				
15-00724	2287	Male	Male	HispNative	3	n	51	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Alive	452	Alive	FALSE	FALSE		0	NA	51	54	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	NA	CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR	NA	12	FALSE	FALSE		positive	positive																														R140Q; MAF 42.3%																						c.1508G>A; MAF 15.4%																		
15-00726	2288	Female	Female	White	1	n	70	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	3+7 (Cytarabine, Daunorubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	78	Alive	203	Alive	FALSE	FALSE		0	NA	25	0	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[19]	NA	NA	Normal	NA	CD13, CD33, CD38, CD117 and subset MPO positive	NA	NA	FALSE	FALSE		negative	positive		negative												negative							negative					negative			negative	negative			negative			negative			negative		negative					negative																				negative				
15-00731	2290	Female	Female	White	1	n	66	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	66	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	3	Consolidation|Induction|Re-induction	Complete Response i	Standard Chemotherapy	20	Standard Chemotherapy	Azacitidine	Consolidation	-1	Alive	183	Alive	FALSE	FALSE		0	0.5	13		2.5	0.5	24.7	9.7	62.1	0	58	48	2.7	1.1		24.4	7.7	46,XX[20]	NA	86.8	Normal	226	CD13, CD33, CD34, CD38, CD58, CD117 and  HLA-DR	6.7	4.33	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative							negative																				negative				
15-00734	2293	Female	Female	White	1	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	153	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	153	Alive	202	Alive	FALSE	FALSE		0	0	93	80	0	1.7	19.3	20.2	13.2	0.6	47	37	3.1	0.79	M5	26.8	8.8	46,XX[20]	977	92.1	Normal	36	Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64	6	42.34	FALSE	FALSE		negative	positive																										p.D835Y; MAF: 40%																																												
15-00742	2300	Female	Female	White	1	n	34	FALSE	FALSE	FALSE	PML-RARA	FALSE	FALSE	y	Pituitary macroadenoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	34	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	n	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	Alive	0	Alive	FALSE	FALSE		1	0	96	47	0	4	60	14	22	0	21	15	4	0.58	M3	30.1	10.7	46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]	191	95.9	21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.	32	CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive	7	0.5	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative							negative																				negative				
15-00755	2304	Male	Male	White	3	n	59	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	Dead	256	Dead-Treatment	FALSE	FALSE		-1	NA	93.2	47.5	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,t(3;4)(p21;q25)[3]/46,XY[17]	NA	NA		NA	CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64	NA	42.91	FALSE	FALSE		positive	positive																					c.2251T>C; MAF 36.9% (33.1% on 3/13/15)																																																	
15-00756	2305	Male	Male	White	1	n	36	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	36	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea	2	Consolidation|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	Alive	213	Alive	FALSE	FALSE		0	0	25	38	0	3.4	29.1	2.6	23.9	0	32	39	2.3	0.7		21	7.5	45,X,-Y,t(8;2;21)(q22;p21;q22)[20]	NA	104.5	RUNX1T1/RUNX1: (92%)	29	CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO	6.7	24.98	FALSE	FALSE		negative	negative										p.E369_Y371delinsH; MAF 31%																																																												
15-00763	2307	Male	Male	White	3	n	23	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	23	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	Allogeneic - Matched Unrelated Donor	-1	Alive	466	Alive	FALSE	FALSE		-4	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]	NA	NA	62% t(8;21) (RUNX1T1;RUNX1) translocation present	NA		NA	NA	FALSE	FALSE		negative	negative								c.6275_6276delTT; MAF unlisted																		negative																																												
15-00764	2308	Male	Male	White	3	n	38	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	40	0	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	y	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	38	Dead	717	Dead-Disease	FALSE	FALSE		0	NA	71	46	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	Normal	NA	CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase	NA	34	FALSE	FALSE		positive	negative																																																																						
15-00766	2310	Male	Male	White	5	n	71	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	71	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Lenalidomide|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	11	Dead-Other	FALSE	FALSE		0	NA	60	14	NA	NA	NA	7	NA	NA		NA	NA	NA		NA	NA	45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2,	NA	NA	FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.	17	Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry.	NA	21.6	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative					negative																								p.G355D; MAF 33.8%	p.P19H; MAF 8.9%				
15-00767	2311	Male	Male	White	2	n	78	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	78	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	347	Dead-Disease	FALSE	FALSE		0	0.2	25	4	1	NA	25	10	60	NA	22	21	4.5	0.82		47.3	15.3	46,XY[20]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	15	CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+)	7.5	5.79	FALSE	FALSE		negative	negative																													negative	negative																																								
15-00777	2314	Male	Male	White	1	n	68	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	Dead	122	Dead-Unknown	FALSE	FALSE		-1	0		83	0	0.8	8.1	9.8	1.6	0.7	29	137	3.3	2.67	M5	35.5	11.4	46,XY[20]	3615	92.4	normal	104	CD11b, partial CD13, partial CD14, CD33, partial CD56, CD58, CD64, subset HLA-DR (20%) and partial MPO positive	6.4	140.18	FALSE	FALSE		negative	negative		p.G645fs*12; MAF 52%																											p.R132L; MAF 47%								Partial tandem duplication 		p.G12A; MAF 36%																					p.P95H; MAF 49%										
15-00778	2315	Male	Male	White	1	n	62	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	-1	Dead	424	Dead-Disease	FALSE	FALSE		0	0	21	2.5	1.7	0	68.3	1.7	25	0	22	9	3.2	0.81		20.6	6.8	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	NA	100.5	EGR1 (73.5%) ;  TP53: (85.5%)	174	CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO	5.8	3.74	FALSE	FALSE		negative	negative									negative					negative							negative					negative			negative	negative			V617F Mutation (~3% mutant allele burden);p.V617F; MAF 1.5%			negative			negative		negative					negative									negative		p.G742D; MAF 35%									p.G266V; MAF 55%			negative	
15-00782	2320	Male	Male	White	2	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	Unknown	NA		FALSE	FALSE		0	0	45	48	2	NA	69	4	2	NA	12	15	3.8	NA		22.7	7.6	46,XY[19]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	27	CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	6.8	1.39	FALSE	FALSE		negative	negative																										negative			R132C; MAF 42%	negative														N935H; MAF 49%											N260fs*223+; MAF 26%					P95L; MAF 38%										
15-00786	2322	Male	Male	White	1	y	40	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	40	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	5	Alive	164	Alive	FALSE	FALSE		0	0	80	27.8	0	0	62.6	4.4	5.2	0	26	22	3.9	0.78		37.6	13.2	46,XY[20]	NA	91.7	normal	66	dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.	7.4	2.68	FALSE	FALSE		negative	negative														p.S28fs*81; MAF 28%																							negative																																	p.R378W; VAF 100%
15-00805	1690	Female	Female	White	1	n	60	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	62	461	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	730	Alive	FALSE	FALSE		-178	0	6	0	1.1	NA	50.8	3.9	44.2	NA	27	22	3.7	0.8		33.7	11.7	46,XX[18]	NA	100.3	normal	15	CD7, CD13, CD33, CD34, CD38, and CD123 positive	6.5	1.8	FALSE	FALSE		negative	positive																																					negative																																	
15-00807	2333	Female	Female	HispNative	1	n	14	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	189	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	252	Alive	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]	NA	NA	All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).	NA		NA	NA	FALSE	FALSE		negative	negative																									p.G79S; MAF 50%											p.D816Y; MAF 45%										p.G12D; MAF 45%																								
15-00811	2337	Male	Male	White	1	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	7	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	168	Dead-Disease	TRUE	FALSE	15-00799	-7	0			1.7	0.9	6.1	8.8	43	0.4	38	29	3.4	0.71		27	9.1	46,XY,add(3)(p24)[cp4]/46,XY[14]	321	95.1	normal	170		6.7	16.65	FALSE	FALSE		positive	positive										p.I423N; MAF <0.5%											p.R882C; MAF 0.9%																																												p.Q548*; MAF 0.7%					
15-00813	2339	Female	Female	White	1	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	53	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	7	Alive	119	Alive	FALSE	FALSE		1	0	45	50	0	19.4	6.4	1.6	11.3	0	73	83	3.3	0.88		29.4	9.6	46,XX[20]	2008	109.3	Normal	33	partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO	6.8	137.54	FALSE	FALSE		negative	negative																					p.R882H; MAF 45%					p.D835Y; MAF 3%											Partial Tandem Duplication									p.G13D; MAF 35%																								
15-00819	2342	Male	Male	White	1	n	64	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	64	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Intrathecal	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate	3	Consolidation|Induction|CNS	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	82	Alive	197	Alive	FALSE	FALSE		0	0.9	90	25.2	4.3	0.9	9.6	44.3	13.9	0.1	31	45	2.6	0.79	M5	22.7	7.7	46,XY,inv(16)(p13q22)[20]	1151	93.8	CBFB	10	dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO	5.5	24.64	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			p.D816V; MAF 45% 			negative		negative					negative									negative											negative				
15-00821	2343	Male	Male	White	1	n	66	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	66	0	Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	231	Dead-Disease	FALSE	FALSE		-20	0.8	0	0	0	2	18.6	9.3	69.3	0		NA	NA	NA		32.1	10.2	46,XY[20]	NA	94.7	Normal	345	The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expression.	NA	8.94	FALSE	FALSE		negative	negative																																																																						
15-00829	2001	Female	Male	Black	2	n	67	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	68	254	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage|Experimental|Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	449	Dead-Disease	TRUE	FALSE	15-00797	-17	NA			NA	NA	NA	NA	NA	NA	18	25	4.1	NA		20.4	6.8	47,XX,+11[5]/48,idem,+19[15]	NA	NA	nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	24		7.4	27.5	TRUE	FALSE	15-00797	positive	negative													p.Y325*; MAF 52%													negative			p.R132G; MAF 51%	negative							MLL-PTD (exons 2-10)																													p.R283C; MAF 49%				
15-00837	2350	Male	Male	White	3	n	72	FALSE	FALSE	TRUE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	72	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine|Momelotinib	2	Hypomethylating/Low Dose Cytarabine|Experimental			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	188	Dead-Disease	FALSE	FALSE		-141	NA		58	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,inv(16)(p13.1q22)[20]	NA	NA		NA		NA	8.21	FALSE	FALSE		negative	negative																																																																						
15-00839	2347	Male	Male	White	1	n	48	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	ADE (Cytarabine, Daunorubicin & Etoposide)	1	Induction	Unknown	Standard Chemotherapy	7	Standard Chemotherapy	ADE (Cytarabine, Daunorubicin & Etoposide)	Induction	7	Dead	33	Dead-Disease	FALSE	FALSE		0	0.2	13		0	0.5	10.2	4.4	84.7	0	84	28	3.9	0.95		42.1	14	46,XY[20]	231	89.2	Normal	330	CD33, CD117 positive, negative for CD34 and HLA-DR	8.2	6.3	FALSE	FALSE		positive	positive																														p.R140Q; MAF 40%																																								
15-00850	2357	Male	Male	White	5	n	62	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Unknown	NA		FALSE	FALSE		1	NA	50	20	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,inv(16)(p13.1q22)[20]	NA	NA	positive for rearrangement of CBFB in 60.5% of cells.	32	positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7.	NA	52.8	FALSE	FALSE		negative	negative														negative							negative			p.D146H; MAF 50%		negative			negative	negative			negative			negative					negative																									negative				
15-00855	2360	Male	Male	HispNative	1	n	8	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid leukaemia associated with Down syndrome	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid leukaemia associated with Down syndrome	8	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	2	ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine	2	Induction|CNS	Complete Response	Standard Chemotherapy	151	Intrathecal	Cytarabine	CNS	151	Alive	172	Alive	FALSE	FALSE		-2	10.8			0	1.8	8.1	13.5	8.1	0	13	25	3.2	0.72		26.8	9.3	47,XY,+21c[20]	NA	90.5	RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.	40		8.2	67.53	FALSE	FALSE		negative	positive														negative							negative					negative			negative	negative			negative			negative			negative							negative																				negative				
15-00858	2362	Female	Female	White	1	n	76	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	5+2 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	5+2 (Cytarabine, Idarubicin)	Re-induction	4	Dead	26	Dead-Disease	FALSE	FALSE		0	0	95	0	0	0.9	16.8	3.5	24.8	1.1	23	22	3.5	1.33		31.5	10.3	46,XX[22]	244	92.6	Normal	29	dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive	7	27.17	FALSE	FALSE		positive	positive		p.G966delG; MAF 50%												negative							p.R736H; MAF 45%					negative			negative	negative			negative			negative			negative							negative																				negative				
15-00864	2337	Male	Male	White	1	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	30	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	168	Dead-Disease	TRUE	FALSE	15-00863;15-00860;15-00799	0	0	8	1	4.7	0.9	40.6	10.4	43.4	0	40	34	3.8	0.73		20.2	7.1	46,XY[12]	235	93.5	normal	17	dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123	6.8	1.06	TRUE	TRUE	15-00811;15-00863	positive	positive										p.I423N; MAF <0.5%											p.R882C, MAF 6%																																												p.Q548*, MAF 6%					
15-00870	2364	Male	Male	White	6	n	71	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Vidaza|Rituximab|Decitabine	2	Consolidation|Maintenance			NA	Standard Chemotherapy	Decitabine	Maintenance	86	Dead	51	Dead-Disease	FALSE	FALSE		0	NA	20	10	1	NA	22	48	16	NA	6	33	3.7	1.57		26	8.1	46,XY[20]	NA	91.9		13	Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3	7	44.8	FALSE	FALSE		negative	negative					p.A603pfs*66; MAF55%																																		p.G12V; MAF 49%																pR320*; MAF 47%					p.P95H; MAF 49%	p.Y636*; MAF 96%									
15-00872	2367	Female	Female	White	1	n	65	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	181	Alive	FALSE	FALSE		0	0	74	60	1.9	15.1	21.7	50	11.3	0	23	32	2.6	0.78		21.6	7.2	46,XX[20]	905	100.5	Normal	150	partial variable CD7, subset CD11b (75%), CD13, CD33, partial CD14 (30%), partial CD64 (70%), CD38, CD58, partial CD117 (30%), CD123, HLA-DR, and partial (50%) MPO positive	6.7	84.69	FALSE	FALSE		positive	positive														p.K298Q; MAF 25%							p.R882C; MAF 44%									p.R140Q; MAF 18%																																								
15-00874	1973	Male	Male	White	1	n	70	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	71	281	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Alive	523	Alive	FALSE	FALSE		0	0	90	90	0	0	27.8	2.9	8.6	0.4	81	43	3.3	NA		31.9	10.2	47,XY,+4[2]/46,XY[18]	235	94.7	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	91	partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117	6.6	73.42	FALSE	FALSE		negative	negative		p.Q588*; MAF 49%																																																																				
15-00883	2416	Female	Female	White	1	n	72	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction|Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	Dead	118	Dead-Disease	FALSE	FALSE		0	0.9	90	78	0	0	2.7	3.6	17.3	1.4	28	23	2.8	0.56		31.7	9.9	46,XX[20]	261	98.1	Normal	211	CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO	6.5	24.01	TRUE	FALSE	15-00884	positive	positive														p.E163*; MAF 39%																																																								
15-00892	2421	Female	Female	White	3	n	72	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Other	1	SGN-CD33A	1	Experimental			NA	Targeted Therapy - Other	SGN-CD33A	Experimental	-1	Dead	179	Dead-Disease	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	positive																					c.2645G>A; MAF 45.4%					c.2503G>T (D835Y); MAF 15.5%																										c.178G>C; MAF 8.4%													c.3955-2A>G; MAF 45.4%					
15-00895	2418	Male	Male	White	1	n	54	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	5	Alive	48	Alive	FALSE	FALSE		0	0.4	4		1.2	0.5	18.4	9.4	70.1	0	124	106	3.6	0.92		39.5	13.2	47,XY,+8[3]/46,XY[17]	491	87.8	1% RUNX1T1	358		7.9	8.43	FALSE	FALSE		negative	positive														negative							negative					p.N841I; MAF 40%;negative			negative	negative			negative			negative			negative							negative																				negative		p.R156H; MAF 40%		
15-00898	2422	Female	Female	White	2	n	44	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	4	Alive	586	Alive	FALSE	FALSE		0	0	18	2	1	NA	29	2	66	NA	13	13	4.2	0.84		31.5	10.6	46,XX[20]	252	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	36	CD2 (-), CD4(partial +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34 (-), CD36(-), CD38(bright +/variable), CD45(+), CD56(-), CD64(-), CD117(+) and HLA-DR(partial +).	7.2	3.63	FALSE	FALSE		negative	positive																													negative	negative																																								
15-00900	2420	Male	Male	White	1	n	24	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	24	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Alive	187	Alive	FALSE	FALSE		0	0			1.8	0.9	23.9	23	7.9	0	37	28	3.7	0.95		32.3	11.3	46,XY[20]	243	92.8	Normal	102		7.1	21.84	FALSE	FALSE		negative	negative																																														p.G12C; MAF 40%																								
15-00903	2423	Male	Female;Male	White	3	n	73	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Lung Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	73	0	Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	7	Dead	36	Dead-Disease	FALSE	FALSE		-24	NA		79	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,X,-Y[20]	NA	NA	Normal	NA		NA	19.64	FALSE	FALSE		negative	negative		c.1940dup; MAF 37.9%				c.3496dup: MAF 7.5%																																																	c.319C>G; MAF 73.9%										c.3803+1G>A; MAF 39.3%					
15-00909	2425	Female	Female	Black	6	n	44	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	47	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Other	1	Radiation	1	Unknown			NA	Targeted Therapy - Other	Radiation	Unknown	14	Unknown	NA		TRUE	FALSE	15-00910	0	NA	90	45	0	NA	28	5	1	NA	30	41	3.3	0.82		29.3	9.6	46,XX[20]	NA	89.9	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined.	5	The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers.	7.3	6.5	FALSE	FALSE		positive	negative																																																																						
15-00912	2426	Female	Female	White	6	n	76	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	77	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Unknown	1	Azacitidine	1	Unknown			NA	Unknown	Azacitidine	Unknown	424	Dead	151	Dead-Unknown	FALSE	FALSE		0	NA	86	50	1	NA	14	5	20	NA	32	20	2.9	0.62		24.3	7.8	48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]	NA	84.1		27	POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58.	5.4	14.3	FALSE	FALSE		negative	negative																																																																						
15-00921	2429	Female	Female	White	1	n	74	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Unknown	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	74	0	Post-Chemotherapy	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC	2	Consolidation|Induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	MiDAC	Consolidation	3	Alive	151	Alive	FALSE	FALSE		-105	0.9			1.9	0.2	27.7	3.5	65.8	0	30	36	4.3	0.8		38.7	13	46,XX[20]	NA	102.9	normal	206		7.3	4.26	FALSE	FALSE																																																																									
15-00929	2433	Female	Female	White	3	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	50	0	Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC	4	Consolidation|Induction|Re-induction|Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	8	Dead	425	Dead-Treatment	TRUE	FALSE	15-00930	-1	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	"showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22)."	NA		NA	10.08	FALSE	FALSE		negative	negative																																																																						
15-00936	2337	Male	Male	White	1	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	63	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	168	Dead-Disease	TRUE	FALSE	15-00938;15-00799	2	1.8			3.6	6.2	23.2	18.7	17	1.3	29	41	3.6	1		20.9	6.9	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	NA	96.3	normal	21		6.8	20.77	TRUE	FALSE	15-00938	positive	positive																					p.R882C; MAF 45%					p.D835H; MAF 15%																																							p.Q548*; MAF 45%					
15-00939	2314	Male	Male	White	1	n	68	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	72	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	Dead	122	Dead-Unknown	TRUE	TRUE	15-00777	-39	0.8			0.9	0	9.3	0	0	0.5	12	14	2.5	0.9		20.6	6.4	46,XY[19]	NA	90.4	normal	60		6.3	6.21	FALSE	FALSE		negative	negative																																																																						
15-00942	2437	Female	Female	Black	6	n	30	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	31	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	27	Standard Chemotherapy	HiDAC	Consolidation	93	Unknown	NA		TRUE	FALSE	15-00943	0	NA	27	43	NA	NA	12	40	5	NA	35	62	4.6	1.01		26.1	8.5	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]	NA	90.6	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.	5	There are increased abnormal cells in the "monocyte" gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression.	7.3	5.3	FALSE	FALSE		negative	negative																																																																						
15-00947	2439	Male	Male	White	1	n	66	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	66	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Alive	133	Alive	FALSE	FALSE		0	0		23	3.5	4.3	39.1	4.4	34.8	4.5	17	20	3.8	1.09	M0	27.1	8.4	46,XY,t(4;9)(q21;p22)[7]/46,sl,add(1)(p13),add(15)(q15)[6]/45,sdl1,-18[4]/49,sdl2,+add(1)(p13),+6,+8,+18[2]/46,XY[1]	NA	98.9	20% CEP 8, 24% RUNX1T1/RUNX1, 23% PML/RARA	21	CD13, CD33, CD34, CD38, CD58, CD117, and HLA-DR positive	7	4.42	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			p.V16F. MAF 15%			negative			negative							negative																				negative				
15-00961	2444	Female	Female	White	1	n	52	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	52	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	81	Alive	181	Alive	FALSE	FALSE		0	0			30	13	9	21	19	0.1	54	50	2.2	0.84		18.8	6.5		NA	98.9		21		6.5	65.58	FALSE	FALSE		negative	negative																																													p.K2181R ; MAF 50%															p.P95H ; MAF 50%										
15-00964	2337	Male	Male	White	1	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	75	Residual Disease|Post-Chemotherapy	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	168	Dead-Disease	TRUE	FALSE	15-00938;15-00799	-10	0			0	0	14.3	2.4	3.2	1.3	41	36	2.6	0.86		22.9	7.6	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	346	92.3	normal	23		5.9	19.3	TRUE	FALSE	15-00938	positive	positive																					p.R882C; MAF 45%					p.D835H; MAF 15%																																							p.Q548*; MAF 45%					
15-00965	2447	Female	Female	White	1	n	61	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	187	Alive	FALSE	FALSE		0	0			0	0	89.9	9.3	0.8	0	43	31	2.4	0.5		19.5	6.5		313	92.4	normal	32		5.8	67.36	FALSE	FALSE		negative	positive																	p.R2353Q; MAF 51%																				negative																												p.Q270*; MAF 90%					
15-00967	2416	Female	Female	White	1	n	72	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	40	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction|Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	Dead	118	Dead-Disease	TRUE	FALSE	15-00933	-15	0	70	3.56	0	1.8	34.8	3.6	0.9	23.2	13	40	3.2	0.55		22.7	7.5	46,XX[5]	339	89.7	Normal	32	CD13+, CD33+, CD38+, variable partial CD56+, partial CD64+, CD117+, dimCD123+, and MPO+	6.4	6.04	TRUE	FALSE	15-00933	positive	positive														p.E163*; MAF 40%																																																								
15-00974	1745	Female	Female	White	1	n	36	FALSE	FALSE	FALSE	GATA2-MECOM	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	38	494	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Peripheral Blood	y	y	y	y	y	y	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	7	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	4	Dead	533	Dead-Disease	FALSE	FALSE		-11	0			0.9	0	13.9	0	0.9	0.4	59	28	2.8	NA		32.6	10.3	46,XX,inv(3)(q21q26)[5]	NA	99.4	FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor	38		6.7	7.08	FALSE	FALSE		negative	negative																																																																						
15-00975	2452	Female	Female	White	6	n	70	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	70	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	37	Standard Chemotherapy	Azacitidine	Induction	37	Unknown	NA		FALSE	FALSE		0	NA	90	17	NA	NA	20	18	2	NA	24	26	3.8	0.76		25	8.2	46,XX,del(5)(q22q35)[20]	NA	87.7	Positive for 5q deletion in 91% of cells.	35	POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10.	6.2	7.7	FALSE	FALSE		positive	negative																										negative											PTD																															p.S34F; MAF 35%		
15-00976	2453	Male	Male	White	1	n	83	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	83	0	Residual Relapse|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221|Azacitidine, SGN-CD33A	2	Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	434	Dead-Disease	FALSE	FALSE		0	0.3	12	3	0	9.4	26.9	24.5	38.9	0	42	47	3.2	1.3		21.1	6.8	46,XY[20]	NA	87.9	Normal	213	CD13, CD33, CD34, CD38, dim CD58, CD117, and dim HLA-DR positive	6	3.72	FALSE	FALSE		negative	negative																	p.M2408V; MAF 48%													p.R140Q; MAF 47%																p.G12D; MAF 49%																								
15-00979	2455	Female	Female	White	1	n	44	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib 	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse	Complete Response i	Standard Chemotherapy	28	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	319	Dead-Disease	FALSE	FALSE		0	0	75	80	0	7.7	10.3	22.2	6.8	0	21	25	2.4	1.25		22.9	7.4	46,XX[20]	705	96.2	Normal	42	CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive	6.2	69.84	FALSE	FALSE		positive	positive																					p.R882H; MAF 48%																																																	
15-00981	2454	Male	Male	White	1	n	75	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Rectal Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Supportive/Palliative Care	2	Hydroxyurea|Decitabine	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	4	Dead	17	Dead-Disease	FALSE	FALSE		0	0	90	90	0	0	5.1	0.8	0.9	1	23	51	2.9	0.97		25.3	8.5	46,XY[20]	728	91.3	Normal	28	CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.	6.6	62.87	FALSE	FALSE		negative	positive																														p.R140Q; MAF 47%																														p.P95L; MAF 37%										
15-00988	2420	Male	Male	White	1	n	24	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	24	42	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Alive	187	Alive	TRUE	TRUE	15-00900	0	0	80		0	0	47.9	45.5	0	0	48	29	3.7	0.92		22.5	8.1	46,XY[21]	176	81.2	Normal	8		6.6	0.6	FALSE	FALSE		negative	negative																																																																						
15-00990	2459	Female	Female	White	1	n	81	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Azacitidine	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Azacitidine	Supportive/Palliative Care	6	Dead	14	Dead-Disease	FALSE	FALSE		0	0	90	70	0	0.8	6.1	72.2	12.2	0.4	62	50	2.9	4.22	M5	22.8	7.3	46,XX[20]	262	90.8	Normal	29	CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive	5.8	97.26	FALSE	FALSE		negative	positive		p.W796fs*22; MAF 48%																																			negative																												p.S825fs*1; MAF 49%					
16-00001	2460	Female	Female	White	1	n	36	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	36	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|Hydroxyurea	3	Consolidation|Induction|Experimental	Refractory	Standard Chemotherapy	1	Standard Chemotherapy	HiDAC	Consolidation	122	Alive	209	Alive	FALSE	FALSE		-2	0	40	60	1.7	0	33.4	5.1	18.8	0.1	38	28	3.2	0.53		22.9	7.6	46,XX,t(16;16)(p13.2;q22)[20]	508	99.6	CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.	24	Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.	7.3	20.44	FALSE	FALSE		negative	negative																																				p.T417_D419delinsY; MAF 33%																																		
16-00003	2461	Male	Male	White	3	n	26	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	16	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	603	Alive	FALSE	FALSE		-7	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[15]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	positive																														p.Arg140Gln; MAF 45.9%																																								
16-00004	2462	Female	Female	White	1	n	82	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	82	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	268	Dead-Disease	FALSE	FALSE		0	0	50		0	1.8	42.8	0	5.4	3.7	13	18	2.8	1.03		27.7	9.2	46,XX	279	91.1	trisomy 8 in 5 of 20 metaphase cells 	44		7	1.36	FALSE	FALSE		negative	negative																					p.R882H; MAF 39%						p.R191C; MAF 51%			p.R172K; MAF 36%																																								
16-00006	2464	Male	Male	White	4	n	77	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	IntermediateOrAdverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	Refractory	Standard Chemotherapy	165	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	Alive	217	Alive	FALSE	FALSE		0	NA	41	18	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	NA	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	NA	2.2	FALSE	FALSE		positive	negative																										negative										negative																																		
16-00007	2464	Male	Male	White	4	n	77	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	Refractory	Standard Chemotherapy	165	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	Alive	217	Alive	TRUE	TRUE	16-00006	0	NA	41	18	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	NA	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	NA	2.2	TRUE	TRUE	16-00006	positive	negative																										negative										negative																																		
16-00010	2437	Female	Female	AdmixedBlack	6	n	30	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	31	25	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	27	Standard Chemotherapy	HiDAC	Consolidation	93	Unknown	NA		TRUE	FALSE	16-00009;15-00943	0	NA	79	64	NA	NA	2	15	1	NA	44	53	4	0.52		29.5	9.6	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]	NA	89.4	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.	69	POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT	7.3	20.3	FALSE	FALSE		negative	negative																																																																						
16-00015	2467	Male	Male	White	1	n	71	TRUE	FALSE	FALSE	None	FALSE	FALSE	y	Squamous cell carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Post-Transplant|Relapse|Post-Chemotherapy	Peripheral Blood	n	y	y	n	y	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	7	7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Post-Transplant Relapse|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Alive	996	Alive	FALSE	FALSE		-1	0	95	50	2.6	0.9	29.8	0	30.7	0.4	15	18	2.8	1.22		27.2	9.6	46,XY[18]	230	96.8	Normal	103	Immunophenotype: dim CD13, CD33, CD117, CD123 and MPO positive.	5.6	7.92	FALSE	FALSE		positive	positive														p.A240fs*83 (7 bp insertion with frameshift); MAF 19%			p.P1150S; MAF 18%													p.R140Q; MAF 29%																														p.P95L; MAF 22%										
16-00017	2468	Female	Female	White	1	n	68	FALSE	FALSE	FALSE	None	TRUE	FALSE	y	Colon Cancer	y	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	Favorable	Favorable	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	68	0	Unknown	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	3	Consolidation|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	MiDAC	Consolidation	100	Alive	188	Alive	FALSE	FALSE		0	0	1		0	2.1	41.7	47.9	8.3	0		NA	1.9	0.84	M4	21.9	7.5	46,XX[20]	533	96.1	Normal	20	CD19, CD20, and surface kappa light chain positive	NA	3.38	FALSE	FALSE		negative	positive																					p.R882H; MAF 34%					p.D835V; MAF 11%													p.G13D; MAF 8%				p.L265P; MAF 8%																											
16-00026	2472	Male	Male	White	3	n	56	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response i	Standard Chemotherapy	12	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	519	Alive	FALSE	FALSE		-1	NA	89.6	51	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	54	84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocytes/monoblasts	NA	31.02	FALSE	FALSE		negative	positive																					p.Val716Asp; MAF 45%					p.Asp835Val; MAF 30.5%																											p.Glu178*; MAF 12%																	
16-00027	2473	Male	Male	AdmixedWhite	2	n	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib	4	Consolidation|Induction|Allogeneic - Child|Maintenance	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Cyclophosphamide	Maintenance	1	Alive	393	Alive	FALSE	FALSE		0	0	91	99.2	0	NA	0.8	0	0	NA	33	27	3	0.85		18.8	6.2	46,XY[29]	808	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	28	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)	6.1	181.08	FALSE	FALSE		positive	negative														negative												negative			R132H; MAF 47.0%	negative							Foundation; MLL-PTD Exons 2-8; not GeneTrails																												SPLICE SITE 3500+1G>A; MAF 48.0%					
16-00031	2477	Male	Male	White	6	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	50	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	97	Alive	576	Alive	TRUE	FALSE	16-00030	0	NA	75	73	NA	NA	6	6	8	NA	44	20	3.5	1		24.8	8	46,XY[20]	NA	91.5	Not Available (no FISH done)	26	These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b.	5.8	17.1	FALSE	FALSE		positive	negative																																																																						
16-00033	2474	Female	Female	White	1	n	58	FALSE	FALSE	FALSE	CBFB-MYH11	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	58	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Alive	274	Alive	FALSE	FALSE		0	0	23	3	0	0.9	50.2	29.8	19.1	0	33	25	3.8	0.76		35.2	11.9	46,XX,inv(16)(p13.1q22)[16]/46,XX[4]	NA	99.7	CBFB: 69/100 cells (69%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement and consistent with the inverted chromosome 16 in the metaphase karyotype.	119	CD13, variable CD15, CD33, CD34, variable CD64, CD117, dim CD123, dim HLA-DR, MPO and subset TdT-positive	7.1	2.35	FALSE	FALSE		negative	negative																																			p.I598V; MAF 50%				p.G12D; MAF 4%							p.G12S; MAF 6%																								
16-00035	2475	Female	Female	White	2	n	54	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	2	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	88	Alive	566	Alive	FALSE	FALSE		0	0		97	0	NA	1	0	2	NA	135	113	2.7	0.51		19.4	6.6		1259	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198]	28	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-).	5.3	175.91	FALSE	FALSE		negative	positive														negative												V592A; MAF 1.0%			negative	R140Q; MAF 47.0%																														P95L; MAF 41.0%										
16-00041	2480	Male	Male	White	4	n	70	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Refractory	Standard Chemotherapy	1	Standard Chemotherapy	Hydroxyurea	Induction	1	Dead	4	Dead-Disease	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	Negative	NA		NA	96	FALSE	FALSE		positive	positive																					p.R882H; MAF 50%															negative																							p.Q210H; MAF 50%						p.S460F; MAF 45%					
16-00046	2482	Male	Male	White	1	n	62	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Lung Cancer|Multiple Sclerosis	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Re-induction	-1	Dead	581	Dead-Unknown	FALSE	FALSE		0	0	40	8	0	1	80	3	8	15.4	15	9	3.8	0.87		25.4	8.2	46,XY,t(8;17)(p21;q11.2),del(17)(q2?4)[5]/46,XY[15]	NA	100.8	Normal	35	dim/partial cCD3, variable CD7, CD13, dimCD33, CD34,  CD38, CD117, dim CD123, dim HLA-DR, partial TdT, and partial MPO positive Monoclonal B cell population identified	7.1	1.04	FALSE	FALSE		negative	negative					p.Y1350*; MAF 65%																				p.T15_G16insP; MAF 50%																														p.E223*; MAF 25%						p.G977fs*8; MAF 55%									
16-00048	2483	Female	Female	Asian	1	n	46	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Anaplastic Astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	46	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	637	Dead-Disease	FALSE	FALSE		0	0.9	25	26.7	1.7	4.3	6.1	32.2	48.7	0.2	14	15	3.1	0.64		32	9.5	46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]	440	80.6	Normal	92	Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a	6.8	42.57	FALSE	FALSE		negative	negative																					p.I824V; VAF 50%						p.S412R; MAF 60%																			p.G13R; MAF 50%									p.T196I ; MAF 50%													p.I24T; MAF 5%		
16-00050	2485	Female	Female	White	1	n	77	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	77	0	Residual Disease	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	253	Dead	341	Dead-Unknown	FALSE	FALSE		0	0.8			2.5	0	15.8	0	70.9	0	62	28	3.3	1.01		24.2	7.9		241	87.7	EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal indicating deleted 16q22. TP53/CEP 17: 12/200 c	16		8	8.29	FALSE	FALSE		negative	negative																					p.E285D; MAF 40% 														p.Y215fs*2; MAF 40%																															p.V272_R273insL; MAF 75% (previously 71% in 4/21/15 peripheral blood)				
16-00056	2490	Female	Female	White	1	n	51	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	2	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	201	Alive	FALSE	FALSE		0	0	95	95	0	0	7.8	0	3.1	0.1	22	12	2.9	0.93		20.6	6.6	46,XX[20]	189	112.6	Normal	57	Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive	6.5	25.02	FALSE	FALSE		negative	positive										p.R420Q; MAF ~20%																p.N841K; MAF ~30%				p.R140Q; MAF ~30%																																								
16-00062	2492	Female	Female	White	2	n	63	FALSE	FALSE	FALSE	None	TRUE	FALSE	y	Breast Cancer|Breast Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	Adverse		MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	63	0	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Unknown	NA		FALSE	FALSE		0	0.3	6		3	NA	54.1	3.7	38.4	NA		NA	NA	NA		26.7	8.8	46,XX,add(5)(q11.2),inv(9)(p11q12)c[1]/46,idem,add(4)(p14),-add(5),+del(5)(q31q35),del(7)(q11.2q34),add(18)(q23) [cp4]/45,idem,-7,der(12)inv(12)(p13q24.1)add(12)(p13),-18,der(21)t(1;21)(p13;p11.2),+mar[cp11]/46,XX[4].	NA	91.8	nuc ish (D5S2064x2,D5S630x2,EGR1x1)[62/200],(D7Z1x2,D7S522x1)[79/200],(D8Z2,D20S108)x2[198],(RUNX1T1x2, RUNX1x3)[10/200],(5'MLL,3'MLL)x3~5(5'MLL con 3'MLLx3~5)[22/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200]	31	The cytospin and smear preparations reveal maturing hematopoietic precursors and scattered small lymphocytes.	NA	2.68	FALSE	FALSE		negative	negative								T3085FS*26; MAF 45.0%																					negative	negative																																				H193Y; MAF 65.0%				
16-00067	2496	Female	Female	HispNative	2	n	53	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	53	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI 	4	Consolidation|Induction|Allogeneic - Child|Maintenance	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Cyclophosphamide	Maintenance	1	Alive	517	Alive	FALSE	FALSE		-1	0	20	8	0	NA	37	20	30	NA	18	23	3.3	0.86		20	6.2	46,XX[20]	426	105.3	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	38	CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).	7	6.63	FALSE	FALSE		negative	negative																													negative	R140Q; MAF 51.0%							Foundation; MLL-PTD exons 2-10										V26G; MAF 1.0%													R94_S101DEL; MAF 40.0%										
16-00070	2497	Male	Male	White	1	n	24	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	24	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	2	Hydroxyurea|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	24	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	24	Alive	28	Alive	FALSE	FALSE		0	3.6	86	73	0	46	12.6	2.7	5.4	0.6	76	35	3.5	1		23.8	8.3	46,XY,t(15;17)(q22;q21)[20]	467	86.2	Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338);	55	CD13, CD33, CD64, dim CD71, dim CD117 and MPO (+).	7.2	42.35	FALSE	FALSE		negative	negative																																																																						
16-00073	2443	Female	Female	White	1	n	63	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	44	Residual Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	Dead	348	Dead-Disease	TRUE	FALSE	15-00954	-44	1.5		38.5	0	0	55	3.5	1.5	0	25	22	3.8	1.3		21.1	7.1	48,XX,+8,+21[16]/46,XX[4]	NA	91.3	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn	18		7.7	19.76	FALSE	FALSE		negative	negative																																																																						
16-00075	2498	Male	Male	White	4	n	69	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	69	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Alive	13	Alive	FALSE	FALSE		0	NA	39	11	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]	NA	NA	COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML	NA	Positive	NA	1.6	FALSE	FALSE		negative	negative														negative												negative										negative																																		
16-00077	2500	Male	Male	White	2	n	78	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Esophageal Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	80	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Consolidation|Induction|Experimental|Maintenance	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Other	AG-120	Experimental	-1	Dead	605	Dead-Disease	FALSE	FALSE		-29	0		70	0	NA	7	3	9	NA	11	57	2.6	1.28		25.6	8.1	45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]	1897	NA	nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	23	CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +).	4.3	240.43	FALSE	FALSE		negative	negative																														negative																																								
16-00078	2499	Female	Female	White	2	n	67	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Unknown	NA		FALSE	FALSE		0	0.8	85	7.7	0	NA	5.1	42.7	40.2	NA	27	41	1.9	0.66		28.7	9.5	46,XX[20]	670	102.5	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	42	CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+).	5.7	56.03	FALSE	FALSE		negative	positive																													negative	negative																Q61K; MAF 43.0%																								
16-00087	2495	Female	Female	White	1	n	24	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	FavorableOrIntermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	24	0	Post-Chemotherapy	Leukapheresis	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	114	Alive	261	Alive	FALSE	FALSE		0	0		97	0	0	1.9	0	1.9	0.2	14	18	2.7	0.51		19.6	6.2		364	108.3	normal	15	CD13, CD33, CD38, CD58, CD117 and CD123 positive.	6.4	181.66	FALSE	FALSE		positive	positive																										p.V592G; MAF 6%			p.W288fs*12; MAF 50%																																									
16-00088	2442	Female	Female	AdmixedBlack	6	n	25	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	26	49	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin	3	Consolidation|Induction|Re-induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	67	Dead	324	Dead-Unknown	FALSE	FALSE		0	NA	98	95	NA	NA	2	3	NA	NA	46	30	4.1	0.54		27.2	8.9	46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]	NA	90.4	This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.	81	These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed.	6.9	67.7	FALSE	FALSE		positive	negative																																																																						
16-00094	2501	Female	Female	White	1	n	37	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	37	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	Azacitidine	Consolidation	-1	Alive	17	Alive	FALSE	FALSE		0	1.7	95	74	2.5	0.8	13.6	14.4	10.2	0.4	23	14	3.1	0.46		27.9	9.2	46,XX[20]	NA	89.4	Normal	49	variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR	7	26.57	FALSE	FALSE		negative	negative		p.A1312V; MAF 50%																																					p.K117N; MAF 48%																														p.R380fs*69 (1 bp deletion with frameshift); MAF 48%	
16-00102	2508	Male	Male	White	4	n	72	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Alive	95	Alive	FALSE	FALSE		0	NA	97	96	NA	NA	NA	NA	NA	NA		NA	NA	NA	M1	NA	NA	46,XY[5]	NA	NA	D5S721, EGR1 del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)   	NA	CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR	NA	125.9	FALSE	FALSE		negative	positive																										p.D839G; MAF~45%				p.R140L; MAF ~50%						negative		p.V2338I; MAF ~50%																						p.P95H, MAF~55%										
16-00109	2511	Male	Male	White	1	n	76	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	7	Dead	8	Dead-Unknown	FALSE	FALSE		-1	0	96	93.3	0	0.7	4.7	0	1.3	0.6	23	43	2.3	0.46		31	10.4	46,XY[20]	839	93.9	Normal	17	CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive	5.1	230.05	FALSE	FALSE		positive	positive																																																																	p.W564*; MAF 50%					
16-00113	2521	Male	Male	White	5	n	85	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	85	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		TRUE	FALSE	16-00114	0	1.5	2		24	NA	11.5	8	55	NA	4	8	3.7	1.2		48.8	16.1	46,XY[20]	NA	NA	Normal	141		6.3	11.4	FALSE	FALSE		negative	negative														negative							negative			c.436G>C; p.D146H		negative			negative	negative			negative			negative			negative							negative																			c.5182G>T; p.E1728X	negative				
16-00115	2522	Male	Male	White	6	n	74	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	74	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	14	Dead-Disease	FALSE	FALSE		0	NA	19	7	4	NA	12	2	51	NA	29	38	3.7	0.86		24.2	7.8	45,XY,-7,del(12)(p11.2p13)[20]	NA	90.6	Monosomy 7 is detected in 87% of cells.	35		6.6	47.5	FALSE	FALSE		negative	negative																																																																						
16-00118	2443	Female	Female	White	1	n	63	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	58	Residual Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	Dead	348	Dead-Disease	TRUE	FALSE	15-00954	-58	0			0	0	12.6	0	0	0.2	16	36	3.1	1.57		20.9	7	48,XX,+8,+21[16]/46,XX[4]	887	89.7	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn	21		7.3	49.93	FALSE	FALSE		negative	negative																																																																						
16-00120	2515	Male	Male	White	3	n	36	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	36	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin	3	Consolidation|Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Methotrexate, Mercaptopurine, Tretinoin	Maintenance	-1	Alive	514	Alive	FALSE	FALSE		-1	NA	91.8	95	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,t(15;17)(q24;q21)[18]/46,XY[2]	NA	NA	Normal	NA	weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase	NA	55.42	FALSE	FALSE		positive	negative														negative																																																								
16-00124	2477	Male	Male	White	6	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	50	30	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	97	Alive	576	Alive	TRUE	FALSE	16-00123;16-00030	-30	NA		68	NA	NA	12	NA	3	NA	20	11	3.8	0.81		24.1	7.9	46,XY[20]	NA	89.6	Not Available (no FISH done)	39		6.4	2.1	TRUE	FALSE	16-00123	positive	negative																					p.r882H; MAF 45%					negative											PTD																		p.E454Gfs*149; MAF 51%															
16-00129	2519	Female	Female	White	5	n	42	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	104	Alive	FALSE	FALSE		0	0	90		0	NA	17	NA	20	NA	17	13	3.6	0.98		21.7	7.3	46,XX[19]	NA	NA	Normal	71	Positive	6.6	18.3	FALSE	FALSE		negative	positive														negative							negative					negative			negative	negative			negative			negative			negative							negative																				negative			c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs	
16-00132	2526	Male	Male	White	6	n	74	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Post-Chemotherapy	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Complete Response	Standard Chemotherapy	498	Standard Chemotherapy	Azacitidine, MLN4924	Induction	498	Unknown	NA		TRUE	FALSE	16-00131	0	NA	6		3.8	NA	48.1	9.5	38.1	NA	41	25	4.4	0.73		36.5	12.7	48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]	NA	94.8	This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.	43	These are positive for CD34, CD117, HLA-DR, and CD33.	6.4	2.1	FALSE	FALSE		negative	negative																																																																						
16-00135	2429	Female	Female	White	1	n	75	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Alive	255	Alive	FALSE	FALSE		0	NA	>95		NA	NA	NA	NA	NA	0	21	23	2.8	NA		17.1	6.1	46,XX,t(9;11)(p22;q23)[20]	NA	97.7	85% MLL rearrangement (c/w karyotype)	19	dim CD13, CD33, CD56, bright CD64, CD117, CD123 and HLA-DR-positive; MPO and CD34-negative	6.1	0.39	FALSE	FALSE		negative	negative																																																																						
16-00139	2530	Female	Female	White	6	n	73	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Ruxolitinib	1	Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	Ruxolitinib	Induction	28	Dead	560	Dead-Unknown	FALSE	FALSE		0	NA			0.5	NA	39.2	7.5	52.5	NA	10	21	4.5	0.87		34.1	10.9		NA	92.4		6		7.6	3.8	FALSE	FALSE		negative	positive																														p.R140Q; MAF 32%			p.V617F; MAF 30%																											p.R94dup; MAF 31%									p.R440Tfs*14; MAF 29%	
16-00143	2532	Male	Male	HispNative	4	n	58	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	58	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Experimental	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	192	Alive	FALSE	FALSE		-1	NA	57	24	NA	NA	NA	NA	NA	NA		NA	NA	NA	M2	NA	NA	47,XY,t(8;22)(p11.2;q11.2),+19[20]	NA	NA	t(8;22) clone observed, consistent with a neoplastic process 	NA	Positive	NA	100.2	FALSE	FALSE		negative	negative														negative							negative					negative										negative																																		
16-00145	2533	Male	Male	Asian	2	n	75	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	Vidaza|Decitabine|Fludarabine, Cytarabine	2	Salvage|Supportive/Palliative Care			NA	Standard Chemotherapy	Fludarabine, Cytarabine	Salvage	-1	Dead	159	Dead-Disease	FALSE	FALSE		0	0	27	2	0	NA	60.2	8.4	29.4	NA	12	15	4.8	0.98		30.7	9.3	46,XY,t(1;12)(p32;p13)[3]/46,XY[17]	215	NA	nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	121	CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +).	7.5	3.09	FALSE	FALSE		negative	negative		G646fs*12; MAF 37.0%			S1608*; MAF 3.0%																					negative			negative	negative									G12R; MAF 5.0%																						Q932fs*6; MAF 91.0%		E601fs*10; MAF 38.0%		C127fs*92; MAF 6.0%					
16-00150	2546	Male	Male	White	6	n	67	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	106	Alive	112	Alive	FALSE	FALSE		0	NA	60		NA	NA	NA	0	NA	NA		NA	NA	NA		NA	NA	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	NA	NA	Trisomy 8 is detected in 28% of cells.	NA	Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64	NA	NA	FALSE	FALSE		negative	negative					p.KB39Qfs*5; MAF 45%																															p.T916A; MAF 50%										p.G12A; MAF 24%														p.P95R; MAF 40%										
16-00151	2547	Male	Male	White	6	n	67	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	67	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Unknown			NA	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Unknown	-1	Unknown	NA		FALSE	FALSE		0	NA	80	10	2	NA	68	4	8	NA	8	10	3.9	0.85		21.2	7.2	46,XY[20]	NA	110.4	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	84	These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b.	5.9	0.9	FALSE	FALSE		negative	negative					MAF 49%																					negative			p.R132C MAF 12%				p.V617F; MAF 43%				PTD							MAF 18%																						p.Y220C; MAF 35%				
16-00157	2538	Male	Male	White	1	n	67	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	Alive	528	Alive	FALSE	FALSE		0	0	93	94	0	0	1	2.8	1.9	0.1	20	30	2.4	1.23		31.2	10.1	46,XY[20]	NA	96.3	Normal	30	partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+.	NA	125.16	FALSE	FALSE		negative	positive														negative							p.R882H; MAF 46% 					p.V592D; MAF 43% 			p.R132H; MAF 46%  	negative						negative			negative		negative					negative									negative	p.K459E; MAF 50% 										negative			negative	
16-00161	2543	Male	Male	White	1	n	65	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	12	Standard Chemotherapy	MiDAC	Consolidation	-1	Dead	189	Dead-Unknown	FALSE	FALSE		0	0.3	40	3	1.4	0	76.5	2.9	18.9	0	32	14	3.7	0.71	M0	28.5	10.2	46,XY[20]	122	96	normal	41	CD13, CD33, bright CD34, CD38, CD58, CD117, and TdT	6.4	3.49	FALSE	FALSE		negative	negative																	p.M118I; MAF 50%																																																					
16-00217	2569	Male	Male	White	1	n	86	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	86	0	Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental			NA	Standard Chemotherapy	Hydroxyurea	Consolidation	55	Dead	596	Dead-Disease	FALSE	FALSE		0	0	23	12.1	0	0.8	8.6	19	59.5	0	16	15	3.4	1.52		27.8	9	47,XY,+8[20]	398	97.5	(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. 	299	dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive	7.6	10	FALSE	FALSE		negative	negative					p.S1139*; MAF 80%									p.R343fs*79; MAF 40%							p.G707fs*72; MAF 45%									p.R140Q; MAF 40%																														p.P95H; MAF 40%										
16-00220	2571	Male	Male	White	3	n	67	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	Alive	31	Alive	FALSE	FALSE		0	NA	71.5	56	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	NA	CD33, CD38, CD56, CD117, and myeloperoxidase	NA	16.24	FALSE	FALSE		negative	positive																																																																	p.Leu1780fs; MAF 46.3%					p.Arg126*; MAF 97.7%
16-00226	2503	Male	Male	White	1	n	79	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	35	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	4	Azacitidine|Decitabine|Hydroxyurea|V212	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Alive	53	Alive	TRUE	FALSE	16-00092	-35	1.7		35	0	0	0.9	64.4	8.7	0.2	9	22	3.1	2.11		25.5	7.8	46,XY[22]	722	95.5	Normal	438	CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive	5.8	116.52	FALSE	FALSE		negative	negative																																																																						
16-00232	2584	Male	Male	White	3	n	58	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	58	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	143	Dead	270	Dead-Disease	FALSE	FALSE		-1	NA	78.3	37	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY,ins(10;11)(p12;q23q23)[9]/49,sl,+4,+6,+21[4]/46,XY[7]	NA	NA	- 11q23 rearrangement involving the KMT2A (MLL) locus in  51/200 (25.5 percent) cells scored,  - 3 copies of the RUNX1 locus at 21q22 in 91/200 (45.5  percent) cells scored.	NA	CD13, partial CD15, CD33, CD34, weak CD64,  very weak partial CD117, and myeloperoxidase	NA	2.64	FALSE	FALSE		negative	negative																																																																						
16-00249	2581	Male	Male	White	6	n	75	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Vidaza	Supportive/Palliative Care	-1	Alive	302	Alive	FALSE	FALSE		0	NA	60	50	NA	NA	NA	2	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		NA	These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers	NA	25	FALSE	FALSE		negative	negative																																																																						
16-00261	2477	Male	Male	White	6	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	50	63	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	97	Alive	576	Alive	TRUE	FALSE	16-00030	0	NA	20		0	NA	90	0	10	NA	15	11	3.6	0.8		20.3	6.9	46,XY[20]	NA	85.7	Not Available (no FISH done)	48	CD117 stains clusters and scattered immature mononuclear cells with atypia, 20%. CD34 is negative.	6.1	0.2	FALSE	FALSE		negative	negative																										negative											negative																																	
16-00264	2225	Female	Female	White	3	n	71	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Follicular lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	72	249	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	280	Dead-Disease	FALSE	FALSE		-37	NA	>95	99	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]	NA	NA	- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.	NA		NA	20.39	FALSE	FALSE		positive	negative																																																																						
16-00267	1241	Male	Male	White	1	n	57	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	60	883	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	953	Alive	FALSE	FALSE		0	0.9		1	0	8.9	18.8	15.2	56.2	5	50	59	3.1	1.2		26.9	9.5	46,XY[20]	420	97.5		152	The atypical, previously identified myeloid blast population (CD117+/CD34-) is not seen. Lymphocytes are about 5%, and mostly T cells which have a reversed CD4:CD8 ratio and no antigen aberrancy. B cells are essentially absent, and NK cells are not increased	6.2	4	FALSE	FALSE		negative	negative																																																																						
16-00269	2593	Female	Female	White	1	n	44	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	99	Alive	170	Alive	TRUE	FALSE	16-00268	0	0	65	11.2	3.5	0	76.7	0	8.6	0	19	11	2.8	0.53		23.7	7.8		197	100.4	Normal	222	CD13, CD33, CD117, CD123, dim HLA-DR and MPO	6.1	2.41	FALSE	FALSE		negative	positive																													p.R132H; MAF 44%																							p.R265Q; MAF 3%																		
16-00271	2594	Female	Female	White	2	n	22	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	22	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib	3	Allogeneic - Sibling|Induction|Experimental	Complete Response	Standard Chemotherapy	39	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	464	Alive	FALSE	FALSE		-1	0	63	42	0	NA	32.7	4.4	26.6	NA	27	39	3.1	0.68		19.3	6	46,XX[20]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]	176	CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).	6.3	22.01	FALSE	FALSE		positive	positive																										negative																																						E54FS*28; MAF 44.0%					A382FS*4; MAF 40.0%	
16-00273	2595	Female	Female	White	3	n	62	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	62	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Dead	169	Dead-Disease	FALSE	FALSE		-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	negative														c.68dup; MAF 21%							c.2645G>A; MAF 43.9%																									c.35G>A; MAF 30.2%																							c.1142C>A; MAF 36.4%	
16-00278	2597	Male	Male	White	5	n	64	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	41	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	440	Alive	FALSE	FALSE		0	0	83	74	0	NA	13	0	13	NA	15	45	4	1.27		25.2	8.7	46,XY[20]	NA	NA	Normal	39	Positive	6	53.3	FALSE	FALSE		positive	positive														negative							c.2645G>A; p.R882H					negative			negative	negative			negative			negative			negative							negative																				negative				
16-00289	2606	Female	Female	White	1	n	65	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	45	Standard Chemotherapy	Azacitidine	Consolidation	34	Dead	142	Dead-Disease	FALSE	FALSE		0	0	95	92.9	0	0.7	3.6	1.4	1.4	0.1	101	55	3.2	0.83		37	12.4	46,XX[20]	697	95.1	normal	42	CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive	6.3	166.91	FALSE	FALSE		positive	positive																																																																						
16-00292	2607	Female	Female	White	1	n	73	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	3	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	3	Dead	4	Dead-Disease	FALSE	FALSE		0	0	90	98.4	0	0	0.8	0	0.8	0.1	18	36	2.9	1.44		25.9	8.2	46,XX[20]	NA	90.6	Normal	19	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO	7.7	122.89	FALSE	FALSE		positive	positive																					p.R326P; MAF 50%									p.R140Q; MAF 40%																																								
16-00294	2547	Male	Male	White	6	n	67	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	67	36	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Unknown			NA	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Unknown	-1	Unknown	NA		FALSE	FALSE		0	NA	1		NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	The translocations normally seen in AML are not detected.	266	No increased or immunophenotypically abnormal blast cell populations identified.	NA	3.2	FALSE	FALSE		negative	negative																																																																						
16-00303	2611	Female	Female	HispNative	5	n	56	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	27	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	Dead	323	Dead-Disease	FALSE	FALSE		0	0	1.5	2	0	NA	23	57	13	NA	67	33	3	1.87		29	9.5	46,XX[19]	NA	NA	Normal	28	Positive	7.5	58.7	FALSE	FALSE		positive	positive		c.1954G>A; p.G652S												negative							c.2644C>T; p.R882C					c.2503G>T; p.D835Y			negative	negative			negative			negative			negative							negative																				negative				
16-00307	2612	Male	Male	White	6	n	71	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Alive	402	Alive	TRUE	FALSE	16-00306	0	NA	75	26	2	NA	15	8	43	NA	118	53	3.8	1.26		22.9	7.7	46,XY,del(7)(q32),add(13)(p11.2)[15]	NA	81.8	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	24	These are positive for CD34, CD117, HLADR, CD33 and CD13	8.7	5	FALSE	FALSE		negative	negative		p.Q428*; MAF 44%												negative												negative			p.R132C; MAF 45%				p.V617F; MAF 57%				PTD																		p.G406Vfs*193; MAF 39%										p.R1366S; MAF 40%					
16-00315	1973	Male	Male	White	1	n	70	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	72	423	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Alive	523	Alive	TRUE	TRUE	15-00874	-142	0			0	0	15.5	6.9	5.2	0	79	38	3.1	0.8		27.9	9.1	47,XY,+4[2]/46,XY[18]	NA	87.7	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	44		6.3	50.58	FALSE	FALSE		negative	negative																																																																						
16-00316	2615	Male	Male	HispNative	7	n	72	FALSE	FALSE	FALSE	Unknown	FALSE	TRUE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	73	0	Residual Disease	Bone Marrow Aspirate	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Alive	0	Alive	FALSE	FALSE		0	NA	20		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
16-00332	2621	Male	Male	White	6	n	72	FALSE	FALSE	FALSE	Unknown	TRUE	FALSE	y	Lung Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	Adverse	Not Enough Information	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	73	0	Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Vidaza	Supportive/Palliative Care	268	Dead	292	Dead-Unknown	FALSE	FALSE		0	NA		4	1	NA	13	5	23	NA	13	57	2.5	1.83		25	8.2		NA	105.9		32		5.8	66.7	FALSE	FALSE		negative	negative		p.R693* MAF 48%																						p.C565R MAF 27%									p.V617F, MAF 26%						p.Q61P, MAF 13%																p.S322Nfs*277, MAF 42%										p.Q866Rfs*14, MAF 39%					p.R295*, MAF 97%
16-00339	2626	Female	Female	White	1	n	70	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		n	n	n	n	n	n	y	n	MYELOPROLIFERATIVE NEOPLASMS	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Intermediate		MYELOPROLIFERATIVE NEOPLASMS	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	70	0	Unknown	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Hydroxyurea	1	Induction	Unknown	Targeted Therapy - Kinase Inhibitor(s)	-1	Targeted Therapy - Kinase Inhibitor(s)	Hydroxyurea	Induction	-1	Alive	1	Alive	FALSE	FALSE		0	1.6	13	6.8	0.8	0	5.7	2.5	72.1	5.7	24	36	2.9	0.95		29.1	8.9	46,XX[20]	953	105.1	Normal	208	CD13, CD33, CD34, partial CD117, CD123, HLA-DR	6.7	109.77	FALSE	FALSE		positive	negative																															p.N159S ; MAF 45%																										p.K666N ; MAF 45%													
16-00344	2628	Male	Male	White	1	n	59	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	96	Alive	188	Alive	TRUE	FALSE	16-00345	0	0	30	10.5	0	0	19.7	0.9	71.4	0	77	27	3.4	1.01		26.4	8.9	46,XY[20]	479	96.4	Normal	101	CD13, CD33, CD117, CD123, and HLA-DR	6.4	4.4	FALSE	FALSE		negative	positive																					p.R882C; MAF 40%																															p.K70R; MAF 40%							p.Q210H ; MAF 55%											
16-00351	2630	Female	Female	HispNative	1	y	46	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	46	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	120	Alive	192	Alive	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	negative														p.T98fs*10 ; MAF 40%																																																			p.Q758*; MAF 45%					
16-00354	2632	Male	Female;Male	White	3	n	79	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		-1	NA	86	87	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]	NA	NA	5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present 	27		NA	70.01	FALSE	FALSE		negative	negative																																				p.Asp816Val; MAF 44.4%																														p.?; MAF 91%				
16-00356	2633	Male	Male	HispNative	6	n	59	FALSE	FALSE	TRUE	Unknown	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	59	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Lenalidomide|3+7 (Cytarabine, Daunorubicin)	2	Unknown|Supportive/Palliative Care			NA	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Unknown	-1	Dead	207	Dead-Unknown	FALSE	FALSE		0	NA		1	9	NA	1	6	58	NA	135	44	3.2	0.79		21.6	7.3		NA	85		22		5.9	9.1	FALSE	FALSE		negative	negative																																														p.Q61H, MAF 21%							p.G273V ,MAF 64%																	
16-00358	2530	Female	Female	White	6	n	73	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	56	Post-Chemotherapy	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	1	Ruxolitinib	1	Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	Ruxolitinib	Induction	28	Dead	560	Dead-Unknown	FALSE	FALSE		1	NA	5		NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46,XX[20] 	NA	NA	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.	24	CD34 positive blasts are rare, <1%	NA	1.8	FALSE	FALSE		negative	positive																																																																						
16-00359	2546	Male	Male	White	6	n	67	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	55	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	4	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	106	Alive	112	Alive	TRUE	TRUE	16-00150	-55	NA	2		NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	NA	NA	Trisomy 8 is detected in 28% of cells.	47	Positive for CD34, CD117, CD13, HLA-DR, CD33 and CD38	NA	2.5	FALSE	FALSE		negative	negative																										negative											negative																																	
16-00366	2640	Female	Female	White	1	n	50	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	50	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	13	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Alive	167	Alive	FALSE	FALSE		0	0.8	63	12	0.8	0	80.9	1.7	7.5	0	26	9	3.2	0.95		30.2	9.8	46,XX[20]	NA	92.1	Normal	94	CD13, dimCD33, CD34, CD38, CD117, dimCD123, dim HLA-DR, and dim MPO positive.	6.2	1.13	FALSE	FALSE		negative	negative		p.N1036S; MAF 50%												p.N321D; MAF 20%							p.R882C; MAF 20%								p.R132C; MAF 20%								Partial tandem duplication 																																	
16-00373	2653	Male	Male	White	1	n	37	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	37	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Other	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Radiation|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Supportive/Palliative Care	Unknown	Standard Chemotherapy	24	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Alive	474	Alive	FALSE	FALSE		0	1.1	1	0	2.8	0.2	30.3	5.2	60.4	0	34	20	4.2	0.93		39.2	14.4	46,XY[20]	154	94.9	Normal	162	dim/partial CD1a, dimCD4, dimCD5, CD33, CD43, dimCD45, CD56, CD68, CD117, and lysozyme positive with Ki67 activity >90%.	7.5	5.35	FALSE	FALSE		negative	negative																																																																	p.L307R; MAF 51%					
16-00374	2654	Female	Female	White	6	n	64	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Endometrial cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	64	0	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Supportive/Palliative Care|Other	5	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	2	Symptom Control|Supportive/Palliative Care			NA	Supportive/Palliative Care	Paclitaxel	Supportive/Palliative Care	274	Alive	448	Alive	FALSE	FALSE		0	NA	1		NA	NA	NA	0	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		100	Granulocytes are significantly decreased	NA	4.2	FALSE	FALSE		negative	negative																																																																						
16-00392	2664	Female	Female	White	1	n	78	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib|Hydroxyurea|Decitabine	2	Consolidation|Experimental			NA	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib	Experimental	7	Dead	24	Dead-Unknown	FALSE	FALSE		-1	0			0	1.6	43.7	9.4	29.7	5.5	27	39	2	0.41	M7	26.2	8.2	46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]	1024	89.4	RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21).	17		5.5	6.28	FALSE	FALSE		negative	negative																											p.M1V; MAF 32%														p.S505N; MAF 70%																								p.V636fs*3; MAF 46%					
16-00400	2665	Male	Male	White	1	n	65	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	66	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Induction	-1	Alive	140	Alive	FALSE	FALSE		0	4.5	50	33	0	0	47.3	8.9	6.3	3.7	39	27	3.4	0.9		29.8	10.3	41~47,XY,+1,del(1)(q42),add(2)(q33),del(5)(q13q33),der(7)add(7)(p22)add(7)(q11.2),-9,10,der(12)add(12)(p13)ins(?;12)(?q13),13,add(13)(q34),-16,17,add(19)(q13.3),21,+r,+1~4mar[cp13]/41~47,idem,-der(7)[cp7]	2840	85.4	deleted 5q, deleted 7q, and monosomy 17 in the majority of cells scored. 52% of cells also had three RUNX1 (21q22) signals consistent with chromosome 21 material being present in marker and/or additional material of uncertain origin	29	dimCD7, CD13, CD33, CD34, partial CD56, CD117, dimCD123	7.1	3.49	FALSE	FALSE		negative	negative																																						p.P2557L (likely benign germline polymorphism); MAF 51%																												p.R248W; MAF 57%				
16-00406	2675	Male	Male	White	1	n	75	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	Vidaza|7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction|Frontline|Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Vidaza	Re-induction	-1	Alive	151	Alive	FALSE	FALSE		0	0	23		1	NA	51	11.2	36.8	NA	23	16	3.4	0.55		27.1	9.1	46,XY[19]	178	88	Normal	28	CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive	6.4	1	FALSE	FALSE		negative	negative																					p.R882H; MAF 41%																																				p.K700E; MAF 43%													
16-00410	2678	Male	Male	White	1	n	62	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	62	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	Alive	320	Alive	FALSE	FALSE		0	0	90	53	0.9	3.5	35.7	1.7	5.2	0.7	28	24	2.8	1.12	M3	19.8	7	46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]	519	85.7	PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.	38	CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)	5.4	9.87	FALSE	FALSE		negative	negative																																																																						
16-00459	2687	Female	Female	HispNative	1	n	61	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	55	Dead	263	Dead-Disease	FALSE	FALSE		0	0			0	0	30.8	10.3	0	0.3	195	75	3.6	0.68		25.4	8.2		1033	95.5		49		6.7	73.28	FALSE	FALSE		positive	positive																																																																						
16-00460	2688	Male	Male	White	3	n	58	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	58	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine	3	Salvage|Induction|Symptom Control	Refractory	Standard Chemotherapy	10	Supportive/Palliative Care	Azacitidine	Symptom Control	-1	Dead	278	Dead-Disease	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	[46,XY]	NA	NA	Normal	NA		NA	4.17	FALSE	FALSE		negative	negative			p.Val1277Ala; MAF 89.5%																		 p.Trp297* (NM_175629.2); MAF 82.1%								p.Arg132Cys (NM_005896.3); MAF 39.1%																																									
16-00465	2690	Male	Male	HispNative	1	n	12	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	12	0	Initial Acute Leukemia Diagnosis	Leukapheresis	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide	3	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Intrathecal	0	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Alive	233	Alive	FALSE	FALSE		1	0	70	85	0	1.8	14.7	51.4	8.3	50	28	150	3.7	0.64	M4	14.3	4.6	47,XY,+8[19]/46,XY[1]	NA	132.4	RUNX1T1 signal consistent with the trisomy 8 clone 	49	dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR	7.1	214.49	FALSE	FALSE		positive	negative																																																																						
16-00466	2685	Male	Male	White	1	n	59	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Bladder Cancer	y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Primary myelofibrosis	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	59	6	Post-Transplant|Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	y	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan|Azacitidine|Sorafenib	4	Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction	Refractory	Standard Chemotherapy	153	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	56	Dead	72	Dead-Disease	TRUE	FALSE	16-00467	0	0	30	25	0.9	0	23.2	11.6	36.6	0	39	22	2.7	NA		27.3	8.6	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	NA	97.2	EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q,	11	CD13, dim CD33, CD43, CD117	6.8	4.54	TRUE	FALSE	16-00467	negative	negative																											p.G283R; MAF 50%										Partial tandem duplication (Pathogenic) 																																	
16-00474	2694	Male	Male	AdmixedBlack	6	n	50	FALSE	TRUE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	FALSE	FALSE		-1	NA	70	91	0	NA	7	2	0	NA	23	25	2.4	0.66		26.6	8.7	46,XY,t(8;21)(q22;q22)[20]	NA	94.7		28		6.3	71.1	FALSE	FALSE		negative	negative		p.P581R, MAF 46%																																														p.D111N, MAF 52%										ASXL1, PDGFRB, SMC1A												
16-00477	2695	Male	Male	Black	1	n	49	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	51	0	Post-Chemotherapy|Post-Transplant	Peripheral Blood	y	y	y	n	y	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	13	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	115	Alive	833	Alive	FALSE	FALSE		-55	0			0	0	19.8	12.9	53.5	5.3	44	29	2.8	NA		30	10.3	46,XY[20]	NA	87.7		193		6.8	4.53	FALSE	FALSE		negative	negative																																																																						
16-00479	2697	Female	Female	White	3	n	39	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Leiomyosarcoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	40	0	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	30	Standard Chemotherapy	Azacitidine	Salvage	4	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]	NA	NA		NA	Increased atypical CD34 positive, CD7 positive myeloblasts	NA	NA	FALSE	FALSE		negative	negative																																																																						
16-00481	2699	Female	Female	White	3	n	60	FALSE	FALSE	FALSE	CBFB-MYH11	FALSE	FALSE	y	Adenocarcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	61	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	Dead	336	Dead-Disease	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX,inv(16)(p13q22)[20]	NA	NA		NA	Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.	NA	NA	FALSE	FALSE		negative	negative																																																																						
16-00483	2612	Male	Male	White	6	n	71	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	57	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	402	Alive	FALSE	FALSE		0	NA	33		NA	NA	NA	8	NA	NA		NA	NA	NA		NA	NA	46,XY,del(7)(q32),add(13)(p11.2)[20]	NA	NA	Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF)	22	They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT.	NA	NA	FALSE	FALSE		negative	negative																										negative											negative																																	
16-00484	2701	Female	Female	White	7	n	NA	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		n	n	n	n	y	u	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	Intermediate		MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	74	0	Unknown	Bone Marrow Aspirate	n	y	y	n	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20], normal female chromosome complement.	NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
16-00486	2687	Female	Female	HispNative	1	n	61	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	9	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	55	Dead	263	Dead-Disease	TRUE	TRUE	16-00459	0	0	98	90	0	0	34.5	5.5	0	0	101	36	3.6	0.56		32.9	11	46,XX[19]	NA	91.9	Normal	23	CD7, CD13, CD33, partial CD34, partial CD64, CD117, CD123, HLA-DR and partial MPO+	6.9	5.84	TRUE	TRUE	16-00459	positive	positive																					p.P777S; MAF 90%								p.R132H; MAF 45%;p.R132H; MAF 41%																																									
16-00491	2704	Female	Female	White	1	n	29	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	29	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	Dead	129	Dead-Disease	FALSE	FALSE		-1	0	98	3.1	2	1	60	13	24	1.7	393	350	2.5	0.69		27.2	9.4	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	NA	105.4	Normal	18	CD11b, CD13, CD14, CD33, CD56 and bright CD64+	5.4	2.42	FALSE	FALSE		negative	positive																																																																						
16-00494	2705	Female	Female	White	1	n	72	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	72	1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	5	Dead	148	Dead-Disease	FALSE	FALSE		0	0	90	94	1.9	0	4.6	89.8	3.7	0.2		NA	2.8	0.93	M5	37.1	11.9	46,XX,t(1;11)(p32;q23)[20]	NA	96.6	MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal	33	dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive	NA	104.44	FALSE	FALSE		negative	negative																					p.E283*; MAF 30%																																																	
16-00498	2706	Female	Female	White	3	n	33	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	33	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	-1	Alive	468	Alive	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.	26	Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.	NA	12.75	FALSE	FALSE		positive	negative																																																																						
16-00504	2708	Female	Female	White	2	n	60	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	60	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	259	Dead-Disease	FALSE	FALSE		0	2	2	0	1	NA	12	12	71	NA	27	NA	4.4	0.99		33.5	11.4	46,XX[20]	NA	95.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	219	The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia.	7.1	5.54	FALSE	FALSE		negative	positive																										R311Q; MAF 48%			negative	negative																																								
16-00510	2712	Male	Male	HispNative	1	n	34	FALSE	TRUE	FALSE	GATA2-MECOM	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	34	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine	3	Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	anti-CD33	Experimental	-1	Dead	291	Dead-Disease	FALSE	FALSE		0	0	60	28.9	0	2.1	44.3	8.2	16.5	5.5	117	61	3.9	1		35.6	11.7	46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]	424	96	D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.	916		7.7	6.13	FALSE	FALSE		negative	negative																																														p.Q61H; MAF 45%																								
16-00519	2713	Male	Male	White	1	n	47	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	47	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	-1	Alive	381	Alive	FALSE	FALSE		0	0		72.9	0	0	20.3	3.4	3.4	6.9	49	21	3.5	1.08		42.6	15	46,XY[20]	353	86.8	Normal	34	CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,	7.4	8.98	FALSE	FALSE		negative	negative														p.R35fs*125; MAF 50%			p.P505L; VAF 45%																																																					
16-00524	2714	Female	Female	White	1	n	34	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	34	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	202	Alive	FALSE	FALSE		-20	1			0	0	72.2	0.9	3.7	0	41	22	3.4	0.71		30.6	10.6	46,XX,inv(16)(p13,1q22)[17]/46,XX[3]	310	104.4	Positive for rearrangement of the CBFB gene at 16q22 on chromosome 16. Negative for BCR-ABL1 translocation or other abnormalities in this panel.	148		7.6	3.21	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			negative			negative		negative					p.G12D; MAF 6%									negative											negative			negative	
16-00525	2715	Female	Female	Asian	1	n	26	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	26	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	-1	Alive	352	Alive	FALSE	FALSE		0	0	95	40.2	0	0	45.5	9.8	4.5	0.2	32	58	3.1	0.69		22.3	7.4	46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]	NA	97.8	CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.	154	CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+	5.8	9.27	FALSE	FALSE		negative	negative																																																				p.D61G; MAF 15%													p.S1039L; MAF 50%					
16-00533	2685	Male	Male	White	1	n	59	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Bladder Cancer	y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Primary myelofibrosis	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	59	27	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	y	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan|Azacitidine|Sorafenib	4	Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction	Refractory	Standard Chemotherapy	153	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	56	Dead	72	Dead-Disease	TRUE	FALSE	16-00467	-21	0.9	70	50	0.9	0	22.8	2.6	36.8	0.2	16	43	2.5	1.62		20.4	6.8	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	1805	91.5	94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8.	8	CD13, dim CD33, partial CD34, dim CD117	7.4	8.35	TRUE	FALSE	16-00467	negative	negative																											p.G283R; MAF 50%										Partial tandem duplication (Pathogenic) 																																	
16-00538	2694	Male	Male	Black	6	n	50	FALSE	FALSE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	21	Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	TRUE	TRUE	16-00474	-22	NA	8	0	0	NA	12	29	54	NA	19	9	2.3	0.51		22.8	7.5	46,XY,t(8;21)(q22;q22)[20]	NA	88.7	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	224		5.1	6.8	TRUE	TRUE	16-00474	negative	negative		p.P581R, MAF 46%																																														p.D111N, MAF 52%										ASXL1, PDGFRB, SMC1A												
16-00540	2721	Female	Female	White	3	n	66	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	66	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Unknown	NA		FALSE	FALSE		0	NA		16	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	47,XX,+8[18]	NA	NA	Normal	NA	Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.	NA	129.5	FALSE	FALSE		positive	negative																																																																					p.Val379fs; MAF 13%	p.Arg415Trp; MAF 48.9%
16-00541	2720	Female	Female	White	1	n	63	FALSE	FALSE	FALSE	None	FALSE	TRUE	n		y	n	n	n	n	n	n	n	MATURE B-CELL NEOPLASMS	Plasma cell myeloma	Adverse		MATURE B-CELL NEOPLASMS	Plasma cell myeloma	63	0	Unknown	Peripheral Blood	y	y	y	n	n	n	1	Standard Chemotherapy	2	CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide)	2	Induction|Re-induction	Unknown	Standard Chemotherapy	16	Standard Chemotherapy	RVD (Bortezomib, Dexamethasone, Lenalidomide)	Re-induction	-1	Alive	0	Alive	TRUE	FALSE	16-00539	0	0			0	0.9	28.7	8.3	60.2	0.6	22	24	2.6	0.99		22	7	44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7]	249	102.8	Abnormal	69		4.9	7.14	FALSE	FALSE		negative	negative																																																																						
16-00547	2723	Male	Male	HispNative	1	n	29	FALSE	FALSE	FALSE	MLLT3-KMT2A	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	29	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	19	Standard Chemotherapy	HiDAC	Re-induction	4	Dead	65	Dead-Unknown	FALSE	FALSE		0	0.9	82	20	0	2.6	26.3	33.4	7.9	3.6	40	19	3.1	0.84		27.3	9.1	46,XY,t(9;11)(p22;q23)[20]	324	89.5	94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.	52	CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive	6.7	3.88	FALSE	FALSE		negative	negative																																																																						
16-00548	2119	Male	Male	White	1	n	76	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	417	Post-Chemotherapy|Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	Dead	520	Dead-Unknown	TRUE	FALSE	16-00557	6	0			0.9	NA	60.3	38.5	0.3	NA	19	19	3.2	1		24.2	8.6	47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]	261	102.5	Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male.	7		7.2	3.4	FALSE	FALSE		negative	negative																																																																						
16-00562	2739	Male	Male	White	6	n	66	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Primary myelofibrosis	Adverse	Not Enough Information	MYELODYSPLASTIC SYNDROMES	Primary myelofibrosis	67	0	Residual Disease	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	1	Hydroxyurea	1	Unknown			NA	Standard Chemotherapy	Hydroxyurea	Unknown	263	Alive	189	Alive	FALSE	FALSE		0	NA	5	5	NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46,XY[17]	NA	NA	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.	37	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. No BCR-ABL1 transcripts are detected. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alterations are detected in the ASXL1, BRAF, EZH2, JAK2, NRAS and SETBP1 genes.	NA	239	FALSE	FALSE		negative	negative		p.A640Dfs*20, MAF 40%					p.G469A, MAF 7%																	MAF 43%		negative							p.V617F, MAF 46%				negative									p.G12S, MAF 18%										p.D868N, MAF 15%														
16-00564	2740	Female	Female	White	6	n	81	FALSE	FALSE	FALSE	None	TRUE	FALSE	y	Rectal Cancer	y	y	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	Adverse	Adverse	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	81	0	Unknown	Bone Marrow Aspirate	y	y	y	n	y	y	1	Other	1	Radiation	1	Unknown			NA	Other	Radiation	Unknown	22	Alive	0	Alive	FALSE	FALSE		0	NA	5	0	NA	NA	NA	2	NA	NA		NA	NA	NA		NA	NA	45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]	NA	NA	9q deletion is present in all metaphase cells analyzed. All cells have also show either missing one X chromosome or an isochromosome for its long arm. It is most likely that the X chromosome abnormalities represent constitutional changes associated with Turner syndrome.	30	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significance are detected in the EZH2 and NF1 genes.	NA	35.1	FALSE	FALSE		negative	negative																								p.L128S ,MAF 49%		negative											negative							p.F2388I, MAF 45%																					p.R1452*, MAF 98%					
16-00566	2741	Male	Male	White	5	n	39	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	40	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	1	Re-induction			NA	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	Unknown	NA		TRUE	FALSE	16-00565	0	0	41	14	0	NA	5	5	76	NA	12	17	3.6	0.83		29.4	10.2	46,XY[15]	NA	NA	Negative	24	Positive	5.9	3.6	TRUE	FALSE	16-00565	positive	positive														negative							negative					negative			negative	negative			negative			negative			negative							negative																				negative				
16-00593	2483	Female	Female	Asian	1	n	46	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Anaplastic Astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	46	163	Residual Disease|Post-Chemotherapy	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	637	Dead-Disease	TRUE	TRUE	16-00048	-11	2.6			0.6	NA	16.2	14	66.6	NA	38	27	3.9	NA		36.3	11.7	46,XX[19]	NA	94.3	Normal	71		6.9	6.8	FALSE	FALSE		negative	negative																																														p.G13R;MAF 47%																								
16-00595	2754	Male	Male	White	3	n	58	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	58	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	-1	Dead	63	Dead-Disease	FALSE	FALSE		-1	NA	60	25	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	44-45,XY,-4,-5,add(7)(q11.2),  der(16)del(16)(p13.1)del(16)(q22),-17,add(18)(q21),+1-3mar[cp18]  /46,XY[2] 	NA	NA		75	Increased CD34+ myeloblasts, representing 42% of leukocytes, suspicious for AML	NA	6.69	FALSE	FALSE		negative	negative																																																																						
16-00599	2760	Male	Male	White	6	n	68	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	68	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Vidaza|Fludarabine, Melphalan|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Unknown	Standard Chemotherapy	22	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	280	Alive	FALSE	FALSE		0	NA	70		NA	NA	NA	1	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		66	These are positive for CD34, CD117, HLADR, CD33, and CD13.	NA	3.5	FALSE	FALSE		positive	negative																										negative											PTD																																	
16-00611	2695	Male	Male	Black	1	n	49	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	51	46	Residual Disease|Post-Transplant|Post-Chemotherapy	Peripheral Blood	y	y	y	n	y	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	13	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	115	Alive	833	Alive	TRUE	FALSE	16-00522	-32	0			0	0	4.2	1.7	6.8	0.6	91	102	3.5	NA		29.9	10.8	46,XY[19]	NA	85.4	Normal	31		6.9	162.21	FALSE	FALSE		negative	positive																																																																						
16-00618	2780	Female	Female	HispNative	5	n	64	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	2	FLX925|7+3 (Cytarabine, Idarubicin)	2	Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	FLX925	Experimental	-1	Dead	385	Dead-Disease	FALSE	FALSE		0	0	35	40	0	NA	30	14	12	NA	11	23	2.7	NA		20.4	6.6	46,XX,t(11;19)(q23;p13.1)[16]/46,sl,add(1)(p34)[2]/46,XX[2]	369	NA	MLL Rearrangment	35	Negative	5.9	42.9	FALSE	FALSE		negative	negative														negative							negative					negative		c.1145G>A; p.R382Q	negative	negative			negative			negative			negative							negative																			c.5162T>G; p.L1721W (SNP)	negative				
16-00627	2785	Male	Male	White	7	n	67	FALSE	FALSE	FALSE	Unknown	TRUE	FALSE	n		y	n	n	n	n	n	y	y	MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	Adverse	Not Enough Information	MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	66	0	Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Cytarabine|Decitabine	2	Induction|Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine	Induction	-1	Unknown	NA		FALSE	FALSE		0	NA	17	7	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	Trisomy 8	NA		NA	NA	FALSE	FALSE		negative	negative		positive																						positive																												positive			positive						positive									
16-00632	2786	Male	Male	White	7	n	59	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA	Atypical monocytes (are about 91.5%). They are CD45+, CD33+, HLADR++.CD13+, CD14+. CD15++, CD64++, CD116++, CD11b+++,CD11c++,CD38+ and CD34(-),CD117(-). A small population of monoclonal B-cells, CD19+, CD5+(<1%)	NA	NA	FALSE	FALSE		positive	positive																					p.Arg882His																																																	
16-00684	2204	Female	Female	White	1	n	2	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	3	397	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	136	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	428	Alive	FALSE	FALSE		0	0	53.74	50	1.7	0	68	5.5	24.8	0	23	24	4.2	0.31		30	10.5	46,XX,t(6;11)(q27;q23)[12]/46,XX[8]	276	87	71/100 (71%) interphase cells scored had the 1 red/ 1 green/ 1 yellow signal pattern, consistent with MLL rearrangement and the 6;11 translocation observed in the metaphase karyotype.	166	CD4, CD11b, variable CD13, CD15, CD33, CD58, CD64, CD117, and dim HLA-DR positive	7	1.81	FALSE	FALSE		negative	negative																																																																						
16-00699	3975	Male	Male	HispNative	2	n	46	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	46	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	9	Dead-Treatment	FALSE	FALSE		0	NA	92	75	NA	NA	5	19	1	NA		NA	2.8	1.13		18.4	6.2	46,XY[20]	NA	113.6	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	31	CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)	NA	151.6	FALSE	FALSE		negative	negative																																																																						
16-00701	2747	Male	Male	White	6	n	62	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	62	34	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor			NA	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	256	Alive	TRUE	FALSE	16-00578	-34	NA		1	0	NA	22	28	42	NA	37	29	4.7	1.03		38.2	12.4	46, XY [20]	NA	91	The abnormalities normally seen in MDS are not detected.	237		7.8	16.4	FALSE	FALSE		negative	negative																																																																						
16-00702	3976	Male	Male	White	7	n	77	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	79	0	Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.	NA		NA	NA	FALSE	FALSE		positive	positive																																																																						
16-00705	3978	Male	Male	White	5	n	59	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI 	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI 	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	1824	Dead-Disease	FALSE	FALSE		0	0	59.5	12	0	NA	55	3	29	NA	37	22	4.1	NA		25.2	8.3	47,XY,+13[2]/94,slx2[2]/46,XY[19]	NA	NA	5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)	46	Negative	6.4	NA	FALSE	FALSE		negative	negative																																																																						
16-00708	3979	Male	Male	HispNative	2	n	70	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	98	Unknown	NA		FALSE	FALSE		0	0	44	31	2	NA	46	0	14	NA	41	18	3.7	0.91		21.6	7.1	47,XY,+21[19]/46,XY[1]	91	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],	35	CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-)	7.7	5.05	FALSE	FALSE		positive	negative					Foundation; R1480*; MAFs: 88%	Foundation; P304fs*117; MAFs: 72%															Foundation; R882H; MAFs: 44%					negative			negative	negative														Foundation; I679fs*21; MAFs: 5%					Foundation; R225*; MAFs: 87%			Foundation; A72T; MAFs: 8%			Foundation; I366fs*114+; MAFs: 57%										Foundation; Q742*; MAFs: 41%					
16-00709	3980	Female	Female	White	3	n	71	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Pyoderma Gangrenosum	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Alive	0	Alive	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA	Relative increase in CD117pos,CD34neg myeloid blasts, representing 16% of total leukocytes, most consistent with myeloid neoplasm such as advanced MDS or AML.	NA	NA	FALSE	FALSE		negative	positive																																																																						
16-00710	2694	Male	Male	Black	6	n	50	FALSE	FALSE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	73	Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	FALSE	FALSE		0	NA	0		NA	NA	NA	0	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	RUNX1/RUNX1T1 fusion negative	126	No morphological evidence of acute leukemia	NA	7.7	FALSE	FALSE		negative	negative																																																																						
16-00724	3986	Female	Female	White	2	n	62	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	198	Dead-Disease	FALSE	FALSE		0	0.8	34	3.3	1.6	NA	14.9	5	68.6	NA	13	11	2.6	0.5		32.4	10.7	46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[	304	NA	nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	36	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +).	5.3	8.35	FALSE	FALSE		negative	negative																										negative			negative	negative							negative																		negative											R213fs; MAF 34%				
16-00731	3990	Female	Female	White	1	n	69	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	69	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	7	7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	ALRN-6924	Salvage	-1	Alive	442	Alive	FALSE	FALSE		0	1.8	40	42.1	0.9	8.8	10.5	9.6	26.3	2.8	27	22	3.4	0.64		23.5	7.1	46,XX[20]	399	103.5	normal	12	CD13, CD34, CD58, CD117, partial MPO and HLA-DR +	6.5	61.22	FALSE	FALSE		positive	negative																	p.S893L; MAF 41%																																						p.A187T; MAF 42%		p.K700E; MAF 51%								p.K751fs*61; MAF 44%					
16-00733	2119	Male	Male	White	1	n	76	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	472	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	Dead	520	Dead-Unknown	TRUE	FALSE	16-00732	0	0	54	13	6.9	NA	51.6	39.6	1.9	NA	20	23	3.2	1		25.4	8.6	47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]	NA	92	Seventeen of twenty cells examined were trisomy 8, previously observed.Two of the trisomy 8 cells had additional non-clonal abnormalities and two cells had an extra 1q attached to a chromosome 22 short arm, also previously observed.	22	The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR positive. Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without  aberrant antigen expression.	7.2	4.5	FALSE	FALSE		negative	negative																																																																						
16-00755	4001	Female	Female	White	1	n	58	FALSE	FALSE	TRUE	GATA2-MECOM	FALSE	FALSE	n		y	n	y	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	58	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	70	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	0	Alive	157	Alive	TRUE	FALSE	16-00751	0	0	21	0	0	2.3	41.7	25.9	30.1	0.1		NA	NA	NA		35.1	11	46,XX,t(3;3)(q21;q26)[20]	NA	107	Abnormal	360	variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123	NA	13.83	FALSE	FALSE		negative	negative																																														p.G12D; MAF 47%											p.K666N; MAF 47%													
16-00765	2704	Female	Male	White	1	n	29	TRUE	FALSE	FALSE	None	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	29	82	Post-Transplant|Post-Chemotherapy|Relapse	Peripheral Blood	y	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	Dead	129	Dead-Disease	TRUE	TRUE	16-00491	-83	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	NA	NA	Normal	NA		NA	NA	TRUE	TRUE	16-00491	negative	positive																																							p.G12V, Mutant Allele frequency: 76%																															
16-00766	4006	Male	Male	White	2	n	81	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	81	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	Dead	97	Dead-Disease	FALSE	FALSE		-32	NA	33	8	4	NA	28	24	44	NA	22	20	4.1	1.07		27.5	9.5	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	333	NA	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	28	CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).	6.6	2.2	FALSE	FALSE		negative	negative																						Foundation; EP300-ZNF205 fusion; MAFs: N/A				negative			negative	negative																																				Foundation; L206fs*41; MAFs: 31%				
16-00770	4007	Female	Female	White	6	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	51	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib	3	Unknown|Induction|Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Unknown	-1	Alive	555	Alive	FALSE	FALSE		0	NA	12		NA	NA	NA	17	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		16	FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO.	NA	1.5	FALSE	FALSE		negative	negative					p.E1348Ifs, MAF 32%																					negative				p.R172K, MAF 41%							negative																																p.T171Cfs*116, MAF 39%	
16-00771	4008	Female	Female	HispNative	6	n	34	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	34	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone	3	Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	35	Intrathecal	Cytarabine	Unknown	6	Dead	157	Dead-Unknown	FALSE	FALSE		0	NA	15		NA	NA	NA	12	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		426		NA	26.4	FALSE	FALSE		negative	negative																		p.A470V, MAF 51%			p.R882C, MAF 51%					negative											negative									p.G13R, MAF 48%																				p.R282Q, MAF 51%				
16-00783	2654	Female	Female	White	6	n	64	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Endometrial cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	64	126	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	2	Supportive/Palliative Care|Other	5	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	2	Symptom Control|Supportive/Palliative Care			NA	Supportive/Palliative Care	Paclitaxel	Supportive/Palliative Care	274	Alive	448	Alive	FALSE	FALSE		0	NA	0		NA	NA	NA	2	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		202	No increased or immunophenotypically abnormal nlast cell populations identified.	NA	3.3	FALSE	FALSE		negative	negative																										negative											negative																																	
16-00810	4028	Female	Female	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Alive	189	Alive	FALSE	FALSE		0	0	83	11.5	1.8	1.8	13.3	63.7	7.9	0.1	69	35	3	0.87	M5	34.7	11.6	46,XX[20]	337	95.6	Normal	146	Positive	6.1	44.83	FALSE	FALSE		negative	positive																													p.R132H; MAF 37%																	p.G13D; MAF 38%																								
16-00815	4030	Female	Female	White	1	n	60	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Complete Response	Standard Chemotherapy	18	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Alive	197	Alive	FALSE	FALSE		-1	0	75	44	0	0.9	28.7	46.1	24.3	0	18	13	2.9	1.19	M5	26.4	8.8	46,XX[20]	222	96.4	Normal	175	Positive	6.9	34.6	FALSE	FALSE		negative	positive																									p.T15_G16insP; MAF 48%																					p.G12S; MAF 40%																			p.H437fs*7; MAF 42%					
16-00818	4029	Female	Female	White	3	n	65	FALSE	FALSE	TRUE	GATA2-MECOM	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	65	3	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		TRUE	FALSE	16-00813	-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]	NA	NA	evidence of monosomy 7 in 191/200 (95.5 percent) cells scored	NA		NA	NA	TRUE	FALSE	16-00813	negative	negative									p.Leu367fs; MAF 24%	p.? ; MAF 16.5%											p.Ala571Pro; MAF 51.5%			p.Pro636Ala; MAF 94.7%		p.Val579Ala; MAF 2.3 %																										p.Gly60Ser; MAF 49.1%			p.Asp198Gly; MAF 63.7%															
16-00820	4032	Male	Male	White	1	n	67	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Residual Disease	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	1932	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	179	Alive	FALSE	FALSE		0	2.6	42.5	54	0.9	0	44.2	2.7	0.9	0	21	15	2	2.62		23.1	7.9	45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]	NA	91.7	5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 chromosome.  	22	Positive	5.3	1.27	FALSE	FALSE		negative	negative																					p.G570E; MAF 44%												p.V617F; MAF 3%																																	p.K132R; MAF 45%				
16-00822	2747	Male	Male	White	6	n	62	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	62	81	Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor			NA	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	256	Alive	TRUE	FALSE	16-00578	0	NA	9		NA	NA	NA	7	NA	NA		NA	NA	NA		NA	NA	46,XY[12]	NA	NA	The abnormalities normally seen in MDS are not detected.	NA	A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts.	NA	NA	TRUE	TRUE	16-00701	negative	negative																																																																						
16-00831	4038	Male	Male	Black	2	n	73	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	77	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Supportive/Palliative Care|Targeted Therapy - Other	6	Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care			NA	Targeted Therapy - Other	AG-221	Experimental	267	Dead	1490	Dead-Disease	FALSE	FALSE		0	NA	95	48	1	NA	42	6	2	NA	14	14	3.5	1.1		27.3	9.4	88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]	453	NA	nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]	23	92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).	6.5	3	FALSE	FALSE		negative	negative																													negative	R140Q (c.419G>A, p.Arg140Gln)																						E76Q			loss															
16-00836	4039	Male	Male	White	1	n	73	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea	1	Induction	Refractory	Standard Chemotherapy	167	Standard Chemotherapy	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Induction	21	Dead	28	Dead-Disease	FALSE	FALSE		0	0	88	38	0	1.7	20.9	60.9	1.7	0.1	27	40	3	1.2		33	11.2	46,XY[20]	NA	105.8	normal	55	Positive	7.5	58.97	FALSE	FALSE		positive	positive																					p.R882H; MAF 42%	p.N674D; MAF 50%																p.M3398V; MAF 51%																																
16-00846	4043	Male	Male	White	6	n	25	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	26	0	Post-Chemotherapy|Relapse	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Unknown|Induction	Complete Response	Standard Chemotherapy	79	Standard Chemotherapy	Bu/Cy/ATG	Unknown	22	Alive	444	Alive	FALSE	FALSE		0	NA		14	8	NA	17	2	54	NA	39	49	3.2	0.79		19.3	6.5		NA	101		33		4.9	1.6	FALSE	FALSE		negative	negative																																																																						
16-00852	3990	Female	Female	White	1	n	69	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	69	46	Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	y	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	7	7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	ALRN-6924	Salvage	-1	Alive	442	Alive	TRUE	TRUE	16-00731	-46	0.5	3		0	NA	50	25.7	23.8	NA	23	16	3.4	NA		31.1	9.9	46,XX[20]	217	95.4	normal	201	Positive	7.1	2.1	TRUE	TRUE	16-00731	positive	negative																																																																						
16-00867	4042	Female	Female	White	1	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	3	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	Hydroxyurea	Induction	8	Dead	8	Dead-Unknown	FALSE	FALSE		-5	0	93	85	0.8	0	16.5	0.8	1.6	0.2	19	21	2.7	0.78		21.1	7.1	46,XX[20]	360	84.4	Normal	43	partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO	5.7	30.54	FALSE	FALSE		positive	positive																														p.R140Q; MAF ~50%																																								
16-00875	4052	Female	Female	Black	6	n	45	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	46	0	Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	25	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	23	Alive	465	Alive	FALSE	FALSE		0	NA	3		NA	NA	NA	4	NA	NA		NA	NA	NA		NA	NA	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	NA	NA		69	MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene.	NA	1.3	FALSE	FALSE		negative	negative																										negative											negative																																	
16-00880	4055	Female	Female	White	3	y	55	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Multiple Sclerosis	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	179	Alive	FALSE	FALSE		0	NA	40	57	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	75	Increased atypical CD117pos, partial CD34+, partial HLA-DR pos myeloblasts (CD7+), representing about 55% of leukocytes, consistent with AML.	NA	16.43	FALSE	FALSE		negative	positive														p.Ala40fs; MAF 20.3%							p.Arg882His; MAF 39.1%																																												p.Gln1501*; MAF 39%					
16-00882	4006	Male	Male	White	2	n	81	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	81	41	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	Dead	97	Dead-Disease	TRUE	TRUE	16-00766	-73	0		70	0	NA	3	1	36	NA	25	33	4.1	1.26		24.1	8.1	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	853	98	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	74	negative	NA	39.12	FALSE	FALSE		negative	negative																																																																						
16-00883	2695	Male	Male	Black	1	n	49	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	51	129	Post-Transplant|Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	n	y	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	13	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	115	Alive	833	Alive	TRUE	FALSE	16-00806	-22	0			6.1	0	7.9	0	6.1	0.1	30	26	3.1	NA		26.2	8.9	46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9]	NA	84.5	Positive	32		7	39.25	TRUE	TRUE	16-00477	negative	positive																																																																						
16-00886	2704	Female	Female	White	1	n	29	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	29	126	Post-Chemotherapy|Residual Disease|Post-Transplant	Peripheral Blood	y	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	Dead	129	Dead-Disease	TRUE	TRUE	16-00491	-127	0			0	0	0	79.2	1	0.2	65	152	3.3	0.68		28.2	9.7	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	9928	90.4	Normal	43		6.3	12.98	TRUE	TRUE	16-00765	negative	positive																																																																						
16-00950	4074	Female	Female	White	1	n	83	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	85	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	604	Dead-Unknown	FALSE	FALSE		0	0			0	0	21.2	1.5	0.8	2.3	17	23	3.7	1.12		27.4	9.2		394	88.4		46		8.7	19.67	FALSE	FALSE		negative	positive																																																																						
16-00951	4075	Male	Male	White	3	n	42	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	42	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Alive	223	Alive	FALSE	FALSE		-3	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]	NA	NA	11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
16-00968	4077	Female	Female	Black	2	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	54	0	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	58	Alive	1874	Alive	FALSE	FALSE		0	0	1		0	NA	62	22	16	NA	65	45	4.2	0.71		31.2	9.8	46,X,t(X;2)(q22;p13)[20]	195	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	143	The findings reveal a small population of CD34(+) myeloblasts demonstrating immunophenotypic variation of unclear significance 	6.7	2.49	FALSE	FALSE		negative	negative																													negative	R140Q (c.419G>A, p.Arg140Gln)																																								
16-00970	4078	Female	Female	Black	2	n	52	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	52	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	10	Dead-Other	FALSE	FALSE		0	0	26	9.5	0	NA	50	0	40.5	NA	27	32	3	0.51		20.9	6.7	39,X,-X,-4,-5,-7,-16,-17,-18[2]/39,idem,add(9)(q22)[3]/38,idem,-12[3]/46,XX[12]	249	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PMLx2,RARAx1)[147/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[125/200]	44	CD4(+), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(+), CD36(-/small subset +), CD38(partial +), CD45(+),CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), MPO(-), and TdT(-)	7.1	1.04	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
16-00981	4083	Female	Female	White	3	n	69	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	69	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Alive	255	Alive	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA	normocytic, normochromic, mild anisopoikilocytosis, no sig. polychromasia. Leukocyte number-decreased,leukocyte morph-within normal limits.	NA	NA	FALSE	FALSE		negative	negative																																																																						
16-01004	4195	Male	Male	White	2	n	70	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	70	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Vidaza	Hypomethylating/Low Dose Cytarabine	4	Alive	95	Alive	FALSE	FALSE		0	0	85	77.8	0	NA	7.4	0	11.1	NA	12	32	2.8	0.62		21.8	7		1195	NA		103		5.2	25.85	FALSE	FALSE		negative	negative																													negative	negative																																								
16-01005	4196	Female	Female	White	5	n	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	153	Alive	FALSE	FALSE		0	1	30	0	0	NA	31	4	6.8	NA	10	11	4.3	NA		32.4	9.9	46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]	NA	NA	Probe: 8 centromere/20q12	83	Negative	7.2	10.6	FALSE	FALSE		negative	negative		c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%												negative							negative					negative			negative	c.419G>A; P.R140Q; MAF 46%			negative			negative			negative							negative																				negative				
16-01009	4028	Female	Female	White	1	n	61	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	34	Post-Chemotherapy	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Alive	189	Alive	TRUE	TRUE	16-01008;16-00810	0	0.7	3.5	0	0	0.7	16.5	5.7	76.4	0	27	12	3.7	0.74		32.7	10.8	46,XX[19]	278	92.6	Normal	295	CD34+ blasts comprise 1% of WBCs. Lymphocytes	7.4	4.05	TRUE	FALSE	16-01008	negative	negative																																																																						
16-01010	4197	Female	Female	White	1	n	45	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	634	Dead-Disease	TRUE	FALSE	16-01104	0	0			0	0	20.4	0	66.7	1	58	44	3.3	1.04		23.8	8.1		401	88.5	Positive	14		7.3	6.18	FALSE	FALSE		positive	positive																																																																						
16-01017	4043	Male	Male	AdmixedHispNative	6	n	25	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	26	28	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Unknown|Induction	Complete Response	Standard Chemotherapy	79	Standard Chemotherapy	Bu/Cy/ATG	Unknown	22	Alive	444	Alive	FALSE	FALSE		0	NA	70	8	NA	NA	NA	4	NA	NA		NA	NA	NA		NA	NA	46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]	NA	NA		10	MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR 	NA	30.2	FALSE	FALSE		negative	negative																																												p.S2496C; MAF 45%		p.Q61K; MAF45%																								
16-01018	2739	Male	Male	White	6	n	66	FALSE	FALSE	FALSE	None	TRUE	FALSE	n		y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Primary myelofibrosis	Intermediate	Not Enough Information	MYELODYSPLASTIC SYNDROMES	Primary myelofibrosis	67	119	Residual Disease	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Hydroxyurea	1	Unknown			NA	Standard Chemotherapy	Hydroxyurea	Unknown	263	Alive	189	Alive	TRUE	TRUE	16-00562	-119	NA	5	0	0	NA	12	8	80	NA		NA	NA	0.93		28.7	8.9	46,XY[17]	NA	81.8	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.	88	These are positive for CD34, CD117, HLADR, CD33 and CD13.	0	5.6	FALSE	FALSE		negative	negative																																																																						
16-01022	4201	Female	Female	White	1	n	52	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	3	MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib 	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA plus Midostaurin	Salvage	-1	Alive	414	Alive	FALSE	FALSE		0	0	51.5	0	0	0	13.2	79.8	4.4	0	52	25	3.6	1.16		30.6	10.2	46,XX[20]	608	102.3	Normal	45	CD11b, CD13, CD14, CD15, CD33, CD56, bright CD64 and dim HLA-DR-positive	7	116.57	FALSE	FALSE		negative	positive																					p.R882C; MAF 45%					p.D835A; MAF 4%																				p.G12D; 17%																			p.G1137D; MAF 31%					
16-01024	4202	Female	Female	White	2	n	62	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	n	n	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	5	Dead	149	Dead-Unknown	FALSE	FALSE		0	0		7	0	NA	50.4	5.2	36.5	NA	17	14	3.8	0.78		NA	7.2		183	NA	nuc ish(RUNX1T1x2,RUNX1x1)[34/200],(ABL1x2,BCRx1)[51/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	32		7	2.18	FALSE	FALSE		negative	negative																													negative	negative			negative																																					
16-01047	4205	Female	Female	White	6	n	67	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	69	0	Post-Chemotherapy|Relapse	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	Cytarabine|Idarubicin and Cytarabine	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	9	Standard Chemotherapy	Cytarabine	Consolidation	40	Alive	927	Alive	FALSE	FALSE		0	NA		94	0	NA	3	0	1	NA	18	52	3.2	1.03		24.6	8.6		NA	93.5		28		5.7	108.9	FALSE	FALSE		positive	positive																													p.R132S, MAF 46%																																									
16-01049	4207	Male	Male	Asian	2	n	78	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	78	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine	4	Induction|Re-induction|Maintenance|Supportive/Palliative Care	Refractory	Supportive/Palliative Care	-1	Standard Chemotherapy	Etoposide, Cytarabine	Supportive/Palliative Care	-1	Dead	372	Dead-Disease	FALSE	FALSE		0	0	20	3.8	7.8	NA	40	5.2	40	NA	9	49	3.1	1.41		25.7	8.5	46,XY[20]	675	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	30	CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).	6.9	4.9	FALSE	FALSE		negative	negative																										negative			negative	negative																																								
16-01055	4210	Female	Female	White	1	n	56	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Salvage|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	183	Alive	FALSE	FALSE		0	0	73	68	0	0.8	19.3	7.6	3.4	0.1	46	25	3.4	0.74		17	5.9	46,XX[20]	NA	91.9	Normal	53	CD13, CD34, CD38, CD117, and dim HLA-DR +.	6.8	40.02	FALSE	FALSE		negative	negative		p.T601A; MAF 45%			p.Y1350fs*1; MAF 43%																p.R882H; MAF 46%					p.A680V; MAF 37%				p.R140Q; MAF 43%																p.Q61K; MAF 9%					p.I117M; MAF 49%				p.N434fs*166; MAF 37%															
16-01059	2530	Female	Female	White	6	n	73	FALSE	FALSE	TRUE	None	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	252	Post-Chemotherapy	Bone Marrow Aspirate	n	y	n	n	y	n	1	Standard Chemotherapy	1	Ruxolitinib	1	Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	Ruxolitinib	Induction	28	Dead	560	Dead-Unknown	TRUE	TRUE	16-00358	-195	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20] 	NA	NA	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
16-01061	4197	Female	Female	White	1	n	45	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	14	Post-Chemotherapy|Residual Disease	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	634	Dead-Disease	TRUE	FALSE	16-01104	0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	Positive	NA		NA	NA	FALSE	FALSE		negative	positive																																																																						
16-01080	4225	Female	Female	White	1	n	69	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	69	1	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	ATRA, Idarubicin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Idarubicin	Induction	-1	Unknown	NA		FALSE	FALSE		-1	1.7	90	59.5	1.7	0.8	13.5	5	6.7	0.9	45	41	3.4	1.09	M3	24.1	8.6	46,XX,t(15;17)(q24;q21)[20]	NA	92.7	PML/RARA fusion	39	dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive	6.5	34.36	FALSE	FALSE		positive	negative														negative							negative								negative	negative			negative			negative			negative		negative				p.P2438L ; MAF 47%	negative									negative											negative			negative	
16-01082	4226	Male	Male	White	1	n	68	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	68	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Unknown	NA		FALSE	FALSE		0	0		10	0.9	0	81.8	4.6	10.9	0	27	26	4.1	1		33.6	11.9	46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]	330	106.7	CBFB, D7S486/ CEP 7	106	CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative	6.9	2.16	FALSE	FALSE		negative	negative																																																																						
16-01093	4229	Male	Male	White	2	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	NA		FALSE	FALSE		0	0	48	6	0	NA	31	14	47	NA	27	27	4.2	0.86		36.9	12.6	47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]	294	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	175		7	2.43	FALSE	FALSE		negative	negative																																																																						
16-01094	2254	Female	Female	White	2	n	52	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	53	462	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	633	Dead-Disease	TRUE	TRUE	15-00653	-463	NA	76	1	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
16-01097	2116	Female	Female	White	1	n	10	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	12	568	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	33	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	-1	Alive	569	Alive	FALSE	FALSE		0	0	46		0	0	81.3	8.3	10.4	18.1	31	27	3.8	0.53		30.5	10.2	47,XX,+10[19]/46,XX[1]	NA	96.8	Normal	11	variable CD7, dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive	7	1.93	FALSE	FALSE		negative	negative																																																																						
16-01098	4230	Female	Female	White	2	n	44	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	216	Alive	FALSE	FALSE		0	NA	64	74	NA	NA	NA	NA	NA	NA	21	34	NA	NA		NA	NA	45,XX,der(13;14)(q10;q10)?c[20]	NA	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	90		NA	99.87	FALSE	FALSE		positive	positive																																																																						
16-01100	4231	Male	Male	White	2	n	65	FALSE	TRUE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Cytarabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	-1	Dead	2	Dead-Unknown	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA	nuc ish (PML,RARA)x2[199]	NA		NA	NA	FALSE	FALSE		negative	positive																																																																						
16-01102	4232	Female	Female	White	2	n	72	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Alive	358	Alive	FALSE	FALSE		0	NA	30	5	NA	NA	NA	NA	NA	NA	37	93	NA	NA		NA	NA	45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]	NA	NA	nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]	16		NA	44.63	FALSE	FALSE		negative	negative																																																																						
16-01103	4197	Female	Female	White	1	n	45	FALSE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	23	Residual Disease|Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	634	Dead-Disease	TRUE	FALSE	16-01104	0	0	90	90	0	0	5	0	0	0	27	43	1.6	0.93		22.5	7.9		NA	82.1	Positive	43	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	5.1	18.38	FALSE	FALSE		positive	positive																																																																						
16-01109	4235	Male	Male	Black	5	n	33	FALSE	TRUE	FALSE	CBFB-MYH11	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	116	Alive	TRUE	FALSE	16-01108	0	0	72	95	0	NA	3	0	1	NA	29	24	3.4	NA		19.8	6.5	46,XY,inv(16)(p13.1q22)[20]	NA	NA	Positive for CBFB rearrangment for 91% of cells	31	Positive	6.6	93.2	TRUE	FALSE	16-01108	negative	negative														negative							negative					negative			negative	negative			negative			negative			negative							negative																			c.652G>A; p.V218M; MAF 50%	negative				
16-01118	2611	Female	Male	HispNative	5	n	56	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	224	Post-Transplant|Relapse	Bone Marrow Aspirate	y	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	27	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	Dead	323	Dead-Disease	TRUE	TRUE	16-00303	-224	NA	90		NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[19]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		positive	positive																																																																						
16-01121	4239	Male	Male	White	3	n	61	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	184	Alive	FALSE	FALSE		0	NA	86	89	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	57		NA	115.15	FALSE	FALSE		positive	positive																					p.Arg326Cys; MAF 44.5%																																												p.Ala911fs; MAF 40.6%					
16-01123	4240	Female	Female	HispNative	1	n	46	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	7	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	-1	Dead	360	Dead-Disease	FALSE	FALSE		2	0			0.9	0.9	29.5	6.9	52.2	0	51	28	3.6	0.78		40	13.2	46,XX[20]	272	87.3	Normal	145		6.7	8.16	FALSE	FALSE		positive	positive																					p.R882H; MAF 35% (previously 32% on 10/10/16)													p.H529R; MAF 49% (previously 52% 10/10/16) 																																				
16-01127	2538	Male	Male	White	1	n	67	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	261	Post-Chemotherapy	Leukapheresis	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	Alive	528	Alive	TRUE	TRUE	16-00157	-52	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	positive																																																																						
16-01138	2315	Male	Male	White	1	n	62	TRUE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	412	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	-1	Dead	424	Dead-Disease	TRUE	TRUE	15-00778	-412	0.9			0	0	7.8	1.7	4.3	0.1	18	21	2.8	1.43		25	8.2	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	564	102.5	EGR1 (73.5%) ;  TP53: (85.5%)	139		6.6	46.79	FALSE	FALSE		negative	negative																																																																						
16-01139	4245	Female	Female	White	1	n	77	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	79	0	Post-Chemotherapy|Residual Disease	Peripheral Blood	n	y	y	n	y	y	1	Supportive/Palliative Care	2	Lenalidomide|Azacitidine	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Lenalidomide	Supportive/Palliative Care	45	Unknown	NA		FALSE	FALSE		-19	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
16-01142	4247	Female	Female	White	1	y	28	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	29	0	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Fludarabine, Cyclophosphamide, TBI, Rituximab	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI, Rituximab	Allogeneic - Sibling	-1	Alive	472	Alive	FALSE	FALSE		0	0	50		1.8	0.9	21	2.6	71.9	1.8	24	11	3.6	0.61		25.5	9	46,XX[20]	174	87.3	Normal	42	CD7, CD13, CD33, CD34, partial CD56, CD117,  HLA-DR,      MPO and dim TdT-positive 	6.8	1.65	FALSE	FALSE		negative	negative		p.D656N; MAF 46%												p.Q311*; MAF 15%																																																			p.R544*; MAF 16%					
16-01151	4248	Male	Male	White	1	n	81	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza, BI836858 (anti-CD33)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Vidaza, BI836858 (anti-CD33)	Induction	-1	Alive	355	Alive	TRUE	FALSE	16-01150	0	0		80	0	7	7.8	0	6.9	0.5	31	42	3.2	1.3		25.1	8.8	46,XY[19]	665	85.1	Normal	16	dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive	7.2	33.81	TRUE	FALSE	16-01150	negative	positive														negative				 p.T640N; MAF: 14%			negative			p.G709D; MAF: 17%		negative			negative	p.R140Q; MAF: 46%			negative		Splice site-Intron 5 3' end mutation; MAF:3%	negative			negative		negative					negative									negative											negative			negative	
16-01185	4252	Male	Male	White	5	n	50	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	50	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	201	Dead-Unknown	FALSE	FALSE		0	0	75	82	2	NA	4	0	8	NA	39	45	3.7	NA		20.1	6.5	46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] 	NA	NA	Loss of 5q31 sequences for 99% of total cells	12	Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR	6.3	119.6	FALSE	FALSE		positive	negative					C.3067T>C; p.F1023L									negative							negative								negative	negative			negative			negative			negative						c.7625G>A; p.S2542N	negative																				negative				
16-01191	4256	Female	Female	White	3	n	65	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	246	Alive	TRUE	FALSE	16-01190	0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	45,XX,-7[20]	NA	NA	7cen (D7Z1), 7q31 (D7S486): monosomy present 	NA		NA	NA	TRUE	FALSE	16-01190	negative	negative																					p.Gln231fs; MAF 33.2%									p.Arg140Gln; MAF 44.2%																p.Gln61Glu; MAF 47.8%																								
16-01192	4201	Female	Female	White	1	n	52	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	52	34	Post-Chemotherapy	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib 	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA plus Midostaurin	Salvage	-1	Alive	414	Alive	TRUE	TRUE	16-01143;16-01022	-6	1.4			0.2	NA	9.2	24.3	64.9	NA	119	151	3.2	0.76		28.4	9.2	46,XX[20] 	380	93.4	Normal	395		6.6	6.5	TRUE	FALSE	16-01143;16-01146	negative	negative														negative							p.R882C; MAF 14%					negative			negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
16-01201	4260	Male	Male	White	1	n	53	FALSE	FALSE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	54	0	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	7	AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	5	Salvage|Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Salvage	-1	Dead	543	Dead-Disease	FALSE	FALSE		0	0	75	90	0	0	22.1	6.2	1.8	0	19	33	1.8	0.84		25.5	8.1	46,XY,t(4;12)(q12;p13)[10]/46,XY[10] 	706	91.4	42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement. Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4. Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML	25	partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive 	6.6	118	FALSE	FALSE		negative	negative														negative							p.R882H; MAF 49%					negative			p.R132S; MAF 48%	negative			negative						negative		negative					negative									p.R166*; MAF 50%					p.P95H; MAF 50%						negative			negative	
16-01210	4263	Male	Male	White	3	n	63	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Child	-1	Alive	395	Alive	FALSE	FALSE		-17	NA	26.3	12	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[11] 	NA	NA	Normal	69		NA	9.28	FALSE	FALSE		negative	negative					p.Tyr354*; MAF 72.2%																p.Thr835Met; MAF 47%								p.Arg132Cys; MAF 2.9%																																									
16-01216	4263	Male	Male	White	3	n	63	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	1	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Child	-1	Alive	395	Alive	TRUE	TRUE	16-01210	-18	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XY[11] 	NA	NA	Normal	NA		NA	NA	TRUE	TRUE	16-01210	negative	negative					p.Tyr354*; MAF 72.2%																p.Thr835Met; MAF 47%								p.Arg132Cys; MAF 2.9%																																									
16-01219	4271	Male	Male	White	1	y	47	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	47	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	317	Alive	FALSE	FALSE		0	0	83	82	3.4	0	23.1	3.4	0	1.6	23	11	3.5	0.95		31.1	10.2	46,XY[20]	290	88.9		24	CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO 	6.5	18.71	FALSE	FALSE		negative	negative														p.I68fs; MAF 50%							negative			p.S519P; MAF 51%		negative			negative	negative			negative			negative					negative					p.G13D, MAF 3%									negative											negative			p.R458*; MAF 23%	
16-01223	4273	Male	Male	White	2	n	73	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	73	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Dead	31	Dead-Unknown	FALSE	FALSE		0	NA	83	59	NA	NA	NA	NA	NA	NA	21	23	NA	NA		NA	NA	46,XY[20]	NA	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	22		NA	24.23	FALSE	FALSE		negative	negative																																																																						
16-01225	4274	Female	Female	White	1	n	61	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	316	Dead-Disease	FALSE	FALSE		-2	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA		NA	NA	FALSE	FALSE		positive	positive														negative							negative								negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
16-01227	4275	Female	Female	HispNative	6	n	39	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	40	0	Post-Chemotherapy|Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	39	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	399	Alive	FALSE	FALSE		0	NA		91	NA	NA	9	NA	NA	NA	21	34	3.8	0.49		29.3	9.9		NA	93.6		66		5.8	73	FALSE	FALSE		negative	positive																																																																						
16-01237	4291	Female	Female	HispNative	6	n	73	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Alive	122	Alive	TRUE	FALSE	16-01238	0	NA	71	3	1	NA	68	8	11	NA	11	23	2.9	0.51		24.9	7.8	46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]	NA	110.7	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	95	blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and  negative for cd11b, cd14, cd64, tdt and mpo.	4.8	63.4	FALSE	FALSE		negative	negative																										negative											negative																																	
16-01254	4299	Female	Female	White	1	n	38	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	38	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	303	Alive	FALSE	FALSE		0	NA	47	21.7	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA	CD117, dimCD4, heterogeneous CD13, CD33, dimCD64 and  MPO positive 	NA	46.27	FALSE	FALSE		negative	positive														negative							p.R882H; MAF 46%					negative			p.R132H; MAF 25%	negative			negative			negative			p.Q61L; MAF 10%		negative					p.G13D; MAF 24%									negative											negative			negative	
16-01262	4303	Female	Female	White	1	n	59	FALSE	TRUE	FALSE	PML-RARA	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	59	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide, Idarubicin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide, Idarubicin	Induction	-1	Alive	28	Alive	FALSE	FALSE		0	0.9	90	90	1.7	44	8.6	0	6	1.5	110	255	2.4	0.86	M3	19.8	6.7	46,XX,t(15;17)(q22;q21)[20]	NA	88.4	86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis. 	30	CD13, CD33, CD58, CD64, CD117, CD123, MPO	5.4	47.35	FALSE	FALSE		negative	negative														negative							negative								negative	negative			negative			negative			negative		negative					negative									negative											negative			negative	
16-01267	4307	Female	Female	AdmixedBlack	7	n	61	TRUE	FALSE	FALSE	None	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	62	0	Post-Chemotherapy|Relapse	Peripheral Blood	n	y	y	n	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	361	Alive	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA		NA	NA	FALSE	FALSE		negative	positive																				VAF: 43.9%	VAF: 42.8%																																																VAF: 23.2%	
16-01270	4317	Female	Female	White	1	n	72	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	74	0	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	1	Experimental			NA	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	16	Unknown	NA		FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA		NA	NA		NA		NA	NA	FALSE	FALSE		negative	negative																																																																						
16-01272	4310	Male	Male	White	6	n	64	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	80	Dead-Unknown	FALSE	FALSE		0	NA	17		NA	NA	NA	5	NA	NA		NA	NA	NA		NA	NA	42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10] 	NA	NA		43	NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes. 	NA	2.2	FALSE	FALSE		negative	negative																					c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36         c.2656C>T; pQ886*    MAF 43%, 36% 					negative											negative							c.2192_2199delTCTTGCCC; p.L731Qfs*3  MAF 38%																						c.610G>T;p.E204*    MAF 51%				
17-00021	4324	Male	Male	White	6	n	66	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Post-Chemotherapy|Relapse	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	HiDAC	Consolidation	63	Alive	300	Alive	FALSE	FALSE		0	NA		8	1	NA	14	19	46	NA	15	22	4.3	0.88		38.3	12.5		NA	97.2		165		6.2	9	FALSE	FALSE		negative	positive																																																																						
17-00025	4325	Female	Female	White	3	n	39	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	39	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Sibling	-1	Alive	173	Alive	FALSE	FALSE		0	NA	70	80	NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA		NA	Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.	NA	190	FALSE	FALSE		positive	positive																					p.Arg882His; MAF 41.8%					p.Val581_Arg595dup; MAF 22%;negative																																												
17-00029	4336	Female	Male	White	6	n	44	TRUE	FALSE	FALSE	Unknown	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	45	0	Post-Transplant|Post-Chemotherapy|Relapse	Bone Marrow Aspirate	n	y	n	n	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)	4	Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	0	Alive	524	Alive	TRUE	FALSE	17-00028	0	NA	83	80	NA	NA	16	1	4	NA	19	20	4.1	0.93		29.7	9.9		NA	96.1		63	POSITIVE for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR) with a signal ratio of 0.045. NOT DETECTED for the FLT3 TKD Mutation. 	7.5	85.5	FALSE	FALSE		positive	negative																										negative				c.419G>A; p.R140Q   MAF 39%							negative							c.5225A>G; p.N17425    MAF 10%					c.901T>G; p.Y301D    MAF 29%				c.482-3T>C;     MAF 8%		c.318G>A; p.W106*     MAF 37%       c.319C>T; p.R107C    MAF 37%			c.3391G>A; p.G1131R     MAF 29%												
17-00033	4359	Male	Male	White	3	n	74	FALSE	FALSE	FALSE	None	FALSE	FALSE	y	Bladder Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	Intermediate-II	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	58	Dead-Disease	FALSE	FALSE		0	NA			NA	NA	NA	NA	NA	NA		NA	NA	NA		NA	NA	46,XX[20]	NA	NA	Normal	NA	Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML.	NA	NA	FALSE	FALSE		negative	positive																																																																						
17-00059	2694	Male	Male	Black	6	n	50	FALSE	FALSE	FALSE	RUNX1-RUNX1T1	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Intermediate	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	51	249	Post-Chemotherapy	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	FALSE	FALSE		0	NA	1		NA	NA	NA	6	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA	RUNX1/RUNX1T1 fusion negative	94	Positive for CD34, CD117, HLADR, CD13 AND CD33. 	NA	6.6	FALSE	FALSE		negative	negative																										negative											negative																																	
17-00064	4363	Male	Male	HispNative	5	n	55	FALSE	TRUE	FALSE	None	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	44	Dead	282	Dead-Disease	FALSE	FALSE		0	0	88.5	64	0	NA	25	4	7	NA	34	36	3.3	NA		31.3	10.9	46,XY[19]	NA	NA	Normal	54	Negative	7.4	24.9	FALSE	FALSE		positive	positive														negative							negative					c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%;negative			c.395G>A; p.R132H; 44%	negative			negative			negative			negative							negative														c.284_307del; p.P95_R102del; MAF 45%						negative				
17-00072	4366	Male	Male	White	1	n	70	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	70	0	Residual Disease|Post-Chemotherapy	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	61	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	362	Dead-Disease	FALSE	FALSE		0	0		53.2	0	16.2	16.2	8.1	6.3	4.5	<20	45	4.6	1.5		31.5	9.8	46,XY[20]	851	92.6	Normal	14		7.6	92.55	FALSE	FALSE		negative	negative					p.S1024; MAF 5%									negative							negative					negative			negative	negative			negative			negative			negative		negative					p.G13D; MAF 34%						p.G60V; MAF 3%			negative					p.P95H; MAF 40%						negative			negative	
17-00077	4317	Female	Female	White	1	n	72	FALSE	FALSE	FALSE	CBFB-MYH11	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	74	33	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	n	y	y	n	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	1	Experimental			NA	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	16	Unknown	NA		TRUE	FALSE	17-00007	-25	2.6	90	74	0	0	6	2.6	2.6	0	12	22	2.7	0.69		19.5	6.5	46,XX,inv(16)(p13q22)[cp20]	807	86.7	CBFB: 79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype. 	9	CD13, CD33, CD34, variable CD38, CD117,  CD123, and HLA-DR +.	5.8	34.76	FALSE	FALSE		negative	negative														negative							negative					negative			negative	negative			negative			p.D816H; MAF 44%			negative		negative					negative									negative											negative			negative	
17-00093	4379	Female	Female	Black	2	n	43	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	43	0	Initial Acute Leukemia Diagnosis	Peripheral Blood	n	y	y	n	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Unknown	NA		FALSE	FALSE		0	NA		48	NA	NA	NA	NA	NA	NA	30	21	NA	NA		NA	NA	46,XX[20]	NA	NA	nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	27		NA	41.91	FALSE	FALSE		positive	negative																										D835			negative	negative																																								
17-00094	4380	Male	Male	White	6	n	57	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	57	0	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	n	y	y	n	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Unknown|Induction	Complete Response	Standard Chemotherapy	26	Standard Chemotherapy	HiDAC	Unknown	77	Alive	153	Alive	FALSE	FALSE		0	NA	20		NA	NA	NA	3	NA	NA		NA	NA	NA		NA	NA	46,XY[20]	NA	NA		49	THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33.	NA	19.3	FALSE	FALSE		negative	negative																					c.2644C>T; p.R882C     MAF 47%					negative							c.1849G>T; p.V617F     MAF 91%				negative																		c.338C>T; p.P113L    MAF 42%         c.592G>A; p.D198N    MAF 46%	c.883G>A; p.V1295M    MAF 47%				c.284C>A; p.P95H    MAF 47%										
17-00096	2747	Male	Male	White	6	n	62	FALSE	FALSE	TRUE	None	FALSE	FALSE	n		y	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	Intermediate	Not Enough Information	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	63	232	Residual Disease	Peripheral Blood	n	y	y	n	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor			NA	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	256	Alive	TRUE	TRUE	16-00822;16-00578	-151	NA			0.1	NA	13.8	9.9	74.1	NA	9	17	4.9	1		41.7	12.9	46,XY[12]	NA	82.2	The abnormalities normally seen in MDS are not detected.	410		7.6	8	FALSE	FALSE		negative	negative																																																																						
